<SEC-DOCUMENT>0001010549-16-000606.txt : 20160516
<SEC-HEADER>0001010549-16-000606.hdr.sgml : 20160516
<ACCEPTANCE-DATETIME>20160516164111
ACCESSION NUMBER:		0001010549-16-000606
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160516
DATE AS OF CHANGE:		20160516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		161654538

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cphi10q033116.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securities Transfer Corp
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div id="DSPFPageHeader">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 15.95pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt; FONT-WEIGHT: bold">
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 15.95pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 15.95pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 18.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 14pt; FONT-WEIGHT: bold">FORM 10-Q</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Mark One)</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="86fbc964ba4e4f83b197e45c860a5599" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.69%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 92.31%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the quarterly period ended <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>March 31, 2016</u></font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c8493624ba2f41ce95139a999f38cc19" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 7.69%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 92.31%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the transition period from ____________ to ____________</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission File Number 001-34471</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 22.8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 18pt; FONT-WEIGHT: bold"><u>CHINA PHARMA HOLDINGS, INC.</u></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Exact name of registrant as specified in its charter)</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="7241451abe5a4526b737e94665fde220" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff; FONT-VARIANT: normal; FONT-STYLE: normal; WIDTH: 50%; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt"><u>Nevada</u></div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #ffffff; FONT-VARIANT: normal; FONT-STYLE: normal; WIDTH: 50%; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt"><u>75-1564807</u></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(State or other jurisdiction of</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(IRS Employer</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">incorporation or organization)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Identification No.)</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Second Floor, No. 17, Jinpan Road</u></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Haikou, Hainan Province, China 570216</u></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Address of principal executive offices) (Zip Code)</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>+86- 898-6681-1730 (China)</u></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Issuer's telephone number, including area code)</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font> No <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font> No <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div id="DSPFPageFooter"></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div id="DSPFPageHeader"></div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check One):</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="86f3ec0428484cc9be9670b6b03316e5" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52.11%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Large accelerated filer&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 47.89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Accelerated filer&#160;&#160; <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 52.11%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Non-accelerated filer&#160; <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(Do not check if a smaller reporting company)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 47.89%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Smaller reporting company&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font></div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9744;</font> No <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#9746;</font></div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">APPLICABLE ONLY TO CORPORATE ISSUERS:</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 43,579,557 shares of Common Stock, $.001 par value, were outstanding as of May 11, 2016.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div id="DSPFPageFooter"></div>

<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">2</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div id="DSPFPageHeader"></div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TABLE OF CONTENTS</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I FINANCIAL INFORMATION</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 481.5pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Page</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="07e90d907b4c4268a521ecb6f0401327" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Item 1.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Financial Statements</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">4&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Condensed Consolidated Balance Sheets as of March 31, 2016 and December 31, 2015 (Unaudited)</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">5&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Ended March 31, 2016 and 2015 (Unaudited)</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">6&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: -2.05pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 2.05pt; FONT-SIZE: 10pt">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2016 and 2015 (Unaudited)</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">7&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: -36pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">Notes to Condensed Consolidated Financial Statements (Unaudited)</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">8&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Item 2.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Management<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">'</font>s Discussion and Analysis of Financial Condition and Results of Operations</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">16&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Item 3.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Quantitative and Qualitative Disclosures about Market Risk</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">23&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Item 4.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Controls and Procedures</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">23&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 95.35%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II OTHER INFORMATION</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">23&#160;</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 95.35%; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 4.65%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 5.84%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Item 6.</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 89.5%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Exhibits</div>
</td>
<td style="TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff; WIDTH: 4.65%; VERTICAL-ALIGN: top">23&#160;</td>
</tr>
</table>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div id="DSPFPageFooter"></div>

<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">3</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div id="DSPFPageHeader"></div>
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART I - FINANCIAL INFORMATION</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1. Financial Statements</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated balance sheets, statements of operations and comprehensive income, and statements of cash flows and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States of America (<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>U.S. GAAP<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the disclosures required by U.S. GAAP for complete financial statements. The financial statements reflect all adjustments, consisting only of normal, recurring adjustments, which are, in the opinion of management, necessary for a fair presentation for the interim periods.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The results of operations for the three-month period ended March 31, 2016 are not necessarily indicative of the results to be expected for the entire fiscal year or any other period.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div id="DSPFPageFooter"></div>
</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">4</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<div>
<div id="DSPFPageHeader"></div>

<div id="DSPFPageFooter"></div>
</div>

<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="1a6c1d16361b49548a54d36cf890fc7f" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED BALANCE SHEETS</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ASSETS</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Assets:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cash and cash equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">7,261,777</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">6,248,760</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Banker's acceptances</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">116,317</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Trade accounts receivable, less allowance for doubtful</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">accounts of $29,598,703 and $28,644,398, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4,791,247</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,882,509</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Other receivables, less allowance for doubtful</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">accounts of $78,558 and $74,400, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">191,958</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">290,739</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Advances to suppliers</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,643,516</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,533,354</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Inventory, less allowance for obsolescence</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">of $6,696,224 and $8,417,095, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">9,917,139</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">9,662,750</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Prepaid expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">195,081</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">339,140</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">25,117,035</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">24,957,252</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Advances for purchases of intangible assets</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">42,309,641</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">42,030,649</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and equipment</font>, net of accumulated depreciation of</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">$10,286,937 and $9,442,912, respectively</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">28,826,692</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">29,393,257</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Intangible assets</font>, net of accumulated amortization of</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">$4,456,837 and $4,360,004, respectively</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">778,766</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">841,075</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TOTAL ASSETS</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">97,032,134</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">97,222,233</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LIABILITIES AND STOCKHOLDERS' EQUITY</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Current Liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Trade accounts payable</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,744,095</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,824,521</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Accrued expenses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">113,627</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">143,409</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Other payables</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,712,024</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,710,283</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Advances from customers</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">932,653</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">595,681</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Other payables - related parties</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,354,567</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,354,567</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Current portion of construction loan facility</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,550,893</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,540,666</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Short-term notes payable</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4,652,678</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4,621,998</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Current Liabilities</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">14,060,537</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">12,791,125</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-current Liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Construction loan facility</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">10,546,069</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">10,784,661</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Deferred revenue</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">534,833</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">708,408</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Long-term deferred tax liability</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">322,012</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">296,890</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Liabilities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">25,463,451</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">24,581,084</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stockholders' Equity:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">no shares issued or outstanding</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Common stock, $0.001 par value; 95,000,000 shares authorized;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">43,579,557 shares and 43,579,557 shares outstanding, respectively</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,580</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,580</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Additional paid-in capital</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">23,590,204</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">23,590,204</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Retained earnings</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">32,387,102</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">33,939,998</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Accumulated other comprehensive income</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">15,547,797</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">15,067,367</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Stockholders' Equity</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">71,568,683</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">72,641,149</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">97,032,134</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">97,222,233</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>

&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">5</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 10.25pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="42e12cb654c5457ba0f90f4fa2f663c3" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AND COMPREHENSIVE INCOME (LOSS)&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three Months</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended March 31,&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Revenue</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,640,494</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,694,930</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cost of revenue</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,071,461</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4,434,706</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Inventory obsolescence (benefit) expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(71,786</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">201,097</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Gross profit</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">640,819</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,059,127</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Operating expenses:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Selling expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">968,507</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">988,953</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">General and administrative expenses</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">318,930</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">472,429</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Research and development expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">93,433</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">160,828</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Bad debt expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">581,300</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,200,003</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Total operating expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,962,170</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4,822,213</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Loss from operations</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,321,351</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(3,763,086</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Other income (expense):</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Interest income</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">33,592</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">26,855</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Interest expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(242,309</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(313,775</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net other expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(208,717</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(286,920</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Loss before income taxes</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,530,068</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,050,006</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Income tax&#160; expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(22,828</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(19,284</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,552,896</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,069,290</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Other comprehensive income - foreign currency</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">translation adjustment</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">480,430</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">435,480</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Comprehensive income (loss)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,072,466</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(3,633,810</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss per share:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Basic</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.04</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.09</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Diluted</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.04</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.09</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>

<br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt">
<div id="DSPFPageHeader"></div>

<div id="DSPFPageFooter"></div>

<br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt">&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">6</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="9c9df99102ff439eba0e083247785107" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARMA HOLDINGS, INC.&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="8">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(Unaudited)&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Three Months</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended March 31,&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Operating Activities:</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,552,896</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,069,290</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Depreciation and amortization</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">857,195</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">951,212</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Bad debt expense</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">581,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,200,003</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Deferred income taxes</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">22,828</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">19,284</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Inventory obsolescence reserve</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,751,863</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">201,097</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Changes in assets and liabilities:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Trade accounts and other receivables</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(61,069</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,408,092</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Advances to suppliers</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(92,039</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(154,575</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Inventory</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,967,359</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">396,521</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Trade accounts payable</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">888,212</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">917,765</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Accrued taxes payable</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(53,955</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">18,019</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Other payables and accrued expenses</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">25,514</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,813</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Advances from customers</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">328,354</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(243,289</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">Prepaid expenses</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">144,262</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">173,919</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by Operating Activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,303,202</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(2,239</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Investing Activities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Purchases of property and equipment</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(39,248</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(47,106</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Used in Investing Activities</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(39,248</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(47,106</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash Flows from Financing Activities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Payments of construction term loan</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(305,835</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Cash Provided by Financing Activity</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(305,835</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Effect of Exchange Rate Changes on Cash</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">54,898</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">22,411</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net (Decrease) Increase in Cash and Cash Equivalents</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,013,017</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(26,934</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cash and Cash Equivalents at Beginning of Period</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">6,248,760</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,295,790</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents at End of Period</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">7,261,777</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,268,856</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental Cash Flow Information:</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Cash paid for interest</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,151,613</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,230,800</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Supplemental Noncash Investing and Financing Activities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Accounts receivable collected with banker's acceptances</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">517,770</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">464,075</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Inventory purchased with banker's acceptances</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">403,081</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">551,167</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The accompanying notes are an integral part of these consolidated financial statements.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">7</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<div id="DSPFPageFooter"></div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 1 &#8211; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Organization and Nature of Operations &#8211; </font>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&#160;&#160;The reincorporation merger was approved by stockholders holding the majority of the Company's outstanding shares of common stock on December 21, 2012.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Foreign Investment Industrial Catalogue<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>(the "Catalogue") jointly issued by China's Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2015 version, effective April 10, 2015) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the "FIE") shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company's business.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson's business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consolidation and Basis of Presentation </font>&#8211; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Accounting Estimates </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">- </font>The methodology used to prepare for the Company's financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company ("Management") to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cash and Cash Equivalents </font>&#8211; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker's acceptances purchased with maturities of three months or less.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Trade Accounts Receivable and Allowance for Doubtful Accounts &#8211; </font>Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $581,300&#160;and $3,200,003 for the three months ended March 31, 2016 and 2015, respectively.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of March 31, 2016, the Company had trade accounts receivable amounting to $16,853,716 from sales that occurred more than one year from that date, which the Company believes are collectable.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">8</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 10.25pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<div id="DSPFPageFooter"></div>

<br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Advances to Suppliers and Advances from Customers</font> &#8211; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory</font> &#8211; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled ($71,786) and $201,097 for the three months ended March 31, 2016 and 2015, respectively. The Company recognized an inventory obsolescence reserve of $6,696,224 and $8,417,095 as of March 31, 2016 and December 31, 2015, respectively.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Valuation of Long-Lived Assets</font> &#8211; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2016 and 2015.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment</font> &#8211; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue Recognition</font> &#8211; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&#160; Revenue is deferred when collectability is not considered to be reasonably assured.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost of Revenues</font> &#8211; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development</font> &#8211; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $93,433 and $160,828 for the three months ended March 31, 2016 and 2015, respectively.&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Basic and Diluted Loss per Common Share </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">- </font>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d6424136fd9a41ec8bc888d8b981ce90" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ended March 31,&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net loss</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(1,552,896</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,069,290</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Basic weighted-average common shares outstanding</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,579,557</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,579,557</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Effect of dilutive securities:</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Warrants</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt">Options</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Diluted weighted-average common shares outstanding</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,579,557</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">43,579,557</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Basic loss per share</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.04</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.09</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Diluted loss per share</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.04</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(0.09</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">There were no potential dilutive common shares outstanding during the three months ended March 31, 2016 and 2015, respectively.&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Credit Risk</font> &#8211; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">9</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 10.25pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&#160;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company's deposits may be at a higher risk of loss.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Rate Risk</font> &#8211; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Accounting Pronouncements</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In May 2014, the FASB issued ASU 2014-09,&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">"Revenue from Contracts with Customers"</font>&#160;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &#160;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In January 2016, the FASB issued Accounting Standards Update 2016-01,&#160;"<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Recognition and Measurement of Financial Assets and Financial Liabilities</font>." The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on its financial statements.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; BACKGROUND-COLOR: #ffffff; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company's financial position, result of operations or cash flows.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 2 &#8211; INVENTORY</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Inventory consisted of the following:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="09b6ab13d0a444ba99bce1b1d2aeb714" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Raw materials</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">12,329,926</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">14,699,736</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Work in process</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">618,329</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Finished goods</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,665,108</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3,380,109</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">16,613,363</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">18,079,845</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Obsolescence reserve</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(6,696,224</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(8,417,095</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; MARGIN-LEFT: 9pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total Inventory</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">9,917,139</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">9,662,750</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 3 - PROPERTY AND EQUIPMENT</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Property and equipment consisted of the following:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">10</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt" id="DSPFPageHeader">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="34a1cbdbe97e4b6989fca92f304bc5c1" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Permit of land use</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">436,836</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">433,956</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Building</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">10,627,311</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">10,557,234</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Plant, machinery and equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">27,521,628</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">27,325,440</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Motor vehicle</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">268,279</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">242,860</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Office equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">259,575</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">256,679</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">39,113,629</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">38,816,169</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Less: accumulated depreciation</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(10,286,937</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(9,422,912</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Property and Equipment, net</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">28,826,692</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">29,393,257</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt" id="DSPFPageFooter"></div>

<div style="LINE-HEIGHT: 10.25pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="7803ede0813749689e9c31e5ed684e8e" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Asset</div>
</td>
<td style="WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;Life - years</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Permit of land use</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">40 - 70</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Building</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">20 - 49</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Plant, machinery and equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5 - 10</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Motor vehicle</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5 - 10</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 69.64%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Office equipment</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.36%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 27%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3-5</div>
</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>

&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended March 31, 2016 and 2015, depreciation expense was $790,254 and $854,485, respectively.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 4 - INTANGIBLE ASSETS</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration ("CFDA"). The Company did not obtain CFDA production approval for any medical formula during the three months ended March 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2016 and 2015, respectively.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&#160;&#160;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $66,941 and $96,726 for the three months ended March 31, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2016 and 2015.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Intangible assets consisted solely of CFDA approved medical formulas as follows:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5fdffd04b6f2476a9480378b2ed36f04" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="WIDTH: 66%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31,</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">December 31,</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 66%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 66%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Gross carrying amount</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,235,603</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5,201,079</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 66%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Accumulated amortization</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,456,837</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">(4,360,004</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">)</div>
</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 66%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net carrying amount</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">778,766</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 14%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">841,075</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">11</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<div id="DSPFPageFooter"></div>
</div>

<br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 5 &#8211; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Prior to entering into contracts with the Company, laboratories typically are required to complete all&#160;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA's approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&#160;&#160;the Company signs the medical formula contracts.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, the Company was obligated to pay laboratories and others approximately $4,785,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">A member of the Company's board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2016 and December 31, 2015 which are recorded as other payables &#8211; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&#160;&#160;Total interest expense of $3,386 was recognized for each of the three months ended March 31, 2016 and 2015.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 7 &#8211; NOTES PAYABLE</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In November 2014, the Company entered into a new line of credit with the same bank on identical terms.&#160;&#160; Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government's current short term rate of 5.6%). In addition, the Company's Chief Executive Officer and Chair of the board of directors personally guaranteed the new line of credit. In November 2015 the Company renewed its line of credit in the amount of RMB 30,000,000 with the same bank.&#160;&#160;The line of credit is payable in two equal installments of RMB 15,000,000 ($2.31 million) payable on September 16, 2016 and October 19, 2016.&#160;&#160;Advances on the line of credit are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 5.06% (based upon 110% of the PRC government's current short term rate of 4.6%). In addition, the Company's Chief Executive Officer and Chairman of the Board personally guaranteed the line of credit.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of March 31, 2016 and December 31, 2015 ($4,652,678 as of March 31, 2016 and $4,621,998 as of December 31, 2015).&#160;&#160;The Company has no additional amounts available to it under this line of credit.&#160;&#160;This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets as of March 31, 2016.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of</font>&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Notes Payable</font> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of March 31, 2016 and December 31, 2015 approximated their fair value because of the immediate or short-term maturity of these financial instruments and because the underlying instruments bear interest rates that approximated current market rates.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">12</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 10.25pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<div id="DSPFPageFooter"></div>
</div>

<br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 8 &#8211; CONSTRUCTION LOAN FACILITY</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company obtained a construction loan facility in the amount of RMB 80,000,000 from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same bank that currently provides the line of credit as discussed in Note 7.&#160;&#160;The proceeds of the loan were used for and are collateralized by the construction of the Company's new production facility and the included production line equipment and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94%. &#160;The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $309,000 (RMB2,000,000) with the remaining annual principal payment of $1,320,000 (8,000,000 RMB) being due in July 2016. As of March 31, 2016, the Company had no additional amounts available to it under this facility.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Principal payments required for the next five years as of March 31, 2016 are as follows:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 70%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d86b7b53982942bd8ecfdded745fa501" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Twelve Months Ending March 31,</div>
</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2017</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,550,893</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2018</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1,240,714</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2019</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,326,339</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2020</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,326,339</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2021</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,326,339</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2022</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2,326,339</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 85%; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 12%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">12,096,962</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter">&#160;</div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value of</font>&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Construction Loan Facility</font> &#8211; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 9 - INCOME TAXES</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Undistributed earnings of Helpson, the Company's foreign subsidiary, since its acquisition, amounted to approximately $38.5 million as of March 31, 2016. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through March 31, 2016, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2012 through December 31, 2015 and the Chinese income tax return for the year ended December 31, 2015 are open for possible examination.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">On March 16, 2007, the National People's Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&#160;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&#160;&#160;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">13</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt" id="DSPFPageHeader">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="9a529654189e4412ab06603f099ed6f8" border="0" cellspacing="0" cellpadding="0" align="center">
<tr>
<td style="WIDTH: 40.33%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 10.12%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 49.55%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Enterprise Income </div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 40.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year</div>
</td>
<td style="WIDTH: 10.12%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; WIDTH: 49.55%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold">Tax Rate&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2015</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 49.55%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">15%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 40.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2016</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 10.12%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 49.55%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">15%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 40.33%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Thereafter</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 10.12%; VERTICAL-ALIGN: top">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 49.55%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">25%</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt" id="DSPFPageFooter"></div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The provision for income taxes consisted of the following:</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5595c3349fdd4ebc9898ba0846689c4a" cellspacing="0" cellpadding="0">
<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="6">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Three Months Ended March 31,</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2015</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Current</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Deferred</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">22,828</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">19,284</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 76%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total income tax expense</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">22,828</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">19,284</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 10.25pt">&#160;</div>

<div style="LINE-HEIGHT: 10.25pt">As of March 31, 2016, the Company had net operating loss carryforwards for PRC tax purposes of approximately $35.5 million which are available to offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $4.1 million which are available to offset future taxable income, if any, through 2036.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&#160;&#160;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&#160;&#160;Management considers projected future taxable income and tax planning strategies in making this assessment.&#160;&#160;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2016 and December 31, 2015.&#160;&#160;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $12,897,790 and $12,798,572 as of March 31, 2016 and December 31, 2015, respectively.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 10 &#8211; FAIR VALUE MEASUREMENTS</font></div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. Level 2 &#8211; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &#8211; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The banker's acceptances are recorded at cost which approximates fair value.&#160;&#160;The Company held the following assets and liabilities recorded at fair value as of March 31, 2016:</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="aa8d97ce9bb740ddb5a5b221c0541060" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="10">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fair Value Measurements at</div>
</td>
<td style="TEXT-ALIGN: left; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="10">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Reporting Date Using&#160;&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</div>
</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">March 31, 2016</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 1</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 2</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; VERTICAL-ALIGN: top" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Level 3</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 52%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Banker's acceptances</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">116,317</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">116,317</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 52%; VERTICAL-ALIGN: top" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Total</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">116,317</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">116,317</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">14</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHINA PHARM HOLDINGS, INC.</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THREE MONTHS ENDED MARCH 31, 2016 and 2015</div>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
 &#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 11 - STOCKHOLDERS' EQUITY</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company's Board.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Employee Stock Options</u></div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2010 Incentive Plan</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">On November 12, 2010, the Company's Board of Directors adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&#160; No options were outstanding as of March 31, 2016 under the Plan.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;There were no securities issued from the Plan during each of the three months ended March 31, 2016 and 2015.&#160;</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three months ended March 31, 2016 and 2015.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company's common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 12 &#8211; COMMITMENTS AND CONTINGENCIES</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Economic environment </font><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">- </font>Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTE 13 &#8211; CONCENTRATIONS</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the three months ended March 31, 2016, no customer accounted for more than 10% of sales and&#160;three customers accounted for 28.5%, 11.4% and 11.0% &#160;of accounts receivable, respectively.&#160;No supplier accounted for greater than 10% of raw material purchases.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the three months ended March 31, 2015, one customer accounted for 19.7% of sales and one supplier accounted for 29.5% of raw material purchases and one customer accounted for 17.3% of accounts receivable.</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="LINE-HEIGHT: 14.4pt; BACKGROUND-COLOR: #ffffff">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">15</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">
<div id="DSPFPageHeader">
<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other periodic filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Business Overview &amp; Recent Developments</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The China Food and Drug Administration ("CFDA") promulgated <font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Good Manufacturing Practices for Pharmaceutical Products</font>&#160;<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2010 revised version</font>) (the "New GMP Standards") on February 12, 2011, which became effective on March 1, 2011.&#160;The New GMP Standards outlines the basic principles and standards for the manufacturing of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Pursuant to those mandatory requirements, the upgrading of our two sterilization production lines was required to be completed by the end of 2013; and the upgrading of our oral solution production lines was required to be completed by the end of 2015. Per CFDA, there were over 7,000 Chinese pharmaceutical enterprises by the end of 2015. The competition in this industry is fierce. One of the key controls adopted by the CFDA to promote industry consolidation and improve the quality of drugs was to implement the New GMP Standards. Although 2015 was the deadline for new GMP upgrading, there were only approximately 1,200 pharmaceutical companies which received the new GMP certificates by the end of 2014.&#160; Insiders believed that thousands of pharmaceutical companies might be forced to shut down or merge with other entities due to unfulfilled new GMP upgrading.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Under this unfavorable economic environment, we aggressively promoted our sales efforts since 2015. Due to the fact that we only received new GMP certificate for the injectable production lines at our new manufacturing facility in November 2014, we missed drug biddings in several provinces prior to November 2014. Those missed biddings negatively impacted our market shares previously secured in those provinces, and dragged our sales in 2015.&#160; Nevertheless, we continued concentrating on enhancing our fundamentals. In January and December 2015, we completed the upgrading and received new GMP certificates for the tablet and capsule production lines, and cephalosporin production lines at our old factories, respectively. The upgrading of these oral solution production lines was completed before the deadline, which positioned us to better meet market demand.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">16</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In order to support our existing products package, we have remained focused on pipeline development. We have experienced delays in obtaining approval for products in our pipeline due to revisions and enhancements in the approval criteria and processes issued by CFDA. These revisions result in additional supplemental materials and trials, higher cost, and longer approval time for certain applications. On March 5, 2016, the PRC State Council issued "<font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Opinions on Carrying out Consistency Evaluation on Quality and Efficacy of Generic Drugs</font>" (the "Opinions"). The Opinions require all chemical generic pipeline products to carry out "Consistency Evaluation" before final registration approval, which will further prolong the registration process. "Consistency Evaluation" requires currently marketed generic products to prove consistency in terms of quality, therapeutic effect, and substitutability during clinical trials with the original drug, which could enhance development of the&#160;pharmaceutical industry, ensure drug safety and effectiveness, promote the upgrading and restructuring of the pharmaceutical industry, and improve international competitiveness.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The status of our pipeline products remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31, 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Trends</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pharmaceutical is one of the most stable industries for future growth. However, its growth rate has declined year by year recently due to certain negative impacts such as medical insurance cost control. According to the medicine research data firm Sinohealth CMH, the 2015 Chinese pharmaceutical market reached a scale of RMB1.38 trillion (in terms of retail pricing), which increased by 7.6% compared to prior year. The growth rate declined by 5.6% compared to prior year, and was a record low in a decade. National Bureau of Statistics data shows that the overall main business revenue of China's pharmaceutical industry was RMB2.55 trillion in 2015, increased by 9.1% compared to RMB 2.33 trillion in 2014. However, for 2015, the annual growth rate is 9.1%, declined by 3.8% compared to 12.9% in 2014.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-BOTTOM: 7.5pt; MARGIN-LEFT: 1.5pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.5pt">The Chinese People's Political Consultative Conference (CPPCC) held a special meeting titled "To Deepen Health Reform" in Beijing on May 10, 2016 with National Development and Reform Commission (NDRC), Ministry of Finance (MOF), CFDA and other governmental departments participated. The participants concluded that China's healthcare reform had achieved significant initial results; however, the results so far had not fulfilled people's expectations. To be specific, the problems of inadequate and overly expensive medical services have not been fundamentally resolved. The participants therefore suggested:</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="253a82ec111b491f8d9190c7ac3fc706" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">(a)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">deepen reform of management model and compensation system of healthcare institutions</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="4ebaf4a689ca4e509df995f5d1d8514e" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">(b)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">promote the reform of medical insurance payment</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="9dbb2d27906440369aaf10da96df66a2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">(c)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">strengthen basic-level health care services, and promote the establishment of diagnosis and treatment hierarchy</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="228229fbe2ec4c5ea18de2b5e7658d75" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">(d)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">strengthen medical and health information technology to promote the realization of information sharing among different healthcare institutions</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="add28f7374624fae9c96a2e2e46951b2" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-LEFT: 36pt; FONT-SIZE: 10pt">(e)</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">strengthen the leadership of healthcare reform to reduce cost and form synergy</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.5pt">We believe that Chinese pharmaceutical enterprises have the opportunity to enjoy a "golden decade" along with China's economic growth, consumption upgrade, aging population, healthcare reform progress, and urbanization; however, the challenges remain due to low industrial concentration, small company size, unfulfilled financing leverage, industrial upgrading and M&amp;A demands.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.5pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; MARGIN-RIGHT: 1.5pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">17</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt; MARGIN-BOTTOM: 6pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-BOTTOM: 6pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 1.5pt">Results of Operations for the Three months ended March 31, 2016</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Under the industrial reform and modification background guided by the government's healthcare reform policies, we actively completed the new GMP upgrading for the majority of our current production facility, and have been aggressively promoting our sales to regain our original market shares. Although there was no immediate reversal of sales trends so far due to the special characteristics of pharmaceutical industry, we strongly believe that our current operations and financial position will allow us to have a foundation for steady business growth in the future.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net loss for the three months ended March 31, 2016 was $1.6 million, compared to net loss of $4.1 million for three months ended March 31, 2015. Our net loss for the three months ended March 31, 2016</font> was significantly less than that in the same period 2015, which was mainly due to the decrease in bad debt expense.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Revenue</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Revenue decreased by 36.1% to $3.6 million for the three months ended March 31, 2016, as compared to $5.7 million for the three months ended March 31, 2015. This decrease was primarily caused by several missed provincial tenders back in 2014 due to the fact that our new GMP certificates were not received until November 2014, therefore we lost related market share and negatively impacted sales afterwards. To be specific, the original tender practice actually lasted until April 2015 given the necessary process and timing of tender and therefore did not create significant negative impact on the sales in first quarter 2015. Therefore, the sales decrease in the first quarter of 2016 compared to its corresponding period in 2015 reflected the outcome of that event. In addition, the government's healthcare-cost-controls also maintained continuous pressure upon our sales.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Set forth below are our revenues by product category in millions USD for the three months ended March 31, 2016 and 2015:</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="89a3a30671954f79be7cc02895c46c91" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid; WIDTH: 34.11%; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" rowspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Product Category</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 38.48%; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended March 31,</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid; WIDTH: 15.02%; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" rowspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net Change</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid; WIDTH: 12.39%; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" rowspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">% Change</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 4px double; WIDTH: 19.71%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2016</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; WIDTH: 18.77%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2015</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 34.11%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">CNS, Cerebral &amp; Cardio Vascular</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 19.71%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$&#160;0.60&#160;&#160;&#160; </div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 18.77%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$&#160;0.70&#160;&#160;&#160; </div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 15.02%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$&#160;-0.10&#160;&#160;&#160; </div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 12.39%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-14%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 34.11%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Anti-Viro/Injection &amp; Respiratory</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 19.71%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2.53</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 18.77%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4.05</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 15.02%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-1.52</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 12.39%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-38%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 34.11%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Digestive Diseases</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 19.71%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">0.19</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 18.77%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">0.14</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 15.02%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">0.05</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 12.39%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">36%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 34.11%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Other</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 19.71%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">0.31</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 18.77%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">0.80</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 15.02%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-0.49</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 12.39%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">-61%</div>
</td>
</tr>
</table>

<div id="DSPFPageFooter"></div>
</div>

<div style="LINE-HEIGHT: 12.55pt">&#160;</div>

<div style="LINE-HEIGHT: 12.55pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The most significant revenue decrease in terms of dollar amount was in our "</font>Anti-Viro/Infection &amp; Respiratory" product category, which generated $2.53 million in sales revenue in the first quarter 2016 compared to $4.05 million a year ago, a decrease of $1.52 million. <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">This decrease was mainly due to the decrease in sales of Cefaclor dispersible tablets in this category, which was caused by market fluctuation .</font></div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Sales in the "Other" category decreased by $0.49 million to $0.31 million in the first quarter 2016 compared to $0.80 million in the same period 2015, which was mainly due to the decrease in sales of Vitamin B6, primarily affected by the market loss due to the missed drug tenders back in late 2014. Our "Digestive Diseases" category generated $0.19 million of sales in the first quarter 2016, compared to $0.14 million in the same period previous year, which represented an increase of $0.05 million.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">18</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Sales in our "CNS Cerebral &amp; Cardio Vascular" category decreased by $0.10 million to $0.60 million in the first quarter 2016 compared to $0.70 million in the same period 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="c0f97043c0664b4eb7bbb6233af7f686" cellspacing="0" cellpadding="0">
<tr>
<td style="BORDER-BOTTOM: #000000 4px double; BORDER-LEFT: #000000 2px solid; WIDTH: 46.51%; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" rowspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Product Category</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 53.49%; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 2px solid; BORDER-RIGHT: #000000 2px solid" colspan="2">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Three Months Ended March 31,</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 4px double; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2016</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2015</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 46.51%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">CNS, Cerebral &amp; Cardio Vascular</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">17%</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">12%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 46.51%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Anti-Viro/ Infection &amp; Respiratory</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">70%</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">71%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 46.51%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Digestive Diseases</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">5%</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3%</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 46.51%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Other</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">9%</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #ffffff; WIDTH: 26.75%; VERTICAL-ALIGN: bottom; BORDER-RIGHT: #000000 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">14%</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For the three months ended March 31, 2016, revenue breakdown by product category remained close to that of the prior year. Sales of the "Anti-Viro/Infection &amp; Respiratory" products category represented 70% and 71% of total sales in the three months ended March 31, 2016 and 2015. The "CNS, Cerebral &amp; Cardio Vascular" category represented 17% and 12% of total sales in the three months ended March 31, 2016 and 2015. The "Digestive Diseases" category represented 5% of total revenue in first quarter 2016 compared to 3% in first quarter 2015.&#160; The "Other" category represented 9% and 14% of revenues in the three months ended March 31, 2016 and 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cost of Revenue</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">For the three months ended March 31, 2016, our cost of revenue was $3.1 million, or 84.4% of total revenue, which represented a decrease of $1.4 million from $4.4 million, or 77.9% of total revenue, in the same period 2015. The decrease in cost of revenue during first quarter 2016 was due to the revenue decrease. The decrease in gross profit margin for the three months ended March 31, 2016 compared to the same period last year was mainly caused by the decrease in sales prices of certain products due to market fluctuation.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Inventory Obsolescence</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We have had decreases in the sales estimates between the time when raw materials were purchased and the time when the sales performance is realized for certain products. We have also assessed the market value of our raw materials. As a result, we determined that certain inventory was slow moving or obsolete. Based on the developed estimates as of March 31, 2016 and 2015, we recognized an additional inventory obsolescence expense of ($0.1) million and $0.2 million for the three months ended March 31, 2016 and 2015, respectively.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Gross Profit and Gross Margin</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Gross profit for the three months ended March 31, 2016 was $0.6 million, compared to $1.1 million in the same period 2015. Our gross profit margin in first quarter 2016 was 17.6% compared to 18.6% in the same period 2015. Without the effect of inventory obsolescence, management estimates that our gross profit would have been approximately 15.6% in the first quarter 2016 and 22.1% in the first quarter 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">On May 5, 2015, the National Development and Reform Commission issued "Notice on Enhancing Drug Price Reform" with the National Health and Family Planning Commission, Human Resources and Social Security and other departments, announced to cancel the government pricing upon the majority of drugs from June 1, 2015, and to improve drug purchasing mechanism, strengthen the medical insurance cost-control, enhance medical practices and price behavior regulation, and establish a market-oriented pricing mechanism for drugs. Going forward, under the macro-environment of medical insurance cost-control, we expect to see continued pricing pressures on most products.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">19</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling Expenses</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our selling expenses for the three months ended March 31, 2016 and 2015 were both $1.0 million, <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">which accounted for 26.6% and 17.4% of the total revenue in first quarter 2016 and 2015 respectively.&#160;&#160;Due to many adjustments in our selling processes under healthcare reform policies, despite the decrease in sales, we still need to maintain personnel and continue our sales activity to support the sales and collection of accounts receivable.</font></div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General and Administrative Expenses</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our general and administrative expenses for the three months ended March 31, 2016 were $0.3 million, compared to $0.5 million in the three months ended March 31, 2015. General and administrative expenses accounted for 8.8% and 8.3% of our total revenues in first quarter 2016 and 2015, respectively.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development Expense</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our research and development expenses for the three months ended March 31, 2016 were $0.1 million, a decrease of $0.1 million from $0.2 million in the three months ended March 31, 2015. Research and development expenses accounted for 2.6% and 2.8% of our total revenues in the first quarter 2016 and 2015, respectively.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bad Debt Expense</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our bad debt expense for the three months ended March 31, 2016 was $0.6 million, compared to $3.2 million in the three months ended March 31, 2015. The decrease was due to having majority of accounts receivable balance fully allowed in 2014 and 2015 under the Company's revised allowance policy as they were over 720 days old.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">In general, our normal credit or payment terms extended to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon.<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</font>Our customers are <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">primarily pharmaceutical</font> distributors who sell our products to mostly government-backed hospitals. Therefore, the aging of our receivables from our customers tend to be long.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $5.8 million and $5.6 million as of March 31, 2016 and December 31, 2015, respectively.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of March 31, 2016 and December 31, 2015:</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="81925b2985d04854b08d1ce77386a598" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 14.29%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 28.57%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">March 31,</div>
</td>
<td style="WIDTH: 3.7%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 28.57%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">December 31,</div>
</td>
</tr>

<tr>
<td style="WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="WIDTH: 14.29%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 28.57%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2016</div>
</td>
<td style="WIDTH: 3.7%; VERTICAL-ALIGN: bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 28.57%; VERTICAL-ALIGN: bottom" colspan="2">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2015</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">1 - 90 Days</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">3.2%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4.0%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">90 - 180 Days</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2.7%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">2.2%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">180 - 360 Days</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">4.2%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">7.9%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">360 - 720 Days</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">16.1%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">14.6%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&gt; 720 Days</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">73.8%</div>
</td>
<td style="BACKGROUND-COLOR: #cceeff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">71.3%</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 24.87%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Total</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">100.0%</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 3.7%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; WIDTH: 14.29%; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">100.0%</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Our bad debt allowance estimate is currently the sum of 10% of accounts receivable that are less than 365 days old, 70% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">We recognize bad debt expense per actual write-offs as well as the changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $29.6 million and $28.6 million as of March 31, 2016 and December 31, 2015, respectively. The changes in the allowance for doubtful accounts during the years ended March 31, 2016 and 2015 were as follows:</div>

<div>&#160;</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="edd20c2dba7b4541aade6bd6ac6bb1c1" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: center; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="5">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the Three Months Ended&#160;</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom" colspan="5">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">March 31,&#160;&#160;</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="PADDING-BOTTOM: 2px; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;2016</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;2015</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance, Beginning of Period</div>
</td>
<td style="WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="TEXT-ALIGN: right; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">28,644,398</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="TEXT-ALIGN: right; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">44,347,451</div>
</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Bad debt expense</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;&#12288;581,300</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom" colspan="3">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;&#12288;3,200,003</div>
</td>
<td style="TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Foreign currency translation adjustment</div>
</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">&#160;373,005</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;&#12288;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom">&#160;220,035</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Balance, End of Period</div>
</td>
<td style="PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 38%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#12288;</div>
</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">29,598,703</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">$</div>
</td>
<td style="BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff; WIDTH: 9%; VERTICAL-ALIGN: bottom" valign="bottom">
<div style="LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">44,767,489</div>
</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff; WIDTH: 1%; VERTICAL-ALIGN: bottom" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Loss from Operations</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our operating loss for the three months ended March 31, 2016 was $1.3 million, compared to $3.8 million in the same period 2015.&#160; The decrease in operating loss for this period is mainly due to the decrease in bad debt expense.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 21.5pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Interest Expense</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Interest expense for the three months ended March 31, 2016<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt"> was $0.2 million, compared to $0.3 million in the same period 2015, which represented a decrease of $0.1 million.</font></div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Income Tax Expense</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the three months ended March 31, 2016 and 2015, our income tax rate was 15%. Income tax expense was ($0.02) million both for the three months ended March 31, 2016 and 2015, respectively. We renewed our "National High-Tech Enterprise" status from the PRC government in the third quarter of 2013. With this designation, for the years ending December 31, 2014, 2015 and 2016, we enjoy a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Loss</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net Loss for three months ended March 31, 2016 was $1.6 million, compared to net loss of $4.1 million for the three months ended March 31, 2015</font>. The reduction in net loss was mainly due to the decrease in bad debt expense, which was partially offset by the decreased revenue.</div>

<div style="LINE-HEIGHT: 12.55pt">&#160;</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
 &#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">20</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">For the three months ended March 31, 2016, loss per basic and dilu</font>ted common share was $0.04, compared to loss per basic and diluted share of $0.09 for the three months ended March 31, 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The number of basic and diluted weighted-average outstanding shares used to calculate loss per s<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">hare was 43,579,557 for both the three months ended March 31, 2016 and 2015.</font></div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our principal sources of liquidity are cash generated from operations and short-term bank loans.&#160;Our cash and cash equivalents was $7.3 million, which represents 7.5% of our total assets as of March 31, 2016, as compared to $6.2 million, which represents 6.4% of our total assets as of December 31, 2015. All of the $7.3 million of cash and cash equivalents as of March 31, 2016 is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, we had a principal balance of $4.7 million in short-term bank loans. This loan is due on October 19, 2016. In addition, we entered into an eight-year construction loan facility with a bank on September 21, 2013. The total loan facility amount is RMB80,000,000 (approximately $13 million), which had been fully utilized through May 7, 2014. The current portion of the construction loan facility is $1.6 million as of March 31, 2016. Both the short-term bank loan and the construction loan facility are from the same bank. The cash flow generated from operating activities was used to fund the remaining construction of our GMP upgrading project in our new facility.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Based on our current operating plan, management believes that our cash provided by operations will be sufficient to meet our working capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and the remaining new GMP upgrading related construction and equipment in our prior facility for the next twelve months. However, if circumstances change and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional financing as necessary for expansion purposes and when we believe market conditions are most advantageous, which may include debt and/or equity financing.&#160;&#160;There can be no assurance that any additional financing will be available on acceptable terms, if at all.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Operating Activities</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Net cash provided by operating activities was $1.3 million in the three months ended March 31, 2016 compared to ($2,239) for the three months ended March 31, 2015. This is mainly due to lower net loss and the outcome of the changes in our sales strategy: we enhanced the control of sales on credit, therefore improved the collection of accounts receivable and advances from customers; and we also enhanced the control over accounts payable in this period.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, our accounts receivable was $4.8 million, compared to $5.9 million as of December 31, 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, net inventory was $9.9 million, remaining close to $9.7 million as of December 31, 2015.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="LINE-HEIGHT: 12.55pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">21</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 12.55pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investing Activities</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">During the three months ended March 31, 2016, net cash used in investing activities was $39,248, compared to $47,106 for the three months ended March 31, 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Financing Activities</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Cash flow used in financing activities was ($305,835) in the three months ended March 31, 2016, while there was no comparable activity incurred in the three months ended March 31, 2015.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies' registered capital prior to their remittance of funds out of the PRC.&#160;&#160;Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends.&#160;As of March 31, 2016 and December 31, 2015, the net assets of Helpson were $67,294,0000 and $68,240,000 respectively.&#160;&#160;Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson's net assets that were designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were $8,145,000 and $8,145,000 (50% of registered capital) as of March 31, 2016 and December 31, 2015 respectively.&#160;Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 12.1% and 11.9%, respectively, of its total net assets as of March 31, 2016 and December 31, 2015, this reserve does not have a major impact on our liquidity.&#160;&#160;There were no allocations to the statutory surplus reserve accounts during the three months ended March 31, 2016.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC.&#160;&#160;Our businesses and assets are primarily denominated in RMB.&#160;&#160;All foreign exchange transactions take place either through the People's Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People's Bank of China.&#160;Approval of foreign currency payments by the People's Bank of China or other regulatory institutions requires submitting a payment application form together with applicable invoices and signed contracts.&#160;These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of Helpson, our PRC subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, we did not have any off-balance sheet arrangements.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commitments</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">As of March 31, 2016, we were obligated to pay laboratories and others approximately $4.8 million over approximately the next four years upon completion of the various phases of contracts to provide CFDA production approval of medical formulas.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 12.55pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, "Organization and Significant Accounting Policies", is incorporated herein by reference.</div>

<div style="LINE-HEIGHT: 12.55pt"><br style="LINE-HEIGHT: 12.55pt">
</div>

<div id="DSPFPageFooter">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 10.25pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"></div>

<div style="LINE-HEIGHT: 10.25pt"><br style="LINE-HEIGHT: 10.25pt">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">22</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 3. Quantitative and Qualitative Disclosures about Market Risk</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">As a <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>smaller reporting company<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font> as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 4. Controls and Procedures</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Evaluation of Disclosure Controls and Procedures</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>disclosure controls and procedures<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font> (as defined in the Securities Exchange Act of 1934 (the <font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>Exchange Act<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">"</font>) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission<font style="FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">'</font>s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2016.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Changes in Internal Controls over Financial Reporting</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II OTHER INFORMATION</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 6. Exhibits</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The exhibits required by this item are set forth in the Exhibit Index attached hereto.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 9.1pt; FONT-FAMILY: 'Times New Roman', Times, serif; COLOR: #000000; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div id="DSPFPageFooter"></div>

<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">23</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>

<div id="DSPFPageHeader"></div>
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="9a7896f28e6a416e955e3872c2f787ea" cellspacing="0" cellpadding="0">
<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">CHINA PHARMA HOLDINGS, INC.</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 16, 2016</div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">By: <font style="BACKGROUND-COLOR: #fefefe; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>/s/ Zhilin Li</u></font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Title: President and Chief Executive Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal executive officer)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 16, 2016</div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">By: <font style="BACKGROUND-COLOR: #fefefe; FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>/s/ Zhilin Li</u></font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Title: Interim Chief Financial Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal financial officer and principal</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">accounting officer)</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>

<tr>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
<td style="BACKGROUND-COLOR: #fefefe; WIDTH: 50%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">24</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT INDEX</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>No.</u></font>&#160;<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Description</u></font></div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">31.1 - Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">31.2 - Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">32.1 - Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.INS - XBRL Instance Document</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.SCH - XBRL Taxonomy Extension Schema Document</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.DEF - XBRL Taxonomy Extension Definition Linkbase Document</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.LAB - XBRL Taxonomy Extension Label Linkbase Document</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="TEXT-ALIGN: center" id="DSPFPageNumberArea"><font style="FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 8pt; FONT-WEIGHT: normal" id="DSPFPageNumber">25</font></div>

<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div id="DSPFPageFooter"></div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securities Transfer Corp
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.1</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRINCIPAL EXECUTIVE OFFICER</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SARBANES-OXLEY ACT OF 2002</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">I, Zhilin Li certify that:</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="77dd69cb7f8745c8a30f191964ac06ac" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="326bd88dd3f14abd853f2ccf8db31eb3" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="6ca4cbae9f96422fa6b0a9c5e1a5ceb6" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="d9d56717d7654209865917aaface7e31" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="3d140013cbc7492d9d3ec282f9878ae6" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 16, 2016</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>/s/ Zhilin Li</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Title: Chief Executive Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal executive officer)</div>

<div id="DSPFPageFooter"></div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securities Transfer Corp
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div id="DSPFPageHeader"></div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="5bc3f3bd8110451d96499c5405c875e0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 31.2</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION OF</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PRINCIPAL FINANCIAL OFFICER</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 302</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">OF THE SARBANES-OXLEY ACT OF 2002</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">I, Zhilin Li, certify that:</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="afce3a8c5f664b8f95abde7ffffbf57a" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">1.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="daec4b31a82f40458898c92c7fc9280d" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="fea4bc649fb44e289ad01fb8b473d5b7" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">3.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="a38466f878ef49498bc4cea2134b3e5a" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">4.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="aac4f3608fce46128c9970c08190b106" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">5.</div>
</td>
<td style="WIDTH: 92.78%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Date: May 16, 2016</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>/s/ Zhilin Li</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Title: Interim Chief Financial Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal financial officer and principal accounting officer)</div>

<div id="DSPFPageFooter"></div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Securities Transfer Corp
    Document created using EDGARfilings PROfile 4.0.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 32.1</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTIFICATION PURSUANT TO</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">18 U.S.C. SECTION 1350,</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AS ADOPTED PURSUANT TO</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The undersigned hereby certifies, in her capacity as Chief Executive Officer and interim Chief Financial Officer of China Pharma Holdings, Inc. (the "Company"), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(1) The Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Dated: May 16, 2016</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>/s/ Zhilin Li</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">President and Chief Executive Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal executive officer)</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>/s/ Zhilin Li</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Name: Zhilin Li</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Title: Interim Chief Financial Officer</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">(principal financial officer and principal</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">accounting officer)</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This certification accompanies each Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of &#167;18 of the Securities Exchange Act of 1934, as amended.</div>

<div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</div>

<div id="DSPFPageFooter"></div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>cphi-20160331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<xbrl xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2015-01-31' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20160331' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrli='http://www.xbrl.org/2003/instance'>
	<link:schemaRef xlink:type='simple' xlink:href='cphi-20160331.xsd' />
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 1 &amp;#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &amp;#150; &lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&apos;s outstanding shares of common stock on December 21, 2012.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &quot;Catalogue&quot;) jointly issued by China&apos;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2015 version, effective April 10, 2015) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &quot;FIE&quot;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&apos;s business.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&apos;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&apos;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation &lt;/i&gt;&lt;/b&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Helpson&apos;s functional currency is the Chinese Renminbi. Helpson&apos;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&apos;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&apos; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;The methodology used to prepare for the Company&apos;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&quot;Management&quot;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/b&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&apos;s acceptances purchased with maturities of three months or less.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $581,300&amp;nbsp;and $3,200,003 for the three months ended March 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of March 31, 2016, the Company had trade accounts receivable amounting to $16,853,716 from sales that occurred more than one year from that date, which the Company believes are collectable.&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt; &amp;#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt; &amp;#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled ($71,786) and $201,097 for the three months ended March 31, 2016 and 2015, respectively. The Company recognized an inventory obsolescence reserve of $6,696,224 and $8,417,095 as of March 31, 2016 and December 31, 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2016 and 2015.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&amp;nbsp; Revenue is deferred when collectability is not considered to be reasonably assured.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $93,433 and $160,828 for the three months ended March 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Three Months&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Ended March 31,&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Net loss&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(1,530,068&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,069,290&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;There were no potential dilutive common shares outstanding during the three months ended March 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&apos; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&apos;s deposits may be at a higher risk of loss.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services.&amp;nbsp; In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In January 2016, the FASB issued Accounting Standards Update 2016-01,&amp;nbsp;&quot;&lt;i&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;.&quot; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on its financial statements.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white&apos;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&apos;s financial position, result of operations or cash flows.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 2 &amp;#150; INVENTORY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;12,329,926&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;14,699,736&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Work in process&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;618,329&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3,665,108&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3,380,109&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;16,613,363&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;18,079,845&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(6,696,224&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(8,417,095&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total Inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;9,917,139&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;9,662,750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;436,836&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;433,956&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;10,627,311&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;10,557,234&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;27,521,628&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;27,325,440&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;268,279&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;242,860&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;259,575&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;256,679&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;39,113,629&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;38,816,169&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(10,286,937&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(9,422,912&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;28,826,692&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;29,393,257&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; style=&apos;width:50%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:69.64%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:3.36%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;Life - years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;20 - 49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended March 31, 2016 and 2015, depreciation expense was $790,254 and $854,485, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 4 - INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (&quot;CFDA&quot;). The Company did not obtain CFDA production approval for any medical formula during the three months ended March 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&amp;nbsp;&amp;nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $66,941 and $96,726 for the three months ended March 31, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&apos;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&apos;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2016 and 2015.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; style=&apos;width:50%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5,235,603&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5,201,079&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,456,837&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,360,004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;778,766&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;841,075&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 5 &amp;#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Prior to entering into contracts with the Company, laboratories typically are required to complete all&amp;nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA&apos;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&amp;nbsp;&amp;nbsp;the Company signs the medical formula contracts.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;As of March 31, 2016, the Company was obligated to pay laboratories and others approximately $4,785,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 6 &amp;#150; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;A member of the Company&apos;s board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2016 and December 31, 2015 which are recorded as other payables &amp;#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&amp;nbsp;&amp;nbsp;Total interest expense of $3,386 was recognized for each of the three months ended March 31, 2016 and 2015.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 7 &amp;#150; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In November 2014, the Company entered into a new line of credit with the same bank on identical terms.&amp;nbsp;&amp;nbsp; Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government&apos;s current short term rate of 5.6%). In addition, the Company&apos;s Chief Executive Officer and Chair of the board of directors personally guaranteed the new line of credit. In November 2015 the Company renewed its line of credit in the amount of RMB 30,000,000 with the same bank.&amp;nbsp;&amp;nbsp;The line of credit is payable in two equal installments of RMB 15,000,000 ($2.31 million) payable on September 16, 2016 and October 19, 2016.&amp;nbsp;&amp;nbsp;Advances on the line of credit are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 5.06% (based upon 110% of the PRC government&apos;s current short term rate of 4.6%). In addition, the Company&apos;s Chief Executive Officer and Chairman of the Board personally guaranteed the line of credit.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of March 31, 2016 and December 31, 2015 ($4,652,678 as of March 31, 2016 and $4,621,998 as of December 31, 2015).&amp;nbsp;&amp;nbsp;The Company has no additional amounts available to it under this line of credit.&amp;nbsp;&amp;nbsp;This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets as of March 31, 2016.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Fair Value of&lt;/i&gt;&lt;/b&gt;&amp;nbsp;&lt;b&gt;&lt;i&gt;Notes Payable&lt;/i&gt;&lt;/b&gt; &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of March 31, 2016 and December 31, 2015 approximated their fair value because of the immediate or short-term maturity of these financial instruments and because the underlying instruments bear interest rates that approximated current market rates.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:LongTermDebtTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 8 &amp;#150; CONSTRUCTION LOAN FACILITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company obtained a construction loan facility in the amount of RMB 80,000,000 from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same bank that currently provides the line of credit as discussed in Note 7.&amp;nbsp;&amp;nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company&apos;s new production facility and the included production line equipment and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government&apos;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94%.&amp;nbsp; The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $309,000 (RMB2,000,000) with the remaining annual principal payment of $1,320,000 (8,000,000 RMB) being due in July 2016. As of March 31, 2016, the Company had no additional amounts available to it under this facility.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Principal payments required for the next five years as of March 31, 2016 are as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;70%&quot; style=&apos;width:70%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:85%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Twelve Months Ending March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;1,550,893&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;1,240,714&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2022&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;12,096,962&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Fair Value of&lt;/i&gt;&lt;/b&gt;&amp;nbsp;&lt;b&gt;&lt;i&gt;Construction Loan Facility&lt;/i&gt;&lt;/b&gt; &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:3pt 0in;line-height:10.25pt&apos;&gt;&lt;b&gt;NOTE 9 - INCOME TAXES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;Undistributed earnings of Helpson, the Company&apos;s foreign subsidiary, since its acquisition, amounted to approximately $38.5 million as of March 31, 2016. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the &quot;more-likely-than-not&quot; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through March 31, 2016, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2012 through December 31, 2015 and the Chinese income tax return for the year ended December 31, 2015 are open for possible examination.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;On March 16, 2007, the National People&apos;s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&amp;nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&amp;nbsp;&amp;nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; border=&quot;0&quot; style=&apos;width:50%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;Enterprise Income &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Tax Rate&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:3pt 0in;line-height:10.25pt&apos;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;22,828&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;19,284&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;&lt;b&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;22,828&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt;line-height:11.4pt&apos;&gt;19,284&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;As of March 31, 2016, the Company had net operating loss carryforwards for PRC tax purposes of approximately $35.5 million which are available to offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $4.1 million which are available to offset future taxable income, if any, through 2036.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&amp;nbsp;&amp;nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&amp;nbsp;&amp;nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2016 and December 31, 2015.&amp;nbsp;&amp;nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $12,897,790 and $12,798,572 as of March 31, 2016 and December 31, 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;b&gt;NOTE 10 &amp;#150; FAIR VALUE MEASUREMENTS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &amp;#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &amp;#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &amp;#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The banker&apos;s acceptances are recorded at cost which approximates fair value.&amp;nbsp;&amp;nbsp;The Company held the following assets and liabilities recorded at fair value as of March 31, 2016:&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;10&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;10&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Reporting Date Using&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;52%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Banker&apos;s acceptances&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;52%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 11 - STOCKHOLDERS&apos; EQUITY&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&apos;s Board.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;u&gt;Employee Stock Options&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;i&gt;2010 Incentive Plan&lt;/i&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;On November 12, 2010, the Company&apos;s Board of Directors adopted the Company&apos;s 2010 Incentive Plan (the &quot;Plan&quot;), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&amp;nbsp; No options were outstanding as of March 31, 2016 under the Plan.&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;There were no securities issued from the Plan during each of the three months ended March 31, 2016 and 2015.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three months ended March 31, 2016 and 2015.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company&apos;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;As of March 31, 2016, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;NOTE 12 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Economic environment &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Substantially all of the Company&apos;s operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company&apos;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&apos;s operations.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In addition, all of the Company&apos;s revenue is denominated in the PRC&apos;s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;&lt;b&gt;NOTE 15 &amp;#150; CONCENTRATIONS&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;For the three months ended March 31, 2016, no customer accounted for more than 10% of sales and&amp;nbsp;three customers accounted for 28.5%, 11.4% and 11.0%&amp;nbsp; of accounts receivable, respectively.&amp;nbsp;No supplier accounted for greater than 10% of raw material purchases.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;For the three months ended March 31, 2015, one customer accounted for 19.7% of sales and one supplier accounted for 29.5% of raw material purchases and one customer accounted for 17.3% of accounts receivable.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:NatureOfOperations contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Organization and Nature of Operations &amp;#150; &lt;/i&gt;&lt;/b&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&apos;s outstanding shares of common stock on December 21, 2012.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &quot;Catalogue&quot;) jointly issued by China&apos;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2015 version, effective April 10, 2015) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &quot;FIE&quot;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&apos;s business.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&apos;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&apos;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:ConsolidationPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Consolidation and Basis of Presentation &lt;/i&gt;&lt;/b&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Helpson&apos;s functional currency is the Chinese Renminbi. Helpson&apos;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&apos;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&apos; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:UseOfEstimates contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Accounting Estimates &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;The methodology used to prepare for the Company&apos;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&quot;Management&quot;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents &lt;/i&gt;&lt;/b&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&apos;s acceptances purchased with maturities of three months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:3pt 0in;line-height:10.25pt&apos;&gt;&lt;b&gt;&lt;i&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/i&gt;&lt;/b&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $581,300&amp;nbsp;and $3,200,003 for the three months ended March 31, 2016 and 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of March 31, 2016, the Company had trade accounts receivable amounting to $16,853,716 from sales that occurred more than one year from that date, which the Company believes are collectable.</us-gaap:ReceivablesPolicyTextBlock>
	<fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Advances to Suppliers and Advances from Customers&lt;/i&gt;&lt;/b&gt; &amp;#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt; &amp;#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled ($71,786) and $201,097 for the three months ended March 31, 2016 and 2015, respectively. The Company recognized an inventory obsolescence reserve of $6,696,224 and $8,417,095 as of March 31, 2016 and December 31, 2015, respectively.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Valuation of Long-Lived Assets&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2016 and 2015.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&amp;nbsp; Revenue is deferred when collectability is not considered to be reasonably assured.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt; &amp;#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/p&gt;</us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $93,433 and $160,828 for the three months ended March 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Loss per Common Share &lt;/i&gt;&lt;/b&gt;&lt;b&gt;- &lt;/b&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Three Months&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Ended March 31,&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Net loss&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(1,530,068&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,069,290&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;There were no potential dilutive common shares outstanding during the three months ended March 31, 2016 and 2015, respectively.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&apos; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&apos;s deposits may be at a higher risk of loss.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<fil:InterestRateRiskPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Interest Rate Risk&lt;/i&gt;&lt;/b&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/p&gt;</fil:InterestRateRiskPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services.&amp;nbsp; In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;In January 2016, the FASB issued Accounting Standards Update 2016-01,&amp;nbsp;&quot;&lt;i&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;.&quot; The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on its financial statements.&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white&apos;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&apos;s financial position, result of operations or cash flows.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Three Months&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Ended March 31,&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Net loss&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(1,530,068&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,069,290&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Effect of dilutive securities:&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Options&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;43,579,557&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Basic loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Diluted loss per share&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.04&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Inventory consisted of the following:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Raw materials&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;12,329,926&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;14,699,736&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Work in process&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;618,329&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Finished goods&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3,665,108&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3,380,109&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;16,613,363&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;18,079,845&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Obsolescence reserve&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(6,696,224&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(8,417,095&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total Inventory&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;9,917,139&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;9,662,750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Property and equipment consisted of the following:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&amp;nbsp;&lt;/p&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;436,836&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;433,956&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;10,627,311&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;10,557,234&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;27,521,628&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;27,325,440&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;268,279&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;242,860&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;259,575&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;256,679&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;39,113,629&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;38,816,169&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Less: accumulated depreciation&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(10,286,937&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(9,422,912&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Property and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;28,826,692&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;29,393,257&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<fil:UsefulLivesOfTheAssetsTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; style=&apos;width:50%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:69.64%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Asset&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:3.36%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;Life - years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Permit of land use&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;40 - 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Building&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;20 - 49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Plant, machinery and equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Motor vehicle&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5 - 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;69%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Office equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;3%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;27%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;3-5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</fil:UsefulLivesOfTheAssetsTableTextBlock>
	<fil:IntangibleAssetsMedicalFormulasTablesTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; style=&apos;width:50%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Gross carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5,235,603&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;5,201,079&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,456,837&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;(4,360,004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;66%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Net carrying amount&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;778,766&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;841,075&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</fil:IntangibleAssetsMedicalFormulasTablesTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Principal payments required for the next five years as of March 31, 2016 are as follows:&lt;/p&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;70%&quot; style=&apos;width:70%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:85%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Twelve Months Ending March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;1,550,893&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2018&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;1,240,714&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2019&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2020&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2021&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2022&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2,326,339&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;85%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;12,096,962&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;50%&quot; style=&apos;width:50%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:40.32%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.12%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.54%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Enterprise Income &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:40.32%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.12%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.54%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Tax Rate&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;15%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;40%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Thereafter&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;10%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;49%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt;</fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The provision for income taxes consisted of the following:&lt;/p&gt; &lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;6&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Three Months Ended March 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Current&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Deferred&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;22,828&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;19,284&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;76%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Total income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;22,828&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;19,284&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef='Y16Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;line-height:10.25pt;margin:3pt 0in&apos;&gt;The banker&apos;s acceptances are recorded at cost which approximates fair value.&amp;nbsp;&amp;nbsp;The Company held the following assets and liabilities recorded at fair value as of March 31, 2016:&lt;/p&gt; &lt;p style=&apos;margin:3pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; style=&apos;width:100%&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;10&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;10&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Reporting Date Using&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;March 31, 2016&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; colspan=&quot;2&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;52%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Banker&apos;s acceptances&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;52%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;Total&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;116,317&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&apos;border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:11.4pt;margin:0in 0in 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited decimals='INF' contextRef='E16Q1' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1 decimals='INF' contextRef='E16Q1' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1>
	<fil:PercetageOfAcquiredByOnnyInHelpson decimals='INF' contextRef='E16Q1' unitRef='Pure'>1.0000</fil:PercetageOfAcquiredByOnnyInHelpson>
	<us-gaap:InventoryRawMaterials decimals='INF' contextRef='E16Q1' unitRef='USD'>12329926</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryRawMaterials decimals='INF' contextRef='E15' unitRef='USD'>14699736</us-gaap:InventoryRawMaterials>
	<us-gaap:InventoryWorkInProcess decimals='INF' contextRef='E16Q1' unitRef='USD'>618329</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryWorkInProcess decimals='INF' contextRef='E15' unitRef='USD'>0</us-gaap:InventoryWorkInProcess>
	<us-gaap:InventoryFinishedGoods decimals='INF' contextRef='E16Q1' unitRef='USD'>3665108</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryFinishedGoods decimals='INF' contextRef='E15' unitRef='USD'>3380109</us-gaap:InventoryFinishedGoods>
	<us-gaap:InventoryGross decimals='INF' contextRef='E16Q1' unitRef='USD'>16613363</us-gaap:InventoryGross>
	<us-gaap:InventoryGross decimals='INF' contextRef='E15' unitRef='USD'>18079845</us-gaap:InventoryGross>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E16Q1' unitRef='USD'>-6696224</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E15' unitRef='USD'>-8417095</us-gaap:InventoryValuationReserves>
	<fil:TotalInventory decimals='INF' contextRef='E16Q1' unitRef='USD'>9917139</fil:TotalInventory>
	<fil:TotalInventory decimals='INF' contextRef='E15' unitRef='USD'>9662750</fil:TotalInventory>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E16Q1' unitRef='USD'>436836</us-gaap:LandAndLandImprovements>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E15' unitRef='USD'>433956</us-gaap:LandAndLandImprovements>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E16Q1' unitRef='USD'>10627311</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E15' unitRef='USD'>10557234</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E16Q1' unitRef='USD'>27521628</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E15' unitRef='USD'>27325440</us-gaap:MachineryAndEquipmentGross>
	<fil:MotorVehicleGross decimals='INF' contextRef='E16Q1' unitRef='USD'>268279</fil:MotorVehicleGross>
	<fil:MotorVehicleGross decimals='INF' contextRef='E15' unitRef='USD'>242860</fil:MotorVehicleGross>
	<fil:OfficeEquipment1 decimals='INF' contextRef='E16Q1' unitRef='USD'>259575</fil:OfficeEquipment1>
	<fil:OfficeEquipment1 decimals='INF' contextRef='E15' unitRef='USD'>256679</fil:OfficeEquipment1>
	<us-gaap:PropertyPlantAndEquipmentGross decimals='INF' contextRef='E16Q1' unitRef='USD'>39113629</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross decimals='INF' contextRef='E15' unitRef='USD'>38816169</us-gaap:PropertyPlantAndEquipmentGross>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E16Q1' unitRef='USD'>-10286937</fil:LessAccumulatedDepreciation>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E15' unitRef='USD'>-9422912</fil:LessAccumulatedDepreciation>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E16Q1' unitRef='USD'>28826692</fil:PropertyAndEquipmentNet>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E15' unitRef='USD'>29393257</fil:PropertyAndEquipmentNet>
	<fil:PermitOfLandUseMinimumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>40</fil:PermitOfLandUseMinimumLife>
	<fil:PermitOfLandUseMaximumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>70</fil:PermitOfLandUseMaximumLife>
	<fil:BuildingMinimumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>20</fil:BuildingMinimumLife>
	<fil:BuildingMaximumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>49</fil:BuildingMaximumLife>
	<fil:PlantMachineryAndEquipmentMinimumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>5</fil:PlantMachineryAndEquipmentMinimumLife>
	<fil:PlantMachineryAndEquipmentMaximumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>10</fil:PlantMachineryAndEquipmentMaximumLife>
	<fil:MotorVehicleMinimumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>5</fil:MotorVehicleMinimumLife>
	<fil:MotorVehicleMaximumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>10</fil:MotorVehicleMaximumLife>
	<fil:OfficeEquipmentMinimumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>3</fil:OfficeEquipmentMinimumLife>
	<fil:OfficeEquipmentMaximumLife decimals='INF' contextRef='E16Q1' unitRef='Pure'>5</fil:OfficeEquipmentMaximumLife>
	<fil:DepreciationExpensePropertyAndEquipment decimals='INF' contextRef='Y16Q1' unitRef='USD'>790254</fil:DepreciationExpensePropertyAndEquipment>
	<fil:DepreciationExpensePropertyAndEquipment decimals='INF' contextRef='Y15Q1' unitRef='USD'>854485</fil:DepreciationExpensePropertyAndEquipment>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y16Q1' unitRef='USD'>66941</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y15Q1' unitRef='USD'>96726</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E16Q1' unitRef='USD'>5235603</fil:GrossCarryingAmount>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E15' unitRef='USD'>5201079</fil:GrossCarryingAmount>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E16Q1' unitRef='USD'>-4456837</fil:AccumulatedAmortization>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E15' unitRef='USD'>-4360004</fil:AccumulatedAmortization>
	<fil:NetCarryingAmount decimals='INF' contextRef='E16Q1' unitRef='USD'>778766</fil:NetCarryingAmount>
	<fil:NetCarryingAmount decimals='INF' contextRef='E15' unitRef='USD'>841075</fil:NetCarryingAmount>
	<fil:CompanyWasObligatedToPayLaboratoriesAndOthers decimals='INF' contextRef='E16Q1' unitRef='USD'>4785000</fil:CompanyWasObligatedToPayLaboratoriesAndOthers>
	<fil:AdvancesOwingToBoardOfDirectors decimals='INF' contextRef='E16Q1' unitRef='USD'>1354567</fil:AdvancesOwingToBoardOfDirectors>
	<fil:AdvancesOwingToBoardOfDirectors decimals='INF' contextRef='E15' unitRef='USD'>1354567</fil:AdvancesOwingToBoardOfDirectors>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E15' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:TotalInterestExpense decimals='INF' contextRef='E16Q1' unitRef='USD'>3386</fil:TotalInterestExpense>
	<fil:TotalInterestExpense decimals='INF' contextRef='E15Q1' unitRef='USD'>3386</fil:TotalInterestExpense>
	<fil:RevolvingLineOfCreditWithABankRmb decimals='INF' contextRef='I151130' unitRef='USD'>30000000</fil:RevolvingLineOfCreditWithABankRmb>
	<fil:AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56 decimals='INF' contextRef='I151130' unitRef='Pure'>0.0616</fil:AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56>
	<fil:LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000 decimals='INF' contextRef='I160916' unitRef='USD'>2310000</fil:LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000>
	<fil:LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000 decimals='INF' contextRef='I161019' unitRef='USD'>2310000</fil:LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 decimals='INF' contextRef='E16Q1' unitRef='USD'>4652678</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000 decimals='INF' contextRef='E15' unitRef='USD'>4621998</fil:OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000>
	<fil:CompanyPrincipalPaymentRmb2000000 decimals='INF' contextRef='E16Q1' unitRef='USD'>309000</fil:CompanyPrincipalPaymentRmb2000000>
	<fil:TotalLoanFacilityAmountRmb80000000 decimals='INF' contextRef='E16Q1' unitRef='USD'>1320000</fil:TotalLoanFacilityAmountRmb80000000>
	<fil:LoanInterestForAnEightYearTerm decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.0573</fil:LoanInterestForAnEightYearTerm>
	<fil:InterestRateWasAdjustedTo decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.0594</fil:InterestRateWasAdjustedTo>
	<fil:PrincipalPayments2017 decimals='INF' contextRef='E16Q1' unitRef='USD'>1550893</fil:PrincipalPayments2017>
	<fil:PrincipalPayments2018 decimals='INF' contextRef='E16Q1' unitRef='USD'>1240714</fil:PrincipalPayments2018>
	<fil:PrincipalPayments2019 decimals='INF' contextRef='E16Q1' unitRef='USD'>2326339</fil:PrincipalPayments2019>
	<fil:PrincipalPayments2020 decimals='INF' contextRef='E16Q1' unitRef='USD'>2326339</fil:PrincipalPayments2020>
	<fil:PrincipalPayments2021 decimals='INF' contextRef='E16Q1' unitRef='USD'>2326339</fil:PrincipalPayments2021>
	<fil:PrincipalPayments2022 decimals='INF' contextRef='E16Q1' unitRef='USD'>2326339</fil:PrincipalPayments2022>
	<fil:TotalPrincipalPaymentsDue decimals='INF' contextRef='E16Q1' unitRef='USD'>12096962</fil:TotalPrincipalPaymentsDue>
	<fil:EnterpriseIncomeTaxRate2015 decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.1500</fil:EnterpriseIncomeTaxRate2015>
	<fil:EnterpriseIncomeTaxRate2016 decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.1500</fil:EnterpriseIncomeTaxRate2016>
	<fil:EnterpriseIncomeTaxRateThereafter decimals='INF' contextRef='E16Q1' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRateThereafter>
	<us-gaap:CurrentIncomeTaxExpenseBenefit decimals='INF' contextRef='Y16Q1' unitRef='USD'>0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit decimals='INF' contextRef='Y16Q1' unitRef='USD'>22828</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit decimals='INF' contextRef='Y15Q1' unitRef='USD'>19284</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<fil:TotalIncomeTaxExpense1 decimals='INF' contextRef='E16Q1' unitRef='USD'>22828</fil:TotalIncomeTaxExpense1>
	<fil:TotalIncomeTaxExpense1 decimals='INF' contextRef='E15Q1' unitRef='USD'>19284</fil:TotalIncomeTaxExpense1>
	<fil:PrcNetOperatingLossCarryForward decimals='INF' contextRef='E16Q1' unitRef='USD'>36800000</fil:PrcNetOperatingLossCarryForward>
	<fil:USNetOperatingLossCarryForward decimals='INF' contextRef='E16Q1' unitRef='USD'>4100000</fil:USNetOperatingLossCarryForward>
	<us-gaap:DeferredTaxAssetsValuationAllowance decimals='INF' contextRef='E16Q1' unitRef='USD'>12897790</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance decimals='INF' contextRef='E15' unitRef='USD'>12798572</us-gaap:DeferredTaxAssetsValuationAllowance>
	<fil:BankersAcceptanceNotes decimals='INF' contextRef='E16Q1' unitRef='USD'>116317</fil:BankersAcceptanceNotes>
	<fil:Total1 decimals='INF' contextRef='E16Q1' unitRef='USD'>116317</fil:Total1>
	<fil:BankersAcceptanceNotesLevel1 decimals='INF' contextRef='E16Q1' unitRef='USD'>0</fil:BankersAcceptanceNotesLevel1>
	<fil:TotalLevel1 decimals='INF' contextRef='E16Q1' unitRef='USD'>0</fil:TotalLevel1>
	<fil:BankersAcceptanceNotesLevel2 decimals='INF' contextRef='E16Q1' unitRef='USD'>116317</fil:BankersAcceptanceNotesLevel2>
	<fil:TotalLevel2 decimals='INF' contextRef='E16Q1' unitRef='USD'>116317</fil:TotalLevel2>
	<fil:BankersAcceptanceNotesLevel3 decimals='INF' contextRef='E16Q1' unitRef='USD'>0</fil:BankersAcceptanceNotesLevel3>
	<fil:TotalLevel3 decimals='INF' contextRef='E16Q1' unitRef='USD'>0</fil:TotalLevel3>
	<fil:CommonSharesAuthorized decimals='INF' contextRef='E16Q1' unitRef='Shares'>95000000</fil:CommonSharesAuthorized>
	<fil:PreferredSharesAuthorized decimals='INF' contextRef='E16Q1' unitRef='Shares'>5000000</fil:PreferredSharesAuthorized>
	<fil:CommonSharesParValue decimals='INF' contextRef='E16Q1' unitRef='UsdPerShare'>0.001</fil:CommonSharesParValue>
	<fil:PreferredSharesParValue decimals='INF' contextRef='E16Q1' unitRef='UsdPerShare'>0.001</fil:PreferredSharesParValue>
	<fil:NumberOfCommonShares decimals='INF' contextRef='I101112' unitRef='Shares'>4000000</fil:NumberOfCommonShares>
	<fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan decimals='INF' contextRef='E16Q1' unitRef='Shares'>175000</fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan>
	<us-gaap:Cash decimals='INF' contextRef='E16Q1' unitRef='USD'>7261777</us-gaap:Cash>
	<us-gaap:Cash decimals='INF' contextRef='E15' unitRef='USD'>6248760</us-gaap:Cash>
	<us-gaap:OtherRestrictedAssetsCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>116317</us-gaap:OtherRestrictedAssetsCurrent>
	<us-gaap:OtherRestrictedAssetsCurrent decimals='INF' contextRef='E15' unitRef='USD'>0</us-gaap:OtherRestrictedAssetsCurrent>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively decimals='INF' contextRef='E16Q1' unitRef='USD'>4791247</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively decimals='INF' contextRef='E15' unitRef='USD'>5882509</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>191958</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E15' unitRef='USD'>290739</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E16Q1' unitRef='USD'>2643516</fil:AdvancesToSuppliers>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E15' unitRef='USD'>2533354</fil:AdvancesToSuppliers>
	<us-gaap:InventoryNet decimals='INF' contextRef='E16Q1' unitRef='USD'>9917139</us-gaap:InventoryNet>
	<us-gaap:InventoryNet decimals='INF' contextRef='E15' unitRef='USD'>9662750</us-gaap:InventoryNet>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>195081</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E15' unitRef='USD'>339140</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>25117035</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E15' unitRef='USD'>24957252</us-gaap:AssetsCurrent>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E16Q1' unitRef='USD'>42309641</fil:AdvancesForPurchasesOfIntangibleAssets>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E15' unitRef='USD'>42030649</fil:AdvancesForPurchasesOfIntangibleAssets>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E16Q1' unitRef='USD'>28826692</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E15' unitRef='USD'>29393257</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E16Q1' unitRef='USD'>778766</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E15' unitRef='USD'>841075</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:Assets decimals='INF' contextRef='E16Q1' unitRef='USD'>97032134</us-gaap:Assets>
	<us-gaap:Assets decimals='INF' contextRef='E15' unitRef='USD'>97222233</us-gaap:Assets>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>3744095</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E15' unitRef='USD'>2824521</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>113627</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>143409</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>1712024</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E15' unitRef='USD'>1710283</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>932653</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E15' unitRef='USD'>595681</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>1550893</us-gaap:LongTermConstructionLoanCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E15' unitRef='USD'>1540666</us-gaap:LongTermConstructionLoanCurrent>
	<us-gaap:NotesPayableCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>4652678</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent decimals='INF' contextRef='E15' unitRef='USD'>4621998</us-gaap:NotesPayableCurrent>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>14060537</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E15' unitRef='USD'>12791125</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>10546069</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E15' unitRef='USD'>10784661</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:DeferredRevenue decimals='INF' contextRef='E16Q1' unitRef='USD'>534833</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue decimals='INF' contextRef='E15' unitRef='USD'>708408</us-gaap:DeferredRevenue>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>322012</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent decimals='INF' contextRef='E15' unitRef='USD'>296890</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:Liabilities decimals='INF' contextRef='E16Q1' unitRef='USD'>25463451</us-gaap:Liabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E15' unitRef='USD'>24581084</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E16Q1' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E15' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E16Q1' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E15' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E16Q1' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E15' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E16Q1' unitRef='USD'>32387102</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E15' unitRef='USD'>33939998</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E16Q1' unitRef='USD'>15547797</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E15' unitRef='USD'>15067367</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E16Q1' unitRef='USD'>71568683</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E15' unitRef='USD'>72641149</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E16Q1' unitRef='USD'>97032134</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E15' unitRef='USD'>97222233</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E16Q1' unitRef='USD'>29598703</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E15' unitRef='USD'>28644398</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E16Q1' unitRef='USD'>78558</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E15' unitRef='USD'>74400</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<fil:AllowanceForObsolescenceOfInventory decimals='INF' contextRef='E16Q1' unitRef='USD'>6696224</fil:AllowanceForObsolescenceOfInventory>
	<fil:AllowanceForObsolescenceOfInventory decimals='INF' contextRef='E15' unitRef='USD'>8417095</fil:AllowanceForObsolescenceOfInventory>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals='INF' contextRef='E16Q1' unitRef='USD'>10286937</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment decimals='INF' contextRef='E15' unitRef='USD'>9442912</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization decimals='INF' contextRef='E16Q1' unitRef='USD'>4456837</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization decimals='INF' contextRef='E15' unitRef='USD'>4360004</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E16Q1' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E15' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E16Q1' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E15' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E16Q1' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E15' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E16Q1' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E15' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E16Q1' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E15' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E16Q1' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E15' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E16Q1' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E15' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E16Q1' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E15' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:Revenues decimals='INF' contextRef='Y16Q1' unitRef='USD'>3640494</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='Y15Q1' unitRef='USD'>5694930</us-gaap:Revenues>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y16Q1' unitRef='USD'>3071461</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y15Q1' unitRef='USD'>4434706</us-gaap:CostOfRevenue>
	<us-gaap:InventoryWriteDown decimals='INF' contextRef='Y16Q1' unitRef='USD'>-71786</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown decimals='INF' contextRef='Y15Q1' unitRef='USD'>201097</us-gaap:InventoryWriteDown>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y16Q1' unitRef='USD'>640819</us-gaap:GrossProfit>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y15Q1' unitRef='USD'>1059127</us-gaap:GrossProfit>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>968507</us-gaap:SellingExpense>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>988953</us-gaap:SellingExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>318930</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>472429</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>93433</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>160828</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y15Q1' unitRef='USD'>3200003</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y16Q1' unitRef='USD'>1962170</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y15Q1' unitRef='USD'>4822213</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1321351</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y15Q1' unitRef='USD'>-3763086</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y16Q1' unitRef='USD'>33592</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y15Q1' unitRef='USD'>26855</us-gaap:InvestmentIncomeInterest>

	<us-gaap:InterestExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>242309</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>313775</us-gaap:InterestExpense>

	<us-gaap:OtherExpenses decimals='INF' contextRef='Y16Q1' unitRef='USD'>208717</us-gaap:OtherExpenses>
	<us-gaap:OtherExpenses decimals='INF' contextRef='Y15Q1' unitRef='USD'>286920</us-gaap:OtherExpenses>

	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1530068</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y15Q1' unitRef='USD'>-4050006</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<fil:IncomeTaxExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>-22828</fil:IncomeTaxExpense>
	<fil:IncomeTaxExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>-19284</fil:IncomeTaxExpense>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1552896</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y15Q1' unitRef='USD'>-4069290</us-gaap:NetIncomeLoss>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y16Q1' unitRef='USD'>480430</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y15Q1' unitRef='USD'>435480</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1072466</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y15Q1' unitRef='USD'>-3633810</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:EarningsPerShareBasic decimals='INF' contextRef='Y16Q1' unitRef='UsdPerShare'>-0.04</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic decimals='INF' contextRef='Y15Q1' unitRef='UsdPerShare'>-0.09</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted decimals='INF' contextRef='Y16Q1' unitRef='UsdPerShare'>-0.04</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted decimals='INF' contextRef='Y15Q1' unitRef='UsdPerShare'>-0.09</us-gaap:EarningsPerShareDiluted>
	<us-gaap:ProfitLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1552896</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss decimals='INF' contextRef='Y15Q1' unitRef='USD'>-4069290</us-gaap:ProfitLoss>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y16Q1' unitRef='USD'>857195</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y15Q1' unitRef='USD'>951212</us-gaap:DepreciationDepletionAndAmortization>
	<fil:IncreaseInBadDebtExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</fil:IncreaseInBadDebtExpense>
	<fil:IncreaseInBadDebtExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>3200003</fil:IncreaseInBadDebtExpense>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y16Q1' unitRef='USD'>22828</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y15Q1' unitRef='USD'>19284</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<fil:InventoryObsolescenceReserve decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1751863</fil:InventoryObsolescenceReserve>
	<fil:InventoryObsolescenceReserve decimals='INF' contextRef='Y15Q1' unitRef='USD'>201097</fil:InventoryObsolescenceReserve>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y16Q1' unitRef='USD'>-61069</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y15Q1' unitRef='USD'>-1408092</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y16Q1' unitRef='USD'>-92039</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y15Q1' unitRef='USD'>-154575</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y16Q1' unitRef='USD'>1967359</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y15Q1' unitRef='USD'>396521</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y16Q1' unitRef='USD'>888212</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y15Q1' unitRef='USD'>917765</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y16Q1' unitRef='USD'>-53955</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y15Q1' unitRef='USD'>18019</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y16Q1' unitRef='USD'>25514</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y15Q1' unitRef='USD'>-4813</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y16Q1' unitRef='USD'>328354</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y15Q1' unitRef='USD'>-243289</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>144262</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>173919</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>1303202</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y15Q1' unitRef='USD'>-2239</us-gaap:NetCashProvidedByUsedInOperatingActivities>

	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y16Q1' unitRef='USD'>39248</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y15Q1' unitRef='USD'>47106</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>-39248</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y15Q1' unitRef='USD'>-47106</us-gaap:NetCashProvidedByUsedInInvestingActivities>

	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y16Q1' unitRef='USD'>305835</us-gaap:ProceedsFromConstructionLoansPayable>
	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y15Q1' unitRef='USD'>0</us-gaap:ProceedsFromConstructionLoansPayable>

	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>-305835</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y15Q1' unitRef='USD'>0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y16Q1' unitRef='USD'>54898</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y15Q1' unitRef='USD'>22411</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y16Q1' unitRef='USD'>1013017</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y15Q1' unitRef='USD'>-26934</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y16Q1' unitRef='USD'>6248760</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y15Q1' unitRef='USD'>5295790</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y16Q1' unitRef='USD'>7261777</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y15Q1' unitRef='USD'>5268856</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y16Q1' unitRef='USD'>1151613</us-gaap:InterestPaid>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y15Q1' unitRef='USD'>1230800</us-gaap:InterestPaid>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y16Q1' unitRef='USD'>517770</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y15Q1' unitRef='USD'>464075</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y16Q1' unitRef='USD'>403081</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y15Q1' unitRef='USD'>551167</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:BadDebtExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</fil:BadDebtExpense>
	<fil:BadDebtExpense decimals='INF' contextRef='Y15Q1' unitRef='USD'>3200003</fil:BadDebtExpense>
	<fil:CompanyHadTradeAccountsReceivableAmounting decimals='INF' contextRef='Y16Q1' unitRef='USD'>16853716</fil:CompanyHadTradeAccountsReceivableAmounting>
	<fil:ChargesToInventoryObsolescenceExpenseTotaled decimals='INF' contextRef='Y16Q1' unitRef='USD'>-71786</fil:ChargesToInventoryObsolescenceExpenseTotaled>
	<fil:ChargesToInventoryObsolescenceExpenseTotaled decimals='INF' contextRef='Y15Q1' unitRef='USD'>201097</fil:ChargesToInventoryObsolescenceExpenseTotaled>
	<fil:CompanyRecognizedAnInventoryObsolescenceReserve decimals='INF' contextRef='Y16Q1' unitRef='USD'>6696224</fil:CompanyRecognizedAnInventoryObsolescenceReserve>
	<fil:CompanyRecognizedAnInventoryObsolescenceReserve decimals='INF' contextRef='Y15' unitRef='USD'>8417095</fil:CompanyRecognizedAnInventoryObsolescenceReserve>
	<fil:ResearchAndDevelopmentExpenses decimals='INF' contextRef='Y16Q1' unitRef='USD'>93433</fil:ResearchAndDevelopmentExpenses>
	<fil:ResearchAndDevelopmentExpenses decimals='INF' contextRef='Y15Q1' unitRef='USD'>160828</fil:ResearchAndDevelopmentExpenses>
	<fil:NetLoss1 decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1530068</fil:NetLoss1>
	<fil:NetLoss1 decimals='INF' contextRef='Y15Q1' unitRef='USD'>-4069290</fil:NetLoss1>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals='INF' contextRef='Y16Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic decimals='INF' contextRef='Y15Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<fil:Warrants decimals='INF' contextRef='Y16Q1' unitRef='USD'>0</fil:Warrants>
	<fil:Options decimals='INF' contextRef='Y16Q1' unitRef='USD'>0</fil:Options>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals='INF' contextRef='Y16Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding decimals='INF' contextRef='Y15Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare decimals='INF' contextRef='Y16Q1' unitRef='UsdPerShare'>-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicShare decimals='INF' contextRef='Y15Q1' unitRef='UsdPerShare'>-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare decimals='INF' contextRef='Y16Q1' unitRef='UsdPerShare'>-0.04</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare decimals='INF' contextRef='Y15Q1' unitRef='UsdPerShare'>-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
	<fil:CompanyForeignSubsidiarySinceItsAcquisition decimals='INF' contextRef='E16Q1' unitRef='USD'>38500000</fil:CompanyForeignSubsidiarySinceItsAcquisition>
	<fil:InvestmentInHelpson decimals='INF' contextRef='E16Q1' unitRef='USD'>23300000</fil:InvestmentInHelpson>
	<fil:NoCustomerAccountedForMoreThanPercentageOfSales decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.1000</fil:NoCustomerAccountedForMoreThanPercentageOfSales>
	<fil:OneCustomerAccounted decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.2850</fil:OneCustomerAccounted>
	<fil:SecondCustomerAccounted decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.1140</fil:SecondCustomerAccounted>
	<fil:ThirdCustomerAccounted decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.1100</fil:ThirdCustomerAccounted>
	<fil:OneCustomerAccountedForPercentageOfSales decimals='INF' contextRef='Y15Q1' unitRef='Pure'>0.1970</fil:OneCustomerAccountedForPercentageOfSales>
	<fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases decimals='INF' contextRef='Y15Q1' unitRef='Pure'>0.2950</fil:OneSupplierAccountedForPercentageOfRawMaterialPurchases>
	<fil:OneCustomerAccountedForPercentageOfAccountsReceivable decimals='INF' contextRef='Y15Q1' unitRef='Pure'>0.1730</fil:OneCustomerAccountedForPercentageOfAccountsReceivable>
	<dei:DocumentType contextRef='Y16Q1'>10-Q</dei:DocumentType>
	<dei:DocumentPeriodEndDate contextRef='Y16Q1'>2016-03-31</dei:DocumentPeriodEndDate>
	<dei:AmendmentFlag contextRef='Y16Q1'>false</dei:AmendmentFlag>
	<dei:EntityRegistrantName contextRef='Y16Q1'>CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef='Y16Q1'>0001106644</dei:EntityCentralIndexKey>
	<dei:TradingSymbol contextRef='Y16Q1'>cphi</dei:TradingSymbol>
	<dei:CurrentFiscalYearEndDate contextRef='Y16Q1'>--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityCommonStockSharesOutstanding decimals='INF' contextRef='I160513' unitRef='Shares'>43579557</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef='Y16Q1'>Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityCurrentReportingStatus contextRef='Y16Q1'>Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityVoluntaryFilers contextRef='Y16Q1'>No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef='Y16Q1'>No</dei:EntityWellKnownSeasonedIssuer>
	<dei:DocumentFiscalYearFocus contextRef='Y16Q1'>2016</dei:DocumentFiscalYearFocus>
	<dei:DocumentFiscalPeriodFocus contextRef='Y16Q1'>Q1</dei:DocumentFiscalPeriodFocus>
	<context id='Y16Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-03-31</endDate>
		</period>
	</context>
	<context id='I160513'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-05-13</instant>
		</period>
	</context>
	<context id='E16Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-03-31</instant>
		</period>
	</context>
	<context id='E15'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-12-31</instant>
		</period>
	</context>
	<context id='Y15Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-03-31</endDate>
		</period>
	</context>
	<context id='Y15'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2015-01-01</startDate>
			<endDate>2015-12-31</endDate>
		</period>
	</context>
	<context id='E15Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-03-31</instant>
		</period>
	</context>
	<context id='I151130'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2015-11-30</instant>
		</period>
	</context>
	<context id='I160916'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-09-16</instant>
		</period>
	</context>
	<context id='I161019'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-10-19</instant>
		</period>
	</context>
	<context id='I101112'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2010-11-12</instant>
		</period>
	</context>
	<unit id='Shares'>
		<measure>shares</measure>
	</unit>
	<unit id='USD'>
		<measure>iso4217:USD</measure>
	</unit>
	<unit id='UsdPerShare'>
		<divide>
			<unitNumerator>
				<measure>iso4217:USD</measure>
			</unitNumerator>
			<unitDenominator>
				<measure>shares</measure>
			</unitDenominator>
		</divide>
	</unit>
	<unit id='Pure'>
		<measure>pure</measure>
	</unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cphi-20160331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<schema xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2015-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20160331' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:num='http://www.xbrl.org/dtr/type/numeric' targetNamespace='http://www.chinapharmaholdings.com/20160331' xmlns:link='http://www.xbrl.org/2003/linkbase' elementFormDefault='qualified' xmlns:xbrli='http://www.xbrl.org/2003/instance' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails" id="idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails">
				<link:definition>000310 - Statement - Numerators and denominators used in the calculation of basic and diluted loss per share (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" id="idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
				<link:definition>000190 - Disclosure - ACCOUNTING POLICIES (POLICIES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS" id="idr_DisclosureINTANGIBLEASSETS">
				<link:definition>000090 - Disclosure - INTANGIBLE ASSETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE" id="idr_DisclosureNOTESPAYABLE">
				<link:definition>000120 - Disclosure - NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS" id="idr_INVENTORYDETAILS">
				<link:definition>000320 - Statement - INVENTORY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails" id="idr_OrganizationAndNatureOfOperationsDetails">
				<link:definition>000290 - Statement - Organization and Nature of Operations (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES" id="idr_DisclosureINTANGIBLEASSETSTABLES">
				<link:definition>000230 - Disclosure - INTANGIBLE ASSETS (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails" id="idr_RELATEDPARTYTRANSACTIONSDetails">
				<link:definition>000410 - Statement - RELATED PARTY TRANSACTIONS (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES" id="idr_DisclosureINCOMETAXES">
				<link:definition>000140 - Disclosure - INCOME TAXES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails" id="idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails">
				<link:definition>000300 - Statement - Trade Accounts Receivable and Allowance for Doubtful Accounts (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" id="idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
				<link:definition>000100 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" id="idr_CAPITALSTOCKTRANSACTIONSDETAILS">
				<link:definition>000520 - Statement - CAPITAL STOCK TRANSACTIONS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" id="idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
				<link:definition>000500 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" id="idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
				<link:definition>000330 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" id="idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
				<link:definition>000240 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS" id="idr_DisclosureCONCENTRATIONS">
				<link:definition>000180 - Disclosure - CONCENTRATIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
				<link:definition>000060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" id="idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
				<link:definition>000220 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY" id="idr_DisclosureINVENTORY">
				<link:definition>000070 - Disclosure - INVENTORY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" id="idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES">
				<link:definition>000260 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" id="idr_DisclosureFAIRVALUEMEASUREMENTS">
				<link:definition>000150 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES" id="idr_DisclosureINVENTORYTABLES">
				<link:definition>000210 - Disclosure - INVENTORY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" id="idr_DisclosureCONSTRUCTIONLOANFACILITY">
				<link:definition>000130 - Disclosure - CONSTRUCTION LOAN FACILITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETS" id="idr_CONSOLIDATEDBALANCESHEETS">
				<link:definition>000020 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT" id="idr_DisclosurePROPERTYANDEQUIPMENT">
				<link:definition>000080 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails" id="idr_IntangibleAssetsAmortizationExpensesDetails">
				<link:definition>000380 - Statement - Intangible assets amortization expenses (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS" id="idr_ASSETSDEPRECIATIONDETAILS">
				<link:definition>000360 - Statement - ASSETS DEPRECIATION (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited" id="idr_CONSOLIDATEDBALANCESHEETSUnaudited">
				<link:definition>000020 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY" id="idr_DisclosureSTOCKHOLDERSEQUITY">
				<link:definition>000160 - Disclosure - STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" id="idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
				<link:definition>000400 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" id="idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
				<link:definition>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES" id="idr_DisclosureINCOMETAXESTABLES">
				<link:definition>000250 - Disclosure - INCOME TAXES (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS" id="idr_NOTESPAYABLESDETAILS">
				<link:definition>000420 - Statement - NOTES PAYABLES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" id="idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
				<link:definition>000370 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" id="idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS">
				<link:definition>000350 - Statement - ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" id="idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS">
				<link:definition>000510 - Statement - FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" id="idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
				<link:definition>000170 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS" id="idr_PROVISIONFORINCOMETAXESDETAILS">
				<link:definition>000480 - Statement - PROVISION FOR INCOME TAXES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" id="idr_DisclosureRELATEDPARTYTRANSACTIONS">
				<link:definition>000110 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" id="idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
				<link:definition>000050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" id="idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
				<link:definition>000440 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES" id="idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES">
				<link:definition>000200 - Disclosure - BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" id="idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
				<link:definition>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" id="idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
				<link:definition>000060 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" id="idr_CONSTRUCTIONLOANFACILITYDETAILS">
				<link:definition>000430 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails" id="idr_SUBSIDYINCOMEDetails">
				<link:definition>000460 - Statement - SUBSIDY INCOME (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" id="idr_ENTERPRISEINCOMETAXRATESDETAILS">
				<link:definition>000470 - Statement - ENTERPRISE INCOME TAX RATES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS" id="idr_CONCENTRATIONSDETAILS">
				<link:definition>000530 - Statement - CONCENTRATIONS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2015-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2014-01-31' schemaLocation='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DocumentAndEntityInformationAbstract' name='DocumentAndEntityInformationAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesToSuppliers' name='AdvancesToSuppliers' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' name='AllowanceForDoubtfulAccountsOnOtherReceivables' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_InventoryPurchasedWithBankerSAcceptances' name='InventoryPurchasedWithBankerSAcceptances' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AccountsReceivableCollectedWithBankerSAcceptances' name='AccountsReceivableCollectedWithBankerSAcceptances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' name='AdvancesForPurchasesOfIntangibleAssetsAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' name='AdvancesForPurchasesOfIntangibleAssetsTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NotesPayable1Abstract' name='NotesPayable1Abstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryTablesAbstract' name='InventoryTablesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentTablesAbstract' name='PropertyAndEquipmentTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_UsefulLivesOfTheAssetsTableTextBlock' name='UsefulLivesOfTheAssetsTableTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsTablesAbstract' name='IntangibleAssetsTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' name='IntangibleAssetsMedicalFormulasTablesTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesTablesAbstract' name='IncomeTaxesTablesAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercetageOfAcquiredByOnnyInHelpson' name='PercetageOfAcquiredByOnnyInHelpson' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_Warrants' name='Warrants' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_Options' name='Options' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_MotorVehicleGross' name='MotorVehicleGross' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PropertyAndEquipmentNet' name='PropertyAndEquipmentNet' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMaximumLife' name='OfficeEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMaximumLife' name='MotorVehicleMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMaximumLife' name='BuildingMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMaximumLife' name='PermitOfLandUseMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMinimumLife' name='OfficeEquipmentMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMinimumLife' name='MotorVehicleMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMinimumLife' name='BuildingMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMinimumLife' name='PermitOfLandUseMinimumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_GrossCarryingAmount' name='GrossCarryingAmount' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetCarryingAmount' name='NetCarryingAmount' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CommonSharesAuthorized' name='CommonSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesAuthorized' name='PreferredSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_NumberOfCommonShares' name='NumberOfCommonShares' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' name='FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_BankersAcceptanceNotes' name='BankersAcceptanceNotes' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_BankersAcceptanceNotesLevel1' name='BankersAcceptanceNotesLevel1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalLevel1' name='TotalLevel1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_BankersAcceptanceNotesLevel2' name='BankersAcceptanceNotesLevel2' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalLevel2' name='TotalLevel2' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_BankersAcceptanceNotesLevel3' name='BankersAcceptanceNotesLevel3' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalLevel3' name='TotalLevel3' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AssetsDepreciationAbstract' name='AssetsDepreciationAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_InterestRateOnAdvancesFromMemberOfBOD' name='InterestRateOnAdvancesFromMemberOfBOD' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' name='OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_InventoryObsolescenceReserve' name='InventoryObsolescenceReserve' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_Total1' name='Total1' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AllowanceForObsolescenceOfInventory' name='AllowanceForObsolescenceOfInventory' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtBeginningOfPeriod' name='CashAndCashEquivalentsAtBeginningOfPeriod' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtEndOfPeriod' name='CashAndCashEquivalentsAtEndOfPeriod' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DebtAbstract' name='DebtAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesForPurchasesOfIntangibleAssets' name='AdvancesForPurchasesOfIntangibleAssets' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' name='AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConstructionLoanFacilityDetailsAbstract' name='ConstructionLoanFacilityDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommitmentAndContingenciesAbstract' name='CommitmentAndContingenciesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfLongTermDebtInstrumentsAbstract' name='ScheduleOfLongTermDebtInstrumentsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EffectOfDilutiveSecuritiesAbstract' name='EffectOfDilutiveSecuritiesAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_OfficeEquipment1' name='OfficeEquipment1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2017' name='PrincipalPayments2017' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2018' name='PrincipalPayments2018' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' name='SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalInventory' name='TotalInventory' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMaximumLife' name='PlantMachineryAndEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_RevolvingLineOfCreditWithABankRmb' name='RevolvingLineOfCreditWithABankRmb' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_PrincipalPayments2019' name='PrincipalPayments2019' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalPrincipalPaymentsDue' name='TotalPrincipalPaymentsDue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConcentrationsDetailsAbstract' name='ConcentrationsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_LessAccumulatedDepreciation' name='LessAccumulatedDepreciation' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AccumulatedAmortization' name='AccumulatedAmortization' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_LoanInterestForAnEightYearTerm' name='LoanInterestForAnEightYearTerm' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLoanFacilityAmountRmb80000000' name='TotalLoanFacilityAmountRmb80000000' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' name='PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' name='IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='credit' id='fil_NetLoss1' name='NetLoss1' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMinimumLife' name='PlantMachineryAndEquipmentMinimumLife' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' name='AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_InterestRateWasAdjustedTo' name='InterestRateWasAdjustedTo' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SubsidyIncomeDetailsAbstract' name='SubsidyIncomeDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' name='OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BasicAndDilutedLossPerCommonShareTablesAbstract' name='BasicAndDilutedLossPerCommonShareTablesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FairValueMeasuresAndDisclosuresAbstract' name='FairValueMeasuresAndDisclosuresAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AccountingPoliciesAbstract1' name='AccountingPoliciesAbstract1' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' name='AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' name='TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_BadDebtExpense' name='BadDebtExpense' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' name='NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationAndNatureOfOperationsAbstract' name='OrganizationAndNatureOfOperationsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryDetailsAbstract' name='InventoryDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' name='PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' name='EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' name='CompanyWasObligatedToPayLaboratoriesAndOthers' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' name='IntangibleAssetsAmortizationExpensesDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AmortizationExpensesRelatingToIntangibleAssets' name='AmortizationExpensesRelatingToIntangibleAssets' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RelatedPartyTransactionsDetailsAbstract' name='RelatedPartyTransactionsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalInterestExpense' name='TotalInterestExpense' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_AdvancesOwingToBoardOfDirectors' name='AdvancesOwingToBoardOfDirectors' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NotesPayablesDetailsAbstract' name='NotesPayablesDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2020' name='PrincipalPayments2020' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2021' name='PrincipalPayments2021' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EnterpriseIncomeTaxRatesDetailsAbstract' name='EnterpriseIncomeTaxRatesDetailsAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2015' name='EnterpriseIncomeTaxRate2015' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRate2016' name='EnterpriseIncomeTaxRate2016' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRateThereafter' name='EnterpriseIncomeTaxRateThereafter' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ProvisionForIncomeTaxesDetailsAbstract' name='ProvisionForIncomeTaxesDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IncomeTaxExpense' name='IncomeTaxExpense' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DeferredIncomeTaxAssetsAbstract' name='DeferredIncomeTaxAssetsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrcNetOperatingLossCarryForward' name='PrcNetOperatingLossCarryForward' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CapitalStockTransactionsAbstract' name='CapitalStockTransactionsAbstract' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CommonSharesParValue' name='CommonSharesParValue' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesParValue' name='PreferredSharesParValue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_EmployeeStockOptions2010IncentivePlanAbstract' name='EmployeeStockOptions2010IncentivePlanAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_NoCustomerAccountedForMoreThanPercentageOfSales' name='NoCustomerAccountedForMoreThanPercentageOfSales' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneCustomerAccountedForPercentageOfSales' name='OneCustomerAccountedForPercentageOfSales' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' name='OneSupplierAccountedForPercentageOfRawMaterialPurchases' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' name='OneCustomerAccountedForPercentageOfAccountsReceivable' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InterestRateRiskPolicyTextBlock' name='InterestRateRiskPolicyTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' name='ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IncreaseInBadDebtExpense' name='IncreaseInBadDebtExpense' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CompanyHadTradeAccountsReceivableAmounting' name='CompanyHadTradeAccountsReceivableAmounting' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ChargesToInventoryObsolescenceExpenseTotaled' name='ChargesToInventoryObsolescenceExpenseTotaled' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CompanyRecognizedAnInventoryObsolescenceReserve' name='CompanyRecognizedAnInventoryObsolescenceReserve' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_ResearchAndDevelopmentExpenses' name='ResearchAndDevelopmentExpenses' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_DepreciationExpensePropertyAndEquipment' name='DepreciationExpensePropertyAndEquipment' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' name='LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyPrincipalPaymentRmb2000000' name='CompanyPrincipalPaymentRmb2000000' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2022' name='PrincipalPayments2022' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyForeignSubsidiarySinceItsAcquisition' name='CompanyForeignSubsidiarySinceItsAcquisition' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_InvestmentInHelpson' name='InvestmentInHelpson' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalIncomeTaxExpense1' name='TotalIncomeTaxExpense1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_USNetOperatingLossCarryForward' name='USNetOperatingLossCarryForward' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' name='TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OneCustomerAccounted' name='OneCustomerAccounted' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SecondCustomerAccounted' name='SecondCustomerAccounted' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ThirdCustomerAccounted' name='ThirdCustomerAccounted' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cphi-20160331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20160331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDBALANCESHEETS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_OperatingExpenses' xlink:to='us-gaap_SellingExpense' use='optional' order='4.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cphi-20160331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20160331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDBALANCESHEETSUnaudited"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINVENTORY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINCOMETAXES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_OrganizationAndNatureOfOperationsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_INVENTORYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_NOTESPAYABLESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_SUBSIDYINCOMEDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cphi-20160331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20160331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CapitalStockTransactionsAbstract' xlink:label='fil_CapitalStockTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CapitalStockTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Capital stock transactions:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='lab_fil_CapitalStockTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes total Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel1' xlink:to='lab_fil_TotalLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalIncomeTaxExpense1' xlink:label='fil_TotalIncomeTaxExpense1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxExpense1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total income tax expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxExpense1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalIncomeTaxExpense1' xlink:to='lab_fil_TotalIncomeTaxExpense1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchase of intangible assets details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization expenses relating to intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:to='lab_fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accumulated amortization on long-term land leases capitalized as part of real property.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccumulatedAmortization' xlink:to='lab_fil_AccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMaximumLife' xlink:to='lab_fil_BuildingMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_BuildingsAndImprovementsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_BuildingsAndImprovementsGross' xlink:to='lab_us-gaap_BuildingsAndImprovementsGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:label='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade Accounts Receivable and Allowance for Doubtful Accounts details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='lab_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Principal payments required for the next five years as of December 31, 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:to='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recent Accounting Pronouncements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:to='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PrepaidExpenseCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PrepaidExpenseCurrent' xlink:to='lab_us-gaap_PrepaidExpenseCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2020</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2020' xlink:to='lab_fil_PrincipalPayments2020'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2017' xlink:to='lab_fil_PrincipalPayments2017'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Outstanding balance due under revolving line of credit (RMB 30,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:to='lab_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:label='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Annual interest rate based upon 110% of PRC government&apos;s current short term rate of 5.6%</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Annual interest rate based upon 110% of PRC government&apos;s current short term rate of 5.6%</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:to='lab_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetCarryingAmount' xlink:to='lab_fil_NetCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyRecognizedAnInventoryObsolescenceReserve' xlink:label='fil_CompanyRecognizedAnInventoryObsolescenceReserve'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedAnInventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company recognized an inventory obsolescence reserve</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedAnInventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company recognized an inventory obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyRecognizedAnInventoryObsolescenceReserve' xlink:to='lab_fil_CompanyRecognizedAnInventoryObsolescenceReserve'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryPurchasedWithBankerSAcceptances' xlink:to='lab_fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued taxes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; Equity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Long-term deferred tax liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:to='lab_us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableTradeCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableTradeCurrent' xlink:to='lab_us-gaap_AccountsPayableTradeCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total principal payments due</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Principal amount due by the company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalPrincipalPaymentsDue' xlink:to='lab_fil_TotalPrincipalPaymentsDue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2022' xlink:label='fil_PrincipalPayments2022'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2022' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2022</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2022' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Principal Payments 2022</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2022' xlink:to='lab_fil_PrincipalPayments2022'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentNet' xlink:to='lab_fil_PropertyAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare' xlink:label='us-gaap_IncomeLossFromContinuingOperationsPerBasicShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic loss per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsPerBasicShare' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_FairValueMeasuresAndDisclosuresAbstract' xlink:label='fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueMeasuresAndDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SCHEDULE OF FAIR VALUE MEASUREMENTS:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueMeasuresAndDisclosuresAbstract' xlink:to='lab_fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest Rate Risk</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy on interest rate risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateRiskPolicyTextBlock' xlink:to='lab_fil_InterestRateRiskPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NatureOfOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and Nature of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NatureOfOperations' xlink:to='lab_us-gaap_NatureOfOperations'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermDebtTextBlock' xlink:to='lab_us-gaap_LongTermDebtTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DebtAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DebtAbstract' xlink:to='lab_fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Used in Investing Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasic' xlink:to='lab_us-gaap_EarningsPerShareBasic'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncomeTaxExpense' xlink:label='fil_IncomeTaxExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income tax expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxExpense' xlink:to='lab_fil_IncomeTaxExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss before income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expenses:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesOutstanding' xlink:to='lab_us-gaap_PreferredStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Voluntary Filers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SecondCustomerAccounted' xlink:label='fil_SecondCustomerAccounted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Second customer accounted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Second customer accounted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SecondCustomerAccounted' xlink:to='lab_fil_SecondCustomerAccounted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 3 total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel3' xlink:to='lab_fil_TotalLevel3'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxAssetsValuationAllowance' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation allowance</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxAssetsValuationAllowance' xlink:to='lab_us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalInterestExpense' xlink:label='fil_TotalInterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total interest expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the cost of borrowed funds accounted for as interest expense for debt.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInterestExpense' xlink:to='lab_fil_TotalInterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets CFDA approved medical formulas details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMinimumLife' xlink:to='lab_fil_BuildingMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryDetailsAbstract' xlink:label='fil_InventoryDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>NetLoss1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryDetailsAbstract' xlink:to='lab_fil_InventoryDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ChargesToInventoryObsolescenceExpenseTotaled' xlink:label='fil_ChargesToInventoryObsolescenceExpenseTotaled'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChargesToInventoryObsolescenceExpenseTotaled' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Charges to inventory obsolescence expense totaled</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ChargesToInventoryObsolescenceExpenseTotaled' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Charges to inventory obsolescence expense totaled</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ChargesToInventoryObsolescenceExpenseTotaled' xlink:to='lab_fil_ChargesToInventoryObsolescenceExpenseTotaled'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Construction Loan Facility:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Useful lives of the assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of useful lives of the assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:to='lab_fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:to='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract' xlink:label='us-gaap_FairValueDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueDisclosuresAbstract' xlink:to='lab_us-gaap_FairValueDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='lab_us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Investing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:to='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapital' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapital' xlink:to='lab_us-gaap_AdditionalPaidInCapital'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:to='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:label='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='lab_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRate2016' xlink:label='fil_EnterpriseIncomeTaxRate2016'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2016' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2016</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2016' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2016</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2016' xlink:to='lab_fil_EnterpriseIncomeTaxRate2016'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation Expense property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DepreciationExpensePropertyAndEquipment' xlink:to='lab_fil_DepreciationExpensePropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMaximumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Warrants' xlink:label='fil_Warrants'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Warrants' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Warrants</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Warrants' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of warrants.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Warrants' xlink:to='lab_fil_Warrants'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BasicAndDilutedLossPerCommonShareTablesAbstract' xlink:label='fil_BasicAndDilutedLossPerCommonShareTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BasicAndDilutedLossPerCommonShareTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BasicAndDilutedLossPerCommonShareTablesAbstract' xlink:to='lab_fil_BasicAndDilutedLossPerCommonShareTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:to='lab_us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RisksAndUncertaintiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='lab_us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:to='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Cash Flow Information:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss from operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenuesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenues {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenuesAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenuesAbstract' xlink:to='lab_us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AllowanceForObsolescenceOfInventory' xlink:label='fil_AllowanceForObsolescenceOfInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForObsolescenceOfInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for obsolescence of inventory</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForObsolescenceOfInventory' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Allowance for obsolescence of inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForObsolescenceOfInventory' xlink:to='lab_fil_AllowanceForObsolescenceOfInventory'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NotesPayableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Short-term notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NotesPayableCurrent' xlink:to='lab_us-gaap_NotesPayableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DueToRelatedPartiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables - related parties</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DueToRelatedPartiesCurrent' xlink:to='lab_us-gaap_DueToRelatedPartiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent' xlink:label='us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherRestrictedAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherRestrictedAssetsCurrent' xlink:to='lab_us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommonSharesParValue' xlink:label='fil_CommonSharesParValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesParValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares par value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesParValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of common stock.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesParValue' xlink:to='lab_fil_CommonSharesParValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel2' xlink:to='lab_fil_BankersAcceptanceNotesLevel2'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_USNetOperatingLossCarryForward' xlink:label='fil_USNetOperatingLossCarryForward'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_USNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>U.S. net operating loss carry forward</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_USNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_USNetOperatingLossCarryForward' xlink:to='lab_fil_USNetOperatingLossCarryForward'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LoanInterestForAnEightYearTerm' xlink:label='fil_LoanInterestForAnEightYearTerm'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LoanInterestForAnEightYearTerm' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loan interest for an eight-year term</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LoanInterestForAnEightYearTerm' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Loan interest for an eight-year term</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LoanInterestForAnEightYearTerm' xlink:to='lab_fil_LoanInterestForAnEightYearTerm'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMaximumLife' xlink:to='lab_fil_PermitOfLandUseMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryGross' xlink:to='lab_us-gaap_InventoryGross'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare' xlink:label='us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted loss per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted weighted-average common shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:to='lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Bad debt expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BadDebtExpense' xlink:to='lab_fil_BadDebtExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryPolicyTextBlock' xlink:to='lab_us-gaap_InventoryPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayable1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayable1Abstract' xlink:to='lab_fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:to='lab_us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DepreciationDepletionAndAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation and amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DepreciationDepletionAndAmortization' xlink:to='lab_us-gaap_DepreciationDepletionAndAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InvestmentIncomeInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InvestmentIncomeInterest' xlink:to='lab_us-gaap_InvestmentIncomeInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization on Intangible assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:to='lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue' xlink:label='us-gaap_DeferredRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredRevenue' xlink:to='lab_us-gaap_DeferredRevenue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesAuthorized' xlink:to='lab_fil_CommonSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2021</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2021' xlink:to='lab_fil_PrincipalPayments2021'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2018</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2018' xlink:to='lab_fil_PrincipalPayments2018'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateWasAdjustedTo' xlink:label='fil_InterestRateWasAdjustedTo'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateWasAdjustedTo' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate was adjusted to</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateWasAdjustedTo' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate was adjusted to</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateWasAdjustedTo' xlink:to='lab_fil_InterestRateWasAdjustedTo'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross' xlink:label='us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment Gross Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentGross' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LandAndLandImprovements' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LandAndLandImprovements' xlink:to='lab_us-gaap_LandAndLandImprovements'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract' xlink:label='us-gaap_InventoryNetAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNetAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNetAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNetAbstract' xlink:to='lab_us-gaap_InventoryNetAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConsolidationPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Consolidation and Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConsolidationPolicyTextBlock' xlink:to='lab_us-gaap_ConsolidationPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureTextBlock' xlink:to='lab_us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:to='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryObsolescenceReserve' xlink:label='fil_InventoryObsolescenceReserve'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence reserve</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryObsolescenceReserve' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryObsolescenceReserve' xlink:to='lab_fil_InventoryObsolescenceReserve'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetIncomeLoss' xlink:to='lab_us-gaap_NetIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherIncomeAndExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='lab_us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingExpense' xlink:to='lab_us-gaap_SellingExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:label='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated depreciation on Property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:to='lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesNoncurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Non-current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Cash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Cash' xlink:to='lab_us-gaap_Cash'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Concentrations Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company made payments as per Construction agreement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='lab_fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes,</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotes' xlink:to='lab_fil_BankersAcceptanceNotes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income tax assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='lab_fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyForeignSubsidiarySinceItsAcquisition' xlink:label='fil_CompanyForeignSubsidiarySinceItsAcquisition'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyForeignSubsidiarySinceItsAcquisition' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company foreign subsidiary, since its acquisition</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyForeignSubsidiarySinceItsAcquisition' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company foreign subsidiary, since its acquisition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyForeignSubsidiarySinceItsAcquisition' xlink:to='lab_fil_CompanyForeignSubsidiarySinceItsAcquisition'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMaximumLife' xlink:to='lab_fil_OfficeEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_MachineryAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_MachineryAndEquipmentGross' xlink:to='lab_us-gaap_MachineryAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Enterprise Income Tax Rates</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:to='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskCreditRisk' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Credit Risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskCreditRisk' xlink:to='lab_us-gaap_ConcentrationRiskCreditRisk'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountingPoliciesAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Policies:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='lab_fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:to='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure of advances for purchases of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Noncash Investing and Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net (Decrease) Increase in Cash and Cash Equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:to='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income - foreign currency translation adjustment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>General and administrative expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_GeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermConstructionLoanCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current portion of construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermConstructionLoanCurrent' xlink:to='lab_us-gaap_LongTermConstructionLoanCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets, net of accumulated amortization of $4,456,837 and $4,360,004, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchasesOfIntangibleAssets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssets' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ThirdCustomerAccounted' xlink:label='fil_ThirdCustomerAccounted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Third customer accounted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Third customer accounted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ThirdCustomerAccounted' xlink:to='lab_fil_ThirdCustomerAccounted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesOwingToBoardOfDirectors' xlink:label='fil_AdvancesOwingToBoardOfDirectors'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesOwingToBoardOfDirectors' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances owing to board of directors</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesOwingToBoardOfDirectors' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Advances owing to board of directors</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesOwingToBoardOfDirectors' xlink:to='lab_fil_AdvancesOwingToBoardOfDirectors'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AssetsDepreciationAbstract' xlink:label='fil_AssetsDepreciationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AssetsDepreciationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Assets Depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AssetsDepreciationAbstract' xlink:to='lab_fil_AssetsDepreciationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMinimumLife' xlink:to='lab_fil_PermitOfLandUseMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consisted of the following details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EffectOfDilutiveSecuritiesAbstract' xlink:label='fil_EffectOfDilutiveSecuritiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EffectOfDilutiveSecuritiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of dilutive securities:</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EffectOfDilutiveSecuritiesAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EffectOfDilutiveSecuritiesAbstract' xlink:to='lab_fil_EffectOfDilutiveSecuritiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NetLoss1' xlink:label='fil_NetLoss1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss {2}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net loss</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetLoss1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>NetLoss1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetLoss1' xlink:to='lab_fil_NetLoss1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='lab_fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and Development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Operating Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CustomerAdvancesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CustomerAdvancesCurrent' xlink:to='lab_us-gaap_CustomerAdvancesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:label='fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One customer accounted for percentage of accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>One customer accounted for percentage of accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:to='lab_fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate Thereafter</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRateThereafter' xlink:to='lab_fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' xlink:label='fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Line of credit is payable in two equal installments of RMB 15,000,000</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank&apos;s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' xlink:to='lab_fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_RevolvingLineOfCreditWithABankRmb' xlink:label='fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRmb' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revolving line of credit with a bank (RMB)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RevolvingLineOfCreditWithABankRmb' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank&apos;s commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RevolvingLineOfCreditWithABankRmb' xlink:to='lab_fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Options' xlink:label='fil_Options'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Options' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Options</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Options' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of options.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Options' xlink:to='lab_fil_Options'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='lab_us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at Beginning of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of Exchange Rate Changes on Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other receivables, less allowance for doubtful accounts of $78,558 and $74,400, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:to='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares par value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesParValue' xlink:to='lab_fil_PreferredSharesParValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 2 total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel2' xlink:to='lab_fil_TotalLevel2'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total loan facility amount (RMB 80,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total loan facility amount (RMB 80,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLoanFacilityAmountRmb80000000' xlink:to='lab_fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ConstructionLoanFacilityDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='lab_fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMinimumLife' xlink:to='lab_fil_OfficeEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:label='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Numerators and denominators used in the calculation of basic and diluted loss per share details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='lab_fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY (TABLES)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryTablesAbstract' xlink:to='lab_fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UseOfEstimates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Estimates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UseOfEstimates' xlink:to='lab_us-gaap_UseOfEstimates'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromConstructionLoansPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payments of construction term loan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromConstructionLoansPayable' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Payments of construction term loan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromConstructionLoansPayable' xlink:to='lab_us-gaap_ProceedsFromConstructionLoansPayable'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in assets and liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncreaseInBadDebtExpense' xlink:label='fil_IncreaseInBadDebtExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncreaseInBadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncreaseInBadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Bad debt expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncreaseInBadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncreaseInBadDebtExpense' xlink:to='lab_fil_IncreaseInBadDebtExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesIssued' xlink:to='lab_us-gaap_PreferredStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory, less allowance for obsolescence of $6,696,224 and $8,417,095, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts of $29,598,703 and $28,644,398, respectively</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' xlink:to='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DocumentAndEntityInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document and Entity Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='lab_fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccountedForPercentageOfSales' xlink:label='fil_OneCustomerAccountedForPercentageOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One customer accounted for percentage of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccountedForPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>No customer accounted for more than percentage of sales</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneCustomerAccountedForPercentageOfSales' xlink:to='lab_fil_OneCustomerAccountedForPercentageOfSales'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:to='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesAuthorized' xlink:to='lab_fil_PreferredSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total bankers acceptance notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Total1' xlink:to='lab_fil_Total1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:label='fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise income tax rates details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Received cash subsidy from the government for the enterprises that suffered losses from the typhoon to resume production</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='lab_fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SubsidyIncomeDetailsAbstract' xlink:label='fil_SubsidyIncomeDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SubsidyIncomeDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SUBSIDY INCOME DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SubsidyIncomeDetailsAbstract' xlink:to='lab_fil_SubsidyIncomeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='lab_fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerSharePolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and Diluted (Loss) Earnings per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerSharePolicyTextBlock' xlink:to='lab_us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Financing Activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss per share:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='lab_us-gaap_EarningsPerShareAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Revenues' xlink:to='lab_us-gaap_Revenues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableOtherCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableOtherCurrent' xlink:to='lab_us-gaap_AccountsPayableOtherCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel1' xlink:to='lab_fil_BankersAcceptanceNotesLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrcNetOperatingLossCarryForward' xlink:label='fil_PrcNetOperatingLossCarryForward'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrcNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PRC net operating loss carry forward</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrcNetOperatingLossCarryForward' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrcNetOperatingLossCarryForward' xlink:to='lab_fil_PrcNetOperatingLossCarryForward'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InvestmentInHelpson' xlink:label='fil_InvestmentInHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Investment in Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Investment in Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InvestmentInHelpson' xlink:to='lab_fil_InvestmentInHelpson'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMaximumLife' xlink:to='lab_fil_MotorVehicleMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Less: accumulated depreciation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LessAccumulatedDepreciation' xlink:to='lab_fil_LessAccumulatedDepreciation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryFinishedGoods' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryFinishedGoods' xlink:to='lab_us-gaap_InventoryFinishedGoods'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic weighted-average common shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:to='lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to Suppliers and Advances from Customers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:to='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:to='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityAbstract' xlink:to='lab_us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfRevenue' xlink:to='lab_us-gaap_CostOfRevenue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesAuthorized' xlink:to='lab_us-gaap_PreferredStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:label='fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>No customer accounted for more than percentage of sales</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>No customer accounted for more than percentage of sales</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:to='lab_fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NotesPayablesDetailsAbstract' xlink:label='fil_NotesPayablesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NotesPayablesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='lab_fil_NotesPayablesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:to='lab_fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossCarryingAmount' xlink:to='lab_fil_GrossCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMinimumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:label='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Estimated useful lives of the assets as follows:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='lab_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipment1' xlink:label='fil_OfficeEquipment1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipment1' xlink:to='lab_fil_OfficeEquipment1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work in process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWorkInProcess' xlink:to='lab_us-gaap_InventoryWorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:label='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company held the following assets and liabilities recorded at fair value as of December 31, 2014</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:to='lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets Medical Formulas</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Intangible Assets Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:to='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ReceivablesPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ReceivablesPolicyTextBlock' xlink:to='lab_us-gaap_ReceivablesPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DebtDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>NOTES PAYABLES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DebtDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>NOTES PAYABLES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DebtDisclosureTextBlock' xlink:to='lab_us-gaap_DebtDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Operating Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareDiluted' xlink:to='lab_us-gaap_EarningsPerShareDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on trade accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:to='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Parentheticals</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net of accumulated depreciation of $10,286,937 and $9,442,912, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:label='fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Provision for income taxes details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='lab_fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2019</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Principal amount paid by the company in 2019</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2019' xlink:to='lab_fil_PrincipalPayments2019'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyPrincipalPaymentRmb2000000' xlink:label='fil_CompanyPrincipalPaymentRmb2000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyPrincipalPaymentRmb2000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company principal payment (RMB2,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyPrincipalPaymentRmb2000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company principal payment (RMB2,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyPrincipalPaymentRmb2000000' xlink:to='lab_fil_CompanyPrincipalPaymentRmb2000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:label='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets amortization expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:to='lab_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleGross' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of motor vehicle gross as on the date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleGross' xlink:to='lab_fil_MotorVehicleGross'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryValuationReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryValuationReserves' xlink:to='lab_us-gaap_InventoryValuationReserves'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at End of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables and accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net other expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherExpenses' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Net other expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherExpenses' xlink:to='lab_us-gaap_OtherExpenses'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestExpense' xlink:to='lab_us-gaap_InterestExpense'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccounted' xlink:label='fil_OneCustomerAccounted'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One customer accounted</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneCustomerAccounted' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>One customer accounted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneCustomerAccounted' xlink:to='lab_fil_OneCustomerAccounted'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:label='fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Employee Stock Options 2010 Incentive Plan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:to='lab_fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel3' xlink:to='lab_fil_BankersAcceptanceNotesLevel3'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal payments required for the next five years are as follows:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_RelatedPartyTransactionsDetailsAbstract' xlink:label='fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS DETAILS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='lab_fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMinimumLife' xlink:to='lab_fil_MotorVehicleMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyHadTradeAccountsReceivableAmounting' xlink:label='fil_CompanyHadTradeAccountsReceivableAmounting'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadTradeAccountsReceivableAmounting' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company had trade accounts receivable amounting</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadTradeAccountsReceivableAmounting' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount classified as trade receivables attributable to disposal group held for sale or disposed of.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyHadTradeAccountsReceivableAmounting' xlink:to='lab_fil_CompanyHadTradeAccountsReceivableAmounting'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OrganizationAndNatureOfOperationsAbstract' xlink:label='fil_OrganizationAndNatureOfOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationAndNatureOfOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and Nature of Operations {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationAndNatureOfOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Organization and Nature of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationAndNatureOfOperationsAbstract' xlink:to='lab_fil_OrganizationAndNatureOfOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='lab_fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-Lived Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:to='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommitmentAndContingenciesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='lab_fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Carrying amount as of the balance sheet date of advances to suppliers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliers' xlink:to='lab_fil_AdvancesToSuppliers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:label='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>One supplier accounted for percentage of raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>One supplier accounted for percentage of raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:to='lab_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonShares' xlink:to='lab_fil_NumberOfCommonShares'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRate2015' xlink:label='fil_EnterpriseIncomeTaxRate2015'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2015' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rate 2015</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRate2015' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRate2015' xlink:to='lab_fil_EnterpriseIncomeTaxRate2015'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:label='fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company was obligated to pay laboratories and others</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company was obligated to pay laboratories and others</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:to='lab_fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Inventory</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInventory' xlink:to='lab_fil_TotalInventory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ResearchAndDevelopmentExpenses' xlink:label='fil_ResearchAndDevelopmentExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ResearchAndDevelopmentExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and development expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ResearchAndDevelopmentExpenses' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Research and development expenses</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ResearchAndDevelopmentExpenses' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity&apos;s use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ResearchAndDevelopmentExpenses' xlink:to='lab_fil_ResearchAndDevelopmentExpenses'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercetageOfAcquiredByOnnyInHelpson' xlink:to='lab_fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:to='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='lab_us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Purchases of property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2009/role/negatedLabel' xml:lang='en-US'>Purchases of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:to='lab_us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive income (loss)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and development expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryWriteDown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory obsolescence (benefit) expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryWriteDown' xlink:to='lab_us-gaap_InventoryWriteDown'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cphi-20160331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- NeoClarus - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20160331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_TradingSymbol' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='16.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDBALANCESHEETSUnaudited"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Cash' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent' xlink:label='us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherRestrictedAssetsCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsAndOtherReceivablesNetCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesToSuppliers' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PrepaidExpenseCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Assets' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LongTermConstructionLoanCurrent' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableCurrent' xlink:label='us-gaap_NotesPayableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_NotesPayableCurrent' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesNoncurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue' xlink:label='us-gaap_DeferredRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_DeferredRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent' xlink:label='us-gaap_DeferredTaxLiabilitiesNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_DeferredTaxLiabilitiesNoncurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AllowanceForObsolescenceOfInventory' xlink:label='fil_AllowanceForObsolescenceOfInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='fil_AllowanceForObsolescenceOfInventory' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' xlink:label='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' xlink:label='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='13.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_Revenues' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWriteDown' xlink:label='us-gaap_InventoryWriteDown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_InventoryWriteDown' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OtherIncomeAndExpensesAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InvestmentIncomeInterest' use='optional' order='1.0'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherExpenses' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncomeTaxExpense' xlink:label='fil_IncomeTaxExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='fil_IncomeTaxExpense' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTax' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_EarningsPerShareAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic' xlink:label='us-gaap_EarningsPerShareBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareBasic' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted' xlink:label='us-gaap_EarningsPerShareDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareDiluted' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_DepreciationDepletionAndAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncreaseInBadDebtExpense' xlink:label='fil_IncreaseInBadDebtExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_IncreaseInBadDebtExpense' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInIncomeTaxes' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryObsolescenceReserve' xlink:label='fil_InventoryObsolescenceReserve'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_InventoryObsolescenceReserve' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInDepositOtherAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidExpense' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='7.0'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='8.0'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromConstructionLoansPayable' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2009/role/negatedLabel'/>

		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='fil_CashAndCashEquivalentsAtBeginningOfPeriod' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='fil_CashAndCashEquivalentsAtEndOfPeriod' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='fil_AccountsReceivableCollectedWithBankerSAcceptances' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='fil_InventoryPurchasedWithBankerSAcceptances' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINVENTORY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureNOTESPAYABLE"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NotesPayable1Abstract' xlink:label='fil_NotesPayable1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock' xlink:label='us-gaap_DebtDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayable1Abstract' xlink:to='us-gaap_DebtDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DebtAbstract' xlink:to='us-gaap_LongTermDebtTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINCOMETAXES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='us-gaap_IncomeTaxDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract' xlink:label='us-gaap_FairValueDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_FairValueDisclosuresAbstract' xlink:to='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EquityAbstract' xlink:to='us-gaap_StockholdersEquityNoteDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='us-gaap_ConcentrationRiskDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NatureOfOperations' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConsolidationPolicyTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_UseOfEstimates' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_CashAndCashEquivalentsPolicyTextBlock' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ReceivablesPolicyTextBlock' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_InventoryPolicyTextBlock' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ResearchAndDevelopmentExpensePolicy' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_EarningsPerSharePolicyTextBlock' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConcentrationRiskCreditRisk' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_InterestRateRiskPolicyTextBlock' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='16.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BasicAndDilutedLossPerCommonShareTablesAbstract' xlink:label='fil_BasicAndDilutedLossPerCommonShareTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' xlink:label='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BasicAndDilutedLossPerCommonShareTablesAbstract' xlink:to='us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryTablesAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='fil_UsefulLivesOfTheAssetsTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='us-gaap_ScheduleOfDebtInstrumentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_FairValueMeasuresAndDisclosuresAbstract' xlink:label='fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:label='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasuresAndDisclosuresAbstract' xlink:to='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_OrganizationAndNatureOfOperationsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OrganizationAndNatureOfOperationsAbstract' xlink:label='fil_OrganizationAndNatureOfOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndNatureOfOperationsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndNatureOfOperationsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndNatureOfOperationsAbstract' xlink:to='fil_PercetageOfAcquiredByOnnyInHelpson' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:label='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_BadDebtExpense' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyHadTradeAccountsReceivableAmounting' xlink:label='fil_CompanyHadTradeAccountsReceivableAmounting'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_CompanyHadTradeAccountsReceivableAmounting' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract' xlink:label='us-gaap_InventoryNetAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='us-gaap_InventoryNetAbstract' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ChargesToInventoryObsolescenceExpenseTotaled' xlink:label='fil_ChargesToInventoryObsolescenceExpenseTotaled'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_ChargesToInventoryObsolescenceExpenseTotaled' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyRecognizedAnInventoryObsolescenceReserve' xlink:label='fil_CompanyRecognizedAnInventoryObsolescenceReserve'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_CompanyRecognizedAnInventoryObsolescenceReserve' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ResearchAndDevelopmentExpenses' xlink:label='fil_ResearchAndDevelopmentExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_ResearchAndDevelopmentExpenses' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:label='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NetLoss1' xlink:label='fil_NetLoss1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='fil_NetLoss1' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' xlink:label='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='us-gaap_WeightedAverageNumberOfSharesOutstandingBasic' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EffectOfDilutiveSecuritiesAbstract' xlink:label='fil_EffectOfDilutiveSecuritiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='fil_EffectOfDilutiveSecuritiesAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Warrants' xlink:label='fil_Warrants'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='fil_Warrants' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Options' xlink:label='fil_Options'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='fil_Options' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' xlink:label='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare' xlink:label='us-gaap_IncomeLossFromContinuingOperationsPerBasicShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsPerBasicShare' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare' xlink:label='us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_INVENTORYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InventoryDetailsAbstract' xlink:label='fil_InventoryDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess' xlink:label='us-gaap_InventoryWorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryWorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods' xlink:label='us-gaap_InventoryFinishedGoods'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryFinishedGoods' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='us-gaap_InventoryValuationReserves' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryDetailsAbstract' xlink:to='fil_TotalInventory' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_LandAndLandImprovements' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_BuildingsAndImprovementsGross' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_MachineryAndEquipmentGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleGross' xlink:label='fil_MotorVehicleGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_MotorVehicleGross' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipment1' xlink:label='fil_OfficeEquipment1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_OfficeEquipment1' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross' xlink:label='us-gaap_PropertyPlantAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='us-gaap_PropertyPlantAndEquipmentGross' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_LessAccumulatedDepreciation' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract' xlink:to='fil_PropertyAndEquipmentNet' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:label='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PermitOfLandUseMinimumLife' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PermitOfLandUseMaximumLife' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_BuildingMinimumLife' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_BuildingMaximumLife' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PlantMachineryAndEquipmentMinimumLife' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_PlantMachineryAndEquipmentMaximumLife' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_MotorVehicleMinimumLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_MotorVehicleMaximumLife' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_OfficeEquipmentMinimumLife' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract' xlink:to='fil_OfficeEquipmentMaximumLife' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AssetsDepreciationAbstract' xlink:label='fil_AssetsDepreciationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AssetsDepreciationAbstract' xlink:to='fil_DepreciationExpensePropertyAndEquipment' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_GrossCarryingAmount' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_AccumulatedAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract' xlink:to='fil_NetCarryingAmount' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_IntangibleAssetsAmortizationExpensesDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:label='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsAmortizationExpensesDetailsAbstract' xlink:to='fil_AmortizationExpensesRelatingToIntangibleAssets' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyWasObligatedToPayLaboratoriesAndOthers' xlink:label='fil_CompanyWasObligatedToPayLaboratoriesAndOthers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='fil_CompanyWasObligatedToPayLaboratoriesAndOthers' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_RELATEDPARTYTRANSACTIONSDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_RelatedPartyTransactionsDetailsAbstract' xlink:label='fil_RelatedPartyTransactionsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AdvancesOwingToBoardOfDirectors' xlink:label='fil_AdvancesOwingToBoardOfDirectors'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_AdvancesOwingToBoardOfDirectors' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_InterestRateOnAdvancesFromMemberOfBOD' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalInterestExpense' xlink:label='fil_TotalInterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsDetailsAbstract' xlink:to='fil_TotalInterestExpense' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_NOTESPAYABLESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NotesPayablesDetailsAbstract' xlink:label='fil_NotesPayablesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_RevolvingLineOfCreditWithABankRmb' xlink:label='fil_RevolvingLineOfCreditWithABankRmb'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_RevolvingLineOfCreditWithABankRmb' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' xlink:label='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' xlink:label='fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' xlink:label='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_NotesPayablesDetailsAbstract' xlink:to='fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyPrincipalPaymentRmb2000000' xlink:label='fil_CompanyPrincipalPaymentRmb2000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_CompanyPrincipalPaymentRmb2000000' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_TotalLoanFacilityAmountRmb80000000' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_LoanInterestForAnEightYearTerm' xlink:label='fil_LoanInterestForAnEightYearTerm'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_LoanInterestForAnEightYearTerm' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InterestRateWasAdjustedTo' xlink:label='fil_InterestRateWasAdjustedTo'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_InterestRateWasAdjustedTo' use='optional' order='4.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2017' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2018' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2019' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2020' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2021' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrincipalPayments2022' xlink:label='fil_PrincipalPayments2022'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2022' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_TotalPrincipalPaymentsDue' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_SUBSIDYINCOMEDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SubsidyIncomeDetailsAbstract' xlink:label='fil_SubsidyIncomeDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CompanyForeignSubsidiarySinceItsAcquisition' xlink:label='fil_CompanyForeignSubsidiarySinceItsAcquisition'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_SubsidyIncomeDetailsAbstract' xlink:to='fil_CompanyForeignSubsidiarySinceItsAcquisition' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_InvestmentInHelpson' xlink:label='fil_InvestmentInHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_SubsidyIncomeDetailsAbstract' xlink:to='fil_InvestmentInHelpson' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_ENTERPRISEINCOMETAXRATESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:label='fil_EnterpriseIncomeTaxRatesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRate2015' xlink:label='fil_EnterpriseIncomeTaxRate2015'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2015' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRate2016' xlink:label='fil_EnterpriseIncomeTaxRate2016'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRate2016' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_EnterpriseIncomeTaxRatesDetailsAbstract' xlink:to='fil_EnterpriseIncomeTaxRateThereafter' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_PROVISIONFORINCOMETAXESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:label='fil_ProvisionForIncomeTaxesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit' xlink:label='us-gaap_CurrentIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='us-gaap_CurrentIncomeTaxExpenseBenefit' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='us-gaap_DeferredIncomeTaxExpenseBenefit' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalIncomeTaxExpense1' xlink:label='fil_TotalIncomeTaxExpense1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ProvisionForIncomeTaxesDetailsAbstract' xlink:to='fil_TotalIncomeTaxExpense1' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_DeferredIncomeTaxAssetsAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PrcNetOperatingLossCarryForward' xlink:label='fil_PrcNetOperatingLossCarryForward'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_PrcNetOperatingLossCarryForward' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_USNetOperatingLossCarryForward' xlink:label='fil_USNetOperatingLossCarryForward'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='fil_USNetOperatingLossCarryForward' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance' xlink:label='us-gaap_DeferredTaxAssetsValuationAllowance'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAbstract' xlink:to='us-gaap_DeferredTaxAssetsValuationAllowance' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:label='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotes' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_Total1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel2' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel2' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel3' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel3' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CAPITALSTOCKTRANSACTIONSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CapitalStockTransactionsAbstract' xlink:label='fil_CapitalStockTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_CommonSharesAuthorized' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_PreferredSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_CommonSharesParValue' xlink:label='fil_CommonSharesParValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_CommonSharesParValue' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_PreferredSharesParValue' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_EmployeeStockOptions2010IncentivePlanAbstract' xlink:label='fil_EmployeeStockOptions2010IncentivePlanAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_EmployeeStockOptions2010IncentivePlanAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_NumberOfCommonShares' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CapitalStockTransactionsAbstract' xlink:to='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20160331.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_NoCustomerAccountedForMoreThanPercentageOfSales' xlink:label='fil_NoCustomerAccountedForMoreThanPercentageOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_NoCustomerAccountedForMoreThanPercentageOfSales' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccounted' xlink:label='fil_OneCustomerAccounted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneCustomerAccounted' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_SecondCustomerAccounted' xlink:label='fil_SecondCustomerAccounted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_SecondCustomerAccounted' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_ThirdCustomerAccounted' xlink:label='fil_ThirdCustomerAccounted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_ThirdCustomerAccounted' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccountedForPercentageOfSales' xlink:label='fil_OneCustomerAccountedForPercentageOfSales'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneCustomerAccountedForPercentageOfSales' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' xlink:label='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20160331.xsd#fil_OneCustomerAccountedForPercentageOfAccountsReceivable' xlink:label='fil_OneCustomerAccountedForPercentageOfAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_OneCustomerAccountedForPercentageOfAccountsReceivable' use='optional' order='7.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6729986864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>May. 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Entity Trading Symbol</a></td>
<td class="text">cphi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735243616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,261,777<span></span>
</td>
<td class="nump">$ 6,248,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Banker's acceptances</a></td>
<td class="nump">116,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively', window );">Trade accounts receivable, less allowance for doubtful accounts of $29,598,703 and $28,644,398, respectively</a></td>
<td class="nump">4,791,247<span></span>
</td>
<td class="nump">5,882,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $78,558 and $74,400, respectively</a></td>
<td class="nump">191,958<span></span>
</td>
<td class="nump">290,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliers', window );">Advances to suppliers</a></td>
<td class="nump">2,643,516<span></span>
</td>
<td class="nump">2,533,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, less allowance for obsolescence of $6,696,224 and $8,417,095, respectively</a></td>
<td class="nump">9,917,139<span></span>
</td>
<td class="nump">9,662,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">195,081<span></span>
</td>
<td class="nump">339,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">25,117,035<span></span>
</td>
<td class="nump">24,957,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssets', window );">Advances for purchases of intangible assets</a></td>
<td class="nump">42,309,641<span></span>
</td>
<td class="nump">42,030,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $10,286,937 and $9,442,912, respectively</a></td>
<td class="nump">28,826,692<span></span>
</td>
<td class="nump">29,393,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $4,456,837 and $4,360,004, respectively</a></td>
<td class="nump">778,766<span></span>
</td>
<td class="nump">841,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">97,032,134<span></span>
</td>
<td class="nump">97,222,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">3,744,095<span></span>
</td>
<td class="nump">2,824,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">113,627<span></span>
</td>
<td class="nump">143,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">1,712,024<span></span>
</td>
<td class="nump">1,710,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Advances from customers</a></td>
<td class="nump">932,653<span></span>
</td>
<td class="nump">595,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other payables - related parties</a></td>
<td class="nump">1,354,567<span></span>
</td>
<td class="nump">1,354,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermConstructionLoanCurrent', window );">Current portion of construction loan facility</a></td>
<td class="nump">1,550,893<span></span>
</td>
<td class="nump">1,540,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Short-term notes payable</a></td>
<td class="nump">4,652,678<span></span>
</td>
<td class="nump">4,621,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">14,060,537<span></span>
</td>
<td class="nump">12,791,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent', window );">Construction loan facility</a></td>
<td class="nump">10,546,069<span></span>
</td>
<td class="nump">10,784,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">534,833<span></span>
</td>
<td class="nump">708,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long-term deferred tax liability</a></td>
<td class="nump">322,012<span></span>
</td>
<td class="nump">296,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">25,463,451<span></span>
</td>
<td class="nump">24,581,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</a></td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">32,387,102<span></span>
</td>
<td class="nump">33,939,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss', window );">Accumulated other comprehensive income</a></td>
<td class="nump">15,547,797<span></span>
</td>
<td class="nump">15,067,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">71,568,683<span></span>
</td>
<td class="nump">72,641,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 97,032,134<span></span>
</td>
<td class="nump">$ 97,222,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchasesOfIntangibleAssets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade accounts receivable, less allowance for doubtful accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccountsOf29598703And28644398Respectively</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermConstructionLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermConstructionLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current and noncurrent portions of a long-term real estate loan with an initial maturity beyond one year or beyond the normal operating cycle, if longer, to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConstructionLoanCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other short-term assets not otherwise listed in the existing taxonomy that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated other comprehensive Income or Loss at the balance sheet date before fresh-start adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=34712771&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6721500384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS PARENTHETICALS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Parentheticals</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts on trade accounts receivable</a></td>
<td class="nump">$ 29,598,703<span></span>
</td>
<td class="nump">$ 28,644,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables', window );">Allowance for doubtful accounts on other receivables</a></td>
<td class="nump">78,558<span></span>
</td>
<td class="nump">74,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForObsolescenceOfInventory', window );">Allowance for obsolescence of inventory</a></td>
<td class="nump">6,696,224<span></span>
</td>
<td class="nump">8,417,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation on Property and equipment</a></td>
<td class="nump">10,286,937<span></span>
</td>
<td class="nump">9,442,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization on Intangible assets</a></td>
<td class="nump">$ 4,456,837<span></span>
</td>
<td class="nump">$ 4,360,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AllowanceForDoubtfulAccountsOnOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForObsolescenceOfInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for obsolescence of inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AllowanceForObsolescenceOfInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockTransactionsParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6730319536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues {1}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3,640,494<span></span>
</td>
<td class="nump">$ 5,694,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">3,071,461<span></span>
</td>
<td class="nump">4,434,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory obsolescence (benefit) expense</a></td>
<td class="num">(71,786)<span></span>
</td>
<td class="nump">201,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">640,819<span></span>
</td>
<td class="nump">1,059,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">968,507<span></span>
</td>
<td class="nump">988,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">318,930<span></span>
</td>
<td class="nump">472,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">93,433<span></span>
</td>
<td class="nump">160,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">581,300<span></span>
</td>
<td class="nump">3,200,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,962,170<span></span>
</td>
<td class="nump">4,822,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,321,351)<span></span>
</td>
<td class="num">(3,763,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">33,592<span></span>
</td>
<td class="nump">26,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(242,309)<span></span>
</td>
<td class="num">(313,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Net other expense</a></td>
<td class="num">(208,717)<span></span>
</td>
<td class="num">(286,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(1,530,068)<span></span>
</td>
<td class="num">(4,050,006)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxExpense', window );">Income tax expense</a></td>
<td class="num">(22,828)<span></span>
</td>
<td class="num">(19,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,552,896)<span></span>
</td>
<td class="num">(4,069,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency translation adjustment</a></td>
<td class="nump">480,430<span></span>
</td>
<td class="nump">435,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (1,072,466)<span></span>
</td>
<td class="num">$ (3,633,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents a sum total of expenses not separately reflected on the income statement for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6721583328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,552,896)<span></span>
</td>
<td class="num">$ (4,069,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">857,195<span></span>
</td>
<td class="nump">951,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncreaseInBadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">581,300<span></span>
</td>
<td class="nump">3,200,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">19,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryObsolescenceReserve', window );">Inventory obsolescence reserve</a></td>
<td class="num">(1,751,863)<span></span>
</td>
<td class="nump">201,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(61,069)<span></span>
</td>
<td class="num">(1,408,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Advances to suppliers</a></td>
<td class="num">(92,039)<span></span>
</td>
<td class="num">(154,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,967,359<span></span>
</td>
<td class="nump">396,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="nump">888,212<span></span>
</td>
<td class="nump">917,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Accrued taxes payable</a></td>
<td class="num">(53,955)<span></span>
</td>
<td class="nump">18,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="nump">25,514<span></span>
</td>
<td class="num">(4,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvances', window );">Advances from customers</a></td>
<td class="nump">328,354<span></span>
</td>
<td class="num">(243,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">144,262<span></span>
</td>
<td class="nump">173,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">1,303,202<span></span>
</td>
<td class="num">(2,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(39,248)<span></span>
</td>
<td class="num">(47,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(39,248)<span></span>
</td>
<td class="num">(47,106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConstructionLoansPayable', window );">Payments of construction term loan</a></td>
<td class="num">(305,835)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activity</a></td>
<td class="num">(305,835)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="nump">54,898<span></span>
</td>
<td class="nump">22,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="nump">1,013,017<span></span>
</td>
<td class="num">(26,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">6,248,760<span></span>
</td>
<td class="nump">5,295,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtEndOfPeriod', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">7,261,777<span></span>
</td>
<td class="nump">5,268,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">1,151,613<span></span>
</td>
<td class="nump">1,230,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsReceivableCollectedWithBankerSAcceptances', window );">Accounts receivable collected with banker's acceptances</a></td>
<td class="nump">517,770<span></span>
</td>
<td class="nump">464,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryPurchasedWithBankerSAcceptances', window );">Inventory purchased with banker's acceptances</a></td>
<td class="nump">$ 403,081<span></span>
</td>
<td class="nump">$ 551,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsReceivableCollectedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountsReceivableCollectedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncreaseInBadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncreaseInBadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryObsolescenceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory obsolescence reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryObsolescenceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryPurchasedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory purchased with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryPurchasedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConstructionLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings to finance the cost of construction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConstructionLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=35736750&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725369296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'><b>NOTE 1 &#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Organization and Nature of Operations &#150; </i></b>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white'>On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company's outstanding shares of common stock on December 21, 2012.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the "Catalogue") jointly issued by China's Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2015 version, effective April 10, 2015) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the "FIE") shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company's business.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson's business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Consolidation and Basis of Presentation </i></b>&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Accounting Estimates </i></b><b>- </b>The methodology used to prepare for the Company's financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company ("Management") to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Cash and Cash Equivalents </i></b>&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker's acceptances purchased with maturities of three months or less.</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $581,300&nbsp;and $3,200,003 for the three months ended March 31, 2016 and 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of March 31, 2016, the Company had trade accounts receivable amounting to $16,853,716 from sales that occurred more than one year from that date, which the Company believes are collectable.</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Advances to Suppliers and Advances from Customers</i></b> &#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Inventory</i></b> &#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled ($71,786) and $201,097 for the three months ended March 31, 2016 and 2015, respectively. The Company recognized an inventory obsolescence reserve of $6,696,224 and $8,417,095 as of March 31, 2016 and December 31, 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Valuation of Long-Lived Assets</i></b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2016 and 2015.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Property and Equipment</i></b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Revenue Recognition</i></b> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&nbsp; Revenue is deferred when collectability is not considered to be reasonably assured.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Cost of Revenues</i></b> &#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Research and Development</i></b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $93,433 and $160,828 for the three months ended March 31, 2016 and 2015, respectively.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Basic and Diluted Loss per Common Share </i></b><b>- </b>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Three Months&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Ended March 31,&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Net loss</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(1,530,068</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,069,290</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Effect of dilutive securities:</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Warrants</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Options</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr></table></div> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>There were no potential dilutive common shares outstanding during the three months ended March 31, 2016 and 2015, respectively.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Credit Risk</i></b> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company's deposits may be at a higher risk of loss.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Interest Rate Risk</i></b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Recent Accounting Pronouncements</i></b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services.&nbsp; In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In January 2016, the FASB issued Accounting Standards Update 2016-01,&nbsp;"<i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>." The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on its financial statements.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white'>Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company's financial position, result of operations or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6603895280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'><b>NOTE 2 &#150; INVENTORY</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>Inventory consisted of the following:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Raw materials</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>12,329,926</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>14,699,736</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Work in process</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>618,329</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Finished goods</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>3,665,108</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>3,380,109</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>16,613,363</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>18,079,845</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Obsolescence reserve</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(6,696,224</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(8,417,095</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Total Inventory</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>9,917,139</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>9,662,750</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a, b, c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725378912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'><b>NOTE 3 - PROPERTY AND EQUIPMENT</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>Property and equipment consisted of the following:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>436,836</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>433,956</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>10,627,311</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>10,557,234</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>27,521,628</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>27,325,440</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>268,279</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>242,860</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>259,575</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>256,679</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>39,113,629</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>38,816,169</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Less: accumulated depreciation</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(10,286,937</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(9,422,912</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Property and Equipment, net</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>28,826,692</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>29,393,257</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table> <p style='margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%;border-collapse:collapse'> <tr> <td valign="top" width="69%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:69.64%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>Asset</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:3.36%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>&nbsp;Life - years</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>40 - 70</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Building</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>20 - 49</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Office equipment</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>3-5</p></td></tr></table></div> <p align="center" style='text-align:center;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended March 31, 2016 and 2015, depreciation expense was $790,254 and $854,485, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6880770368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b>NOTE 4 - INTANGIBLE ASSETS</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration ("CFDA"). The Company did not obtain CFDA production approval for any medical formula during the three months ended March 31, 2016 and 2015 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2016 and 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&nbsp;&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $66,941 and $96,726 for the three months ended March 31, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2016 and 2015.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Intangible assets consisted solely of CFDA approved medical formulas as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%'> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Gross carrying amount</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>5,235,603</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>5,201,079</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Accumulated amortization</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,456,837</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,360,004</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Net carrying amount</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>778,766</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>841,075</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725369296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract', window );"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock', window );">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'><b>&nbsp;</b></p> <p style='line-height:10.25pt;margin:3pt 0in'><b>NOTE 5 &#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Prior to entering into contracts with the Company, laboratories typically are required to complete all&nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA's approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&nbsp;&nbsp;the Company signs the medical formula contracts.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>As of March 31, 2016, the Company was obligated to pay laboratories and others approximately $4,785,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of advances for purchases of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6880770080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b>NOTE 6 &#150; RELATED PARTY TRANSACTIONS</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>A member of the Company's board of directors had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2016 and December 31, 2015 which are recorded as other payables &#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&nbsp;&nbsp;Total interest expense of $3,386 was recognized for each of the three months ended March 31, 2016 and 2015.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725375104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayable1Abstract', window );"><strong>NOTES PAYABLES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLES</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b>NOTE 7 &#150; NOTES PAYABLE</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In November 2014, the Company entered into a new line of credit with the same bank on identical terms.&nbsp;&nbsp; Advances on the line of credit were due one year from the date of the advance and were collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.16% (based upon 110% of the PRC government's current short term rate of 5.6%). In addition, the Company's Chief Executive Officer and Chair of the board of directors personally guaranteed the new line of credit. In November 2015 the Company renewed its line of credit in the amount of RMB 30,000,000 with the same bank.&nbsp;&nbsp;The line of credit is payable in two equal installments of RMB 15,000,000 ($2.31 million) payable on September 16, 2016 and October 19, 2016.&nbsp;&nbsp;Advances on the line of credit are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 5.06% (based upon 110% of the PRC government's current short term rate of 4.6%). In addition, the Company's Chief Executive Officer and Chairman of the Board personally guaranteed the line of credit.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of March 31, 2016 and December 31, 2015 ($4,652,678 as of March 31, 2016 and $4,621,998 as of December 31, 2015).&nbsp;&nbsp;The Company has no additional amounts available to it under this line of credit.&nbsp;&nbsp;This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets as of March 31, 2016.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Fair Value of</i></b>&nbsp;<b><i>Notes Payable</i></b> &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable outstanding as of March 31, 2016 and December 31, 2015 approximated their fair value because of the immediate or short-term maturity of these financial instruments and because the underlying instruments bear interest rates that approximated current market rates.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayable1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NotesPayable1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725361792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtAbstract', window );"><strong>CONSTRUCTION LOAN FACILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONSTRUCTION LOAN FACILITY</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b>NOTE 8 &#150; CONSTRUCTION LOAN FACILITY</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company obtained a construction loan facility in the amount of RMB 80,000,000 from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same bank that currently provides the line of credit as discussed in Note 7.&nbsp;&nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company's new production facility and the included production line equipment and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government's eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94%.&nbsp; The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. In January 2016, the Company made a principal payment in the amount of approximately $309,000 (RMB2,000,000) with the remaining annual principal payment of $1,320,000 (8,000,000 RMB) being due in July 2016. As of March 31, 2016, the Company had no additional amounts available to it under this facility.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Principal payments required for the next five years as of March 31, 2016 are as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="70%" style='width:70%'> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:85%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Twelve Months Ending March 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Amount</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>1,550,893</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>1,240,714</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2022</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>12,096,962</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Fair Value of</i></b>&nbsp;<b><i>Construction Loan Facility</i></b> &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725334368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><!--egx--><p style='margin:3pt 0in;line-height:10.25pt'><b>NOTE 9 - INCOME TAXES</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.</p> <p style='margin:3pt 0in;line-height:10.25pt'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>Undistributed earnings of Helpson, the Company's foreign subsidiary, since its acquisition, amounted to approximately $38.5 million as of March 31, 2016. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through March 31, 2016, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2012 through December 31, 2015 and the Chinese income tax return for the year ended December 31, 2015 are open for possible examination.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>On March 16, 2007, the National People's Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&nbsp;&nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>&nbsp;</p> <div align="center"> <table cellspacing="0" cellpadding="0" width="50%" border="0" style='width:50%;border-collapse:collapse'> <tr> <td valign="top" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'><b>Enterprise Income </b></p></td></tr> <tr> <td valign="top" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'><b>Year</b></p></td> <td valign="top" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Tax Rate&nbsp;</b></p></td></tr> <tr> <td valign="top" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>2015</p></td> <td valign="top" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>15%</p></td></tr> <tr> <td valign="top" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>2016</p></td> <td valign="top" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:white;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>15%</p></td></tr> <tr> <td valign="top" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40.32%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>Thereafter</p></td> <td valign="top" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10.12%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:49.54%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'>25%</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p> <p align="center" style='text-align:center;margin:3pt 0in;line-height:10.25pt'>The provision for income taxes consisted of the following:</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>&nbsp;</p> <div align="center"> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%'> <tr> <td valign="top" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'><b>Three Months Ended March 31,</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'><b>2016</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p align="center" style='text-align:center;margin:0in 0in 0pt;line-height:11.4pt'><b>2015</b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>Current</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>$</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>-</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>$</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>-</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>Deferred</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>22,828</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:white;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>19,284</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:76%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'><b>Total income tax expense</b></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>$</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>22,828</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt;line-height:11.4pt'>$</p></td> <td valign="bottom" width="9%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:9%;background:#cceeff;border-bottom:black 1.5pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt;line-height:11.4pt'>19,284</p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:#cceeff;border-bottom:#f0f0f0;padding-bottom:1.5pt;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>As of March 31, 2016, the Company had net operating loss carryforwards for PRC tax purposes of approximately $35.5 million which are available to offset any future taxable income through 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $4.1 million which are available to offset future taxable income, if any, through 2036.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp;&nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&nbsp;&nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2016 and December 31, 2015.&nbsp;&nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $12,897,790 and $12,798,572 as of March 31, 2016 and December 31, 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725308816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;<b>NOTE 10 &#150; FAIR VALUE MEASUREMENTS</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The banker's acceptances are recorded at cost which approximates fair value.&nbsp;&nbsp;The Company held the following assets and liabilities recorded at fair value as of March 31, 2016:</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Fair Value Measurements at</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Reporting Date Using&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Description</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31, 2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 1</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 2</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 3</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Banker's acceptances</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Total</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6605387312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'><b>NOTE 11 - STOCKHOLDERS' EQUITY</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company's Board.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><u>Employee Stock Options</u></b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><i>2010 Incentive Plan</i></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>On November 12, 2010, the Company's Board of Directors adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March 31, 2016, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&nbsp; No options were outstanding as of March 31, 2016 under the Plan.</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;There were no securities issued from the Plan during each of the three months ended March 31, 2016 and 2015.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three months ended March 31, 2016 and 2015.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company's common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>As of March 31, 2016, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725333104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b>NOTE 12 &#150; COMMITMENTS AND CONTINGENCIES</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Economic environment </i></b><b>- </b>Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommitmentAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6610712288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'><b>NOTE 15 &#150; CONCENTRATIONS</b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>For the three months ended March 31, 2016, no customer accounted for more than 10% of sales and&nbsp;three customers accounted for 28.5%, 11.4% and 11.0%&nbsp; of accounts receivable, respectively.&nbsp;No supplier accounted for greater than 10% of raw material purchases.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'>For the three months ended March 31, 2015, one customer accounted for 19.7% of sales and one supplier accounted for 29.5% of raw material purchases and one customer accounted for 17.3% of accounts receivable.</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735215520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountingPoliciesAbstract1', window );"><strong>Accounting Policies:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Organization and Nature of Operations &#150; </i></b>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white'>On December 31, 2012, China Pharma Holdings, Inc consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company's outstanding shares of common stock on December 21, 2012.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the "Catalogue") jointly issued by China's Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2015 version, effective April 10, 2015) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the "FIE") shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company's business.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson's business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Consolidation and Basis of Presentation </i></b>&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Accounting Estimates </i></b><b>- </b>The methodology used to prepare for the Company's financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company ("Management") to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Cash and Cash Equivalents </i></b>&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker's acceptances purchased with maturities of three months or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:3pt 0in;line-height:10.25pt'><b><i>Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </i></b>Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $581,300&nbsp;and $3,200,003 for the three months ended March 31, 2016 and 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p>Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts. As of March 31, 2016, the Company had trade accounts receivable amounting to $16,853,716 from sales that occurred more than one year from that date, which the Company believes are collectable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Advances to Suppliers and Advances from Customers</i></b> &#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected.</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Inventory</i></b> &#150; Inventory is stated at the lower of cost or net realizable value, computed on an average cost basis. We charge inventory obsolescence expense for inventory allowance to write down our inventory to the lower of cost or estimated market value or to completely write off obsolete or excess inventory. Charges to inventory obsolescence expense totaled ($71,786) and $201,097 for the three months ended March 31, 2016 and 2015, respectively. The Company recognized an inventory obsolescence reserve of $6,696,224 and $8,417,095 as of March 31, 2016 and December 31, 2015, respectively.</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Valuation of Long-Lived Assets</i></b> &#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2016 and 2015.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Property and Equipment</i></b> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Revenue Recognition</i></b> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved.&nbsp; Revenue is deferred when collectability is not considered to be reasonably assured.</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Cost of Revenues</i></b> &#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Research and Development</i></b> &#150; Research and development expenditures are recorded as expenses in the period in which they occur. Research and development expenses were $93,433 and $160,828 for the three months ended March 31, 2016 and 2015, respectively.&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted (Loss) Earnings per Common Share</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Basic and Diluted Loss per Common Share </i></b><b>- </b>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Three Months&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Ended March 31,&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Net loss</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(1,530,068</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,069,290</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Effect of dilutive securities:</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Warrants</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Options</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr></table></div> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>There were no potential dilutive common shares outstanding during the three months ended March 31, 2016 and 2015, respectively.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><!--egx--><p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Credit Risk</i></b> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company's deposits may be at a higher risk of loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Interest Rate Risk</i></b> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'><b><i>Recent Accounting Pronouncements</i></b></p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services.&nbsp; In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>In January 2016, the FASB issued Accounting Standards Update 2016-01,&nbsp;"<i>Recognition and Measurement of Financial Assets and Financial Liabilities</i>." The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income, and separate presentation of financial assets and financial liabilities by measurement category and form of financial asset. Additionally, the amendments eliminate the requirement to disclose the methods and significant assumptions used to estimate the fair value of financial instruments. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Other than an amendment relating to presenting in comprehensive income the portion of the total change in the fair value of a liability resulting from a change in instrument-specific credit risk (if the entity has elected to measure the liability at fair value), early adoption is not permitted. The Company does not anticipate the amendment will have any impact on its financial statements.</p> <p style='margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in;background:white'>Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company's financial position, result of operations or cash flows.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountingPoliciesAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountingPoliciesAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy on interest rate risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e4975-111524<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3-5<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the accounting policy for determining revenue earned from providing cargo and freight related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6880651504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BasicAndDilutedLossPerCommonShareTablesAbstract', window );"><strong>BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted loss per share:</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Three Months&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Ended March 31,&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Net loss</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(1,530,068</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,069,290</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Effect of dilutive securities:</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Warrants</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Options</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted weighted-average common shares outstanding</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>43,579,557</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Basic loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr align="left"> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Diluted loss per share</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.04</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(0.09</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BasicAndDilutedLossPerCommonShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BasicAndDilutedLossPerCommonShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6881077904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryTablesAbstract', window );"><strong>INVENTORY (TABLES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'>Inventory consisted of the following:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Raw materials</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>12,329,926</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>14,699,736</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Work in process</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>618,329</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Finished goods</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>3,665,108</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>3,380,109</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>16,613,363</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>18,079,845</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Obsolescence reserve</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(6,696,224</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(8,417,095</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Total Inventory</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>9,917,139</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>9,662,750</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6608927376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTablesAbstract', window );"><strong>PROPERTY AND EQUIPMENT (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'>Property and equipment consisted of the following:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;&nbsp;</p> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>436,836</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>433,956</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Building</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>10,627,311</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>10,557,234</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>27,521,628</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>27,325,440</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>268,279</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>242,860</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Office equipment</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>259,575</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>256,679</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Total</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>39,113,629</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>38,816,169</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Less: accumulated depreciation</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(10,286,937</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(9,422,912</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Property and Equipment, net</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>28,826,692</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>29,393,257</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UsefulLivesOfTheAssetsTableTextBlock', window );">Useful lives of the assets</a></td>
<td class="text"><!--egx--><p style='line-height:10.25pt;margin:3pt 0in'>Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%;border-collapse:collapse'> <tr> <td valign="top" width="69%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:69.64%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>Asset</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:3.36%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:27%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>&nbsp;Life - years</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Permit of land use</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>40 - 70</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Building</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>20 - 49</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Plant, machinery and equipment</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Motor vehicle</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>5 - 10</p></td></tr> <tr> <td valign="top" width="69%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:69.64%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Office equipment</p></td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:3.36%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="27%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:27%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>3-5</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_UsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6603898352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsTablesAbstract', window );"><strong>Intangible Assets (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock', window );">Intangible Assets Medical Formulas</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Intangible assets consisted solely of CFDA approved medical formulas as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%'> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>December 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:66%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Gross carrying amount</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>5,235,603</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>5,201,079</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Accumulated amortization</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,456,837</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>(4,360,004</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>)</p></td></tr> <tr> <td valign="top" width="66%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:66%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Net carrying amount</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>778,766</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="14%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:14%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>841,075</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabluar disclosure of Intangible Assets Medical Formulas</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsMedicalFormulasTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6605443392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract', window );"><strong>Schedule of Construction Loan Facility:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal payments required for the next five years as of December 31, 2015</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Principal payments required for the next five years as of March 31, 2016 are as follows:</p> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="70%" style='width:70%'> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:85%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Twelve Months Ending March 31,</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Amount</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;width:1%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2017</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>1,550,893</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2018</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>1,240,714</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2019</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2020</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2021</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2022</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>2,326,339</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="85%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:85%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>12,096,962</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div> <p style='line-height:10.25pt;margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfLongTermDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6881126416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTablesAbstract', window );"><strong>INCOME TAXES (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock', window );">Schedule of Enterprise Income Tax Rates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%;border-collapse:collapse'> <tr> <td valign="top" width="40%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:40.32%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="10%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.12%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.54%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Enterprise Income </b></p></td></tr> <tr> <td valign="top" width="40%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:40.32%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Year</b></p></td> <td valign="top" width="10%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.12%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.54%;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;margin:0in 0in 0pt'><b>Tax Rate&nbsp;</b></p></td></tr> <tr> <td valign="top" width="40%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2015</p></td> <td valign="top" width="10%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>15%</p></td></tr> <tr> <td valign="top" width="40%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>2016</p></td> <td valign="top" width="10%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>15%</p></td></tr> <tr> <td valign="top" width="40%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:40.32%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>Thereafter</p></td> <td valign="top" width="10%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:10.12%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:49.54%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'>25%</p></td></tr></table></div> <p style='margin:3pt 0in'>&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for income taxes</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The provision for income taxes consisted of the following:</p> <p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Three Months Ended March 31,</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>2015</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Current</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Deferred</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>22,828</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>19,284</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="76%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:76%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Total income tax expense</b></p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>22,828</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>19,284</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725331888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueMeasuresAndDisclosuresAbstract', window );"><strong>SCHEDULE OF FAIR VALUE MEASUREMENTS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Company held the following assets and liabilities recorded at fair value as of December 31, 2014</a></td>
<td class="text"><!--egx--><p style='text-align:justify;line-height:10.25pt;margin:3pt 0in'>The banker's acceptances are recorded at cost which approximates fair value.&nbsp;&nbsp;The Company held the following assets and liabilities recorded at fair value as of March 31, 2016:</p> <p style='margin:3pt 0in'>&nbsp;</p> <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Fair Value Measurements at</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Reporting Date Using&nbsp;&nbsp;&nbsp;</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'><b>Description</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>March 31, 2016</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 1</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 2</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="top" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="center" style='text-align:center;line-height:11.4pt;margin:0in 0in 0pt'><b>Level 3</b></p></td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0in;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Banker's acceptances</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:#cceeff;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr> <tr> <td valign="top" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:52%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>Total</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>116,317</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='line-height:11.4pt;margin:0in 0in 0pt'>$</p></td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0in;padding-left:0in;width:9%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p align="right" style='text-align:right;line-height:11.4pt;margin:0in 0in 0pt'>-</p></td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0in;width:1%;padding-right:0in;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in'> <p style='margin:0in 0in 0pt'>&nbsp;</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueMeasuresAndDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FairValueMeasuresAndDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a,b,bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=SL7498348-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735377920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationAndNatureOfOperationsAbstract', window );"><strong>Organization and Nature of Operations {1}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited', window );">Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1', window );">Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercetageOfAcquiredByOnnyInHelpson', window );">Percetage of acquired by Onny in Helpson</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationAndNatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationAndNatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercetageOfAcquiredByOnnyInHelpson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percetage of acquired by Onny in Helpson</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercetageOfAcquiredByOnnyInHelpson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6730212320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Accounts Receivable and Allowance for Doubtful Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract', window );"><strong>Trade Accounts Receivable and Allowance for Doubtful Accounts details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">$ 581,300<span></span>
</td>
<td class="nump">$ 3,200,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyHadTradeAccountsReceivableAmounting', window );">Company had trade accounts receivable amounting</a></td>
<td class="nump">16,853,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ChargesToInventoryObsolescenceExpenseTotaled', window );">Charges to inventory obsolescence expense totaled</a></td>
<td class="num">(71,786)<span></span>
</td>
<td class="nump">201,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyRecognizedAnInventoryObsolescenceReserve', window );">Company recognized an inventory obsolescence reserve</a></td>
<td class="nump">6,696,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,417,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">$ 93,433<span></span>
</td>
<td class="nump">$ 160,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ChargesToInventoryObsolescenceExpenseTotaled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges to inventory obsolescence expense totaled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ChargesToInventoryObsolescenceExpenseTotaled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyHadTradeAccountsReceivableAmounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as trade receivables attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyHadTradeAccountsReceivableAmounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyRecognizedAnInventoryObsolescenceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company recognized an inventory obsolescence reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyRecognizedAnInventoryObsolescenceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724202976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Numerators and denominators used in the calculation of basic and diluted loss per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract', window );"><strong>Numerators and denominators used in the calculation of basic and diluted loss per share details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetLoss1', window );">Net loss</a></td>
<td class="num">$ (1,530,068)<span></span>
</td>
<td class="num">$ (4,069,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EffectOfDilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Warrants', window );">Warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Options', window );">Options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic loss per share</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted loss per share</a></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EffectOfDilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EffectOfDilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NetLoss1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Options">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Options</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Warrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Warrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 20<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 18<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724242608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryDetailsAbstract', window );"><strong>Inventory Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 12,329,926<span></span>
</td>
<td class="nump">$ 14,699,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">618,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,665,108<span></span>
</td>
<td class="nump">3,380,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory gross</a></td>
<td class="nump">16,613,363<span></span>
</td>
<td class="nump">18,079,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence reserve</a></td>
<td class="num">(6,696,224)<span></span>
</td>
<td class="num">(8,417,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInventory', window );">Total Inventory</a></td>
<td class="nump">$ 9,917,139<span></span>
</td>
<td class="nump">$ 9,662,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NetLoss1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6721863232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract', window );"><strong>Property and equipment consisted of the following details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Permit of land use</a></td>
<td class="nump">$ 436,836<span></span>
</td>
<td class="nump">$ 433,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">10,627,311<span></span>
</td>
<td class="nump">10,557,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
<td class="nump">27,521,628<span></span>
</td>
<td class="nump">27,325,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleGross', window );">Motor vehicle</a></td>
<td class="nump">268,279<span></span>
</td>
<td class="nump">242,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipment1', window );">Office equipment</a></td>
<td class="nump">259,575<span></span>
</td>
<td class="nump">256,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment Gross Total</a></td>
<td class="nump">39,113,629<span></span>
</td>
<td class="nump">38,816,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LessAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">(10,286,937)<span></span>
</td>
<td class="num">(9,422,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">$ 28,826,692<span></span>
</td>
<td class="nump">$ 29,393,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LessAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LessAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of motor vehicle gross as on the date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentConsistedOfTheFollowingDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724399376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract', window );"><strong>Estimated useful lives of the assets as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMinimumLife', window );">Permit of land use minimum life</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMaximumLife', window );">Permit of land use maximum life</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMinimumLife', window );">Building minimum life</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMaximumLife', window );">Building maximum life</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMinimumLife', window );">Plant, machinery and equipment minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMaximumLife', window );">Plant, machinery and equipment maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMinimumLife', window );">Motor vehicle minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMaximumLife', window );">Motor vehicle maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMinimumLife', window );">Office equipment minimum life</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMaximumLife', window );">Office equipment maximum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EstimatedUsefulLivesOfTheAssetsAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plant, machinery and equipment minimum life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725295792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS DEPRECIATION (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AssetsDepreciationAbstract', window );"><strong>Assets Depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DepreciationExpensePropertyAndEquipment', window );">Depreciation Expense property and equipment</a></td>
<td class="nump">$ 790,254<span></span>
</td>
<td class="nump">$ 854,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AssetsDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AssetsDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DepreciationExpensePropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DepreciationExpensePropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724253424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract', window );"><strong>Intangible assets CFDA approved medical formulas details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 5,235,603<span></span>
</td>
<td class="nump">$ 5,201,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,456,837)<span></span>
</td>
<td class="num">(4,360,004)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 778,766<span></span>
</td>
<td class="nump">$ 841,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization on long-term land leases capitalized as part of real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725407472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets amortization expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract', window );"><strong>Intangible assets amortization expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationExpensesRelatingToIntangibleAssets', window );">Amortization expenses relating to intangible assets</a></td>
<td class="nump">$ 66,941<span></span>
</td>
<td class="nump">$ 96,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationExpensesRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AmortizationExpensesRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsAmortizationExpensesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsAmortizationExpensesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6725965504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract', window );"><strong>Advances for purchase of intangible assets details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyWasObligatedToPayLaboratoriesAndOthers', window );">Company was obligated to pay laboratories and others</a></td>
<td class="nump">$ 4,785,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyWasObligatedToPayLaboratoriesAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company was obligated to pay laboratories and others</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyWasObligatedToPayLaboratoriesAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724204576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RelatedPartyTransactionsDetailsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesOwingToBoardOfDirectors', window );">Advances owing to board of directors</a></td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateOnAdvancesFromMemberOfBOD', window );">Interest rate on advances from Member of BOD</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 3,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesOwingToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances owing to board of directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesOwingToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateOnAdvancesFromMemberOfBOD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate on advances from Member of BOD</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateOnAdvancesFromMemberOfBOD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RelatedPartyTransactionsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RelatedPartyTransactionsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724432688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLES (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 19, 2016</div></th>
<th class="th"><div>Sep. 16, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NotesPayablesDetailsAbstract', window );"><strong>NOTES PAYABLES DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RevolvingLineOfCreditWithABankRmb', window );">Revolving line of credit with a bank (RMB)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56', window );">Annual interest rate based upon 110% of PRC government's current short term rate of 5.6%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000', window );">Line of credit is payable in two equal installments of RMB 15,000,000</a></td>
<td class="nump">$ 2,310,000<span></span>
</td>
<td class="nump">$ 2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000', window );">Outstanding balance due under revolving line of credit (RMB 30,000,000)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,652,678<span></span>
</td>
<td class="nump">$ 4,621,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual interest rate based upon 110% of PRC government's current short term rate of 5.6%</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AnnualInterestRateBasedUpon110OfPrcGovernmentSCurrentShortTermRateOf56</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LineOfCreditIsPayableInTwoEqualInstallmentsOfRmb15000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NotesPayablesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NotesPayablesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding balance due under revolving line of credit (RMB 30,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OutstandingBalanceDueUnderRevolvingLineOfCreditRMB30000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RevolvingLineOfCreditWithABankRmb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RevolvingLineOfCreditWithABankRmb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724342576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConstructionLoanFacilityDetailsAbstract', window );"><strong>Construction loan facility details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyPrincipalPaymentRmb2000000', window );">Company principal payment (RMB2,000,000)</a></td>
<td class="nump">$ 309,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLoanFacilityAmountRmb80000000', window );">Total loan facility amount (RMB 80,000,000)</a></td>
<td class="nump">$ 1,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LoanInterestForAnEightYearTerm', window );">Loan interest for an eight-year term</a></td>
<td class="nump">5.73%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateWasAdjustedTo', window );">Interest rate was adjusted to</a></td>
<td class="nump">5.94%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyPrincipalPaymentRmb2000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company principal payment (RMB2,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyPrincipalPaymentRmb2000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConstructionLoanFacilityDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ConstructionLoanFacilityDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConstructionLoanFacilityDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateWasAdjustedTo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate was adjusted to</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateWasAdjustedTo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LoanInterestForAnEightYearTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan interest for an eight-year term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LoanInterestForAnEightYearTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLoanFacilityAmountRmb80000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loan facility amount (RMB 80,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLoanFacilityAmountRmb80000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6611374496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract', window );"><strong>Principal payments required for the next five years are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2017', window );">Principal Payments 2017</a></td>
<td class="nump">$ 1,550,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2018', window );">Principal Payments 2018</a></td>
<td class="nump">1,240,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2019', window );">Principal Payments 2019</a></td>
<td class="nump">2,326,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2020', window );">Principal Payments 2020</a></td>
<td class="nump">2,326,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2021', window );">Principal Payments 2021</a></td>
<td class="nump">2,326,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2022', window );">Principal Payments 2022</a></td>
<td class="nump">2,326,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalPrincipalPaymentsDue', window );">Total principal payments due</a></td>
<td class="nump">$ 12,096,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2018">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2018</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount paid by the company in 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2022">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal Payments 2022</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2022</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalPrincipalPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Principal amount due by the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalPrincipalPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6881244144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSIDY INCOME (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SubsidyIncomeDetailsAbstract', window );"><strong>SUBSIDY INCOME DETAILS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyForeignSubsidiarySinceItsAcquisition', window );">Company foreign subsidiary, since its acquisition</a></td>
<td class="nump">$ 38,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InvestmentInHelpson', window );">Investment in Helpson</a></td>
<td class="nump">$ 23,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyForeignSubsidiarySinceItsAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company foreign subsidiary, since its acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyForeignSubsidiarySinceItsAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InvestmentInHelpson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Helpson</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InvestmentInHelpson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SubsidyIncomeDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SubsidyIncomeDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724480400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ENTERPRISE INCOME TAX RATES (DETAILS)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesDetailsAbstract', window );"><strong>Enterprise income tax rates details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2015', window );">Enterprise Income Tax Rate 2015</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRate2016', window );">Enterprise Income Tax Rate 2016</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRateThereafter', window );">Enterprise Income Tax Rate Thereafter</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2015">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2015</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2015</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRate2016">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate 2016</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRate2016</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRateThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRateThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received cash subsidy from the government for the enterprises that suffered losses from the typhoon to resume production</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRatesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735377152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROVISION FOR INCOME TAXES (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ProvisionForIncomeTaxesDetailsAbstract', window );"><strong>Provision for income taxes details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">22,828<span></span>
</td>
<td class="nump">$ 19,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalIncomeTaxExpense1', window );">Total income tax expense</a></td>
<td class="nump">$ 22,828<span></span>
</td>
<td class="nump">$ 19,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ProvisionForIncomeTaxesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ProvisionForIncomeTaxesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalIncomeTaxExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalIncomeTaxExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section I<br> -Subsection 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6735199648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrcNetOperatingLossCarryForward', window );">PRC net operating loss carry forward</a></td>
<td class="nump">$ 36,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_USNetOperatingLossCarryForward', window );">U.S. net operating loss carry forward</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 12,897,790<span></span>
</td>
<td class="nump">$ 12,798,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrcNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrcNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_USNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_USNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6724694224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract', window );"><strong>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotes', window );">Bankers acceptance notes</a></td>
<td class="nump">$ 116,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Total1', window );">Total</a></td>
<td class="nump">116,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel1', window );">Bankers acceptance notes Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel1', window );">Total Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel2', window );">Bankers acceptance notes Level 2</a></td>
<td class="nump">116,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel2', window );">Total Level 2</a></td>
<td class="nump">116,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel3', window );">Bankers acceptance notes Level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel3', window );">Total Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 3</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Total1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total bankers acceptance notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Total1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes total Level 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 2 total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 3 total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6721861024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL STOCK TRANSACTIONS (DETAILS) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Nov. 12, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CapitalStockTransactionsAbstract', window );"><strong>Capital stock transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesParValue', window );">Common shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesParValue', window );">Preferred shares par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EmployeeStockOptions2010IncentivePlanAbstract', window );"><strong>Employee Stock Options 2010 Incentive Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonShares', window );">Number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan', window );">Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CapitalStockTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CapitalStockTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EmployeeStockOptions2010IncentivePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EmployeeStockOptions2010IncentivePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6728368800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS (DETAILS)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConcentrationsDetailsAbstract', window );"><strong>Concentrations Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NoCustomerAccountedForMoreThanPercentageOfSales', window );">No customer accounted for more than percentage of sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneCustomerAccounted', window );">One customer accounted</a></td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SecondCustomerAccounted', window );">Second customer accounted</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ThirdCustomerAccounted', window );">Third customer accounted</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneCustomerAccountedForPercentageOfSales', window );">One customer accounted for percentage of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases', window );">One supplier accounted for percentage of raw material purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OneCustomerAccountedForPercentageOfAccountsReceivable', window );">One customer accounted for percentage of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConcentrationsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company made payments as per Construction agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConcentrationsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NoCustomerAccountedForMoreThanPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No customer accounted for more than percentage of sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NoCustomerAccountedForMoreThanPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneCustomerAccounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One customer accounted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneCustomerAccounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneCustomerAccountedForPercentageOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One customer accounted for percentage of accounts receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneCustomerAccountedForPercentageOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneCustomerAccountedForPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No customer accounted for more than percentage of sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneCustomerAccountedForPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One supplier accounted for percentage of raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OneSupplierAccountedForPercentageOfRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SecondCustomerAccounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second customer accounted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SecondCustomerAccounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ThirdCustomerAccounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Third customer accounted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ThirdCustomerAccounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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MJ-'DZ3#T[#-U4K"AOL-0$2U9O *&F>+.G<<H+*WOD!;+[HP%*^N[E$6Q.+X
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MF^OO]:T-9BCPH3EVX__%PW/7-Z?7D.7B5/V<KH?S>+U.OQ3J%B8'X"T WP)
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MVZD"  !R"@  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;(V6W9*;(!2
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M-Y://=D).]G*^_90FD,_W*;VOIUJT>FA;\[OI?6MOM_\#U!+ P04    " !
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MA\O<7;?38<]TTS>G][.KZP':^E]02P,$%     @ 0(6P2!YH.'6@ 0  L0,
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R%4\MNVS 0_!6"'Q#*DI*V
MABP@3A"TAP)!#NV9EE82$9*KD)25_GWYL!7;39.+N+N:F9WEHYK1/-L!P)%7
M);7=T,&Y<<V8;090W%[A"-K_Z= H[GQJ>F9' [R-)"59GF4W3'&A:5W%VJ.I
M*YR<%!H>#;&34MS\V8+$>4-7]%AX$OW@0H'5%5MXK5"@K4!-#'0;>KM:;\N
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MUR7>W<S,SOJ1]6C>; /@R$Y);5>T<:Y=,F:+!A2W%]B"]G\J-(H[GYJ:V=8
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M+C0M\EA[-$6.O9-"PZ,AME>*F_<-2!S6=$'WA2?1M"X46)&SF5<)!=H*U,1
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M0GCK8S->J3%QV,T/9'FEQ7]02P,$%     @ 0(6P2![NUMZA 0  L0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULA5/+;MLP$/P5@A\0RK2<M(8L
M($X1I(<"00[MF996$A&2JY"4E?Q]2,I6;"=M+^+N:F9VEH]B1/OL.@!/7K4R
M;D,[[_LU8Z[J0 MWA3V8\*=!JX4/J6V9ZRV(.I&T8CS+KID6TM"R2+5'6Q8X
M>"4-/%KB!JV%?=N"PG%#%_18>))MYV.!E06;>;748)Q$0RPT&WJ[6&_SB$B
MWQ)&=Q*3Z'V'^!R3G_6&9M$"**A\5!!AV<,=*!6%0N.7@^9'RT@\C8_J]VG:
MX'XG'-RA^B-KWP6S&24U-&)0_@G'!SB,L(J"%2J7OJ0:G$=]I%"BQ>NT2I/6
M<?K#;PZTKPG\0. SX5N6C$^-DLT?PHNRL#@2UXMX=HMU@-LH$I1)\.92FJ:?
MJOMRD7\OV#X*G6&V$X9/F!G!@OJ7+?AYBRT_H?/_TY<7#I>)OOSD\*\"^85
MG@3R?XYXAEEE%TW8R9YJL&VZ.HY4.!@_;=Y<G6_G+4]G\@$OBUZT\$O85AI'
M=NC#R:9#;1 ]!!/9U8J2+KR?.5'0^!C>A-A.5VI*//;'!S*_TO(=4$L#!!0
M   ( $"%L$BBH]C?G0$  +$#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;(53VT[C,!#]%<L?@).T!52ED2BK%3P@(1[@V4TFB87MR=I. W^/[:2A
M+9=]B6<FYYPYXTL^H'FU+8 C;TIJNZ&M<]V:,5NVH+B]P ZT_U.C4=SYU#3,
M=@9X%4E*LBQ)+IGB0M,BC[5'4^38.RDT/!IB>Z6X>=^"Q&%#4WHH/(FF=:'
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M$/[TL9FNU)0X[)<'LK[2XA-02P,$%     @ 0(6P2/SU"\:@ 0  L0,  !D
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M].%DTZ'6B!Z"B>SJFI(VO)\Y45#[&-Z&V(Y7:DP\=H<',K_2XAM02P,$%
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M<R]S:&5E=#,P+GAM;(V5RXZ;,!B%7P6Q[^ +&(@(4D-5M8M*HUFT:R=Q AK
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M?.-3#=@8[D4K[3/:GZ42W34DCCKV[MJFM^W%O<G3*2P< *< > L V7\#T!2
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M[H_N8G$#)8;K/7F[K,N_4$L#!!0    ( $"%L$AFY%IM!0(  , &   9
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M/%&DCP/B54#L I(I(%M"]KX-K\F=)HWB-"/QEJY:ZDA(\N?'0,D**%D Y9M
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M1D@@D^#-I3#M/F=/#7_@-3M%T)5FFS5\TI2SA@7^MTWX31.> .4$6/X?4-X
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MI3+3G9X+=ZS=0O'N>DE--V7Z#U!+ P04    " ! A;!(':B(+L,!  ",!
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M=:/-9:X8DT2)H9TZQ5H]M%-!227U-%9S;M\>6TC6WU[2Z3G/_P!02P,$%
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M<]&[87Y(QP'#@<0.5^%24>.(9H.QD7['@+.+30C08!$RQCW#Z:*\ITW58"9
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MQ![>MQV^V+ZRL*\S(>@#&"NXVY1-%S@SV&8:KD+<(RIYOF6A.SG.?XSI,M)
M=<&=2)UQH-=C-#*"D0$,,H.%RG/47"'$\&40/H9!3@H?^J_1C4ZV> W'6!GG
M14).4)X/]!,R7,(D0UV%>(7V.($6LP']*!,)78^ @9]1HTA#XR/SA?*H*N5^
M/Z-R  "ZTR9@[XL>(4*?"R?;LDVU+'(DV$6V14!K*R4 '%0!)NWI5IAE031U
MIX9CL;, -0G;O,E%!R+P 8B$DXY*5!]XIZ"$K+Z"@]@XXM'?JXP*1SR _;5
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M6@L'HWB;TW@VL+'^1 *R.!.T(]+R#&%4>%UUE)C)5$ND6J-'3X^ A"WJS;R
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M4Z_HYJ%S)KINOPWFFJ<:7OMV4G4>>IG)T4'^B(>&G(/8^Z!-XV,V1^67;!Q
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MSY[A^S3-?OK_4$L! A0#%     @ /86P2+Q++,#> 0  @!T  !,
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M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $"%L$B97)PC$ 8  )PG   3
M          "  6L*  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M0(6P2*7K<DU! @  X D   T              ( !K!   'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " ! A;!(:-39B_@$  !I#P  #P              @ $8
M$P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 0(6P2.^M>,1V @  )@D
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M965T-2YX;6Q02P$"% ,4    " ! A;!('F@X=: !  "Q P  &
M    @ $E*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M0(6P2#\R:!2: 0  L0,  !@              ( !^RP  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( $"%L$AG\,\AH $  +$#   8
M          "  <LN  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " ! A;!(0VY9Q)\!  "Q P  &               @ &A,   >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 0(6P2.M2TRJ> 0  L0,
M !D              ( !=C(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " ! A;!(BD*K)Y\!  "Q P  &0              @ %+-
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $"%L$A4=[\.
MGP$  +$#   9              "  2$V  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ 0(6P2![NUMZA 0  L0,  !D
M ( !]S<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !
MA;!(HJ/8WYT!  "Q P  &0              @ '/.0  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( $"%L$C;4ZA_GP$  +$#   9
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M970Q.2YX;6Q02P$"% ,4    " ! A;!(HXBZF)\!  "Q P  &0
M    @ &A10  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M $"%L$CJVI$HH@$  +$#   9              "  7='  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ 0(6P2$B!2I"P 0  %@0  !D
M             ( !4$D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " ! A;!(IVYI7*$!  "Q P  &0              @ $W2P  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $"%L$C\]0O&H $
M +$#   9              "  0]-  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ 0(6P2"Z_<52M 0  %@0  !D              ( !
MYDX  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ! A;!(
MU,DGPJ$!  "Q P  &0              @ '*4   >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( $"%L$B/#BHDE $   $$   9
M      "  :)2  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ 0(6P2&H<TW16 @  %P<  !D              ( !;50  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " ! A;!(C(9!?$L"  ";!P
M&0              @ 'Z5@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( $"%L$AM"\1?*P(  (L&   9              "  7Q9  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ 0(6P2'Y^YJU?
M @  N <  !D              ( !WEL  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " ! A;!(9N1:;04"  # !@  &0
M@ %T7@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $"%
ML$C48E"QRP$  $<$   9              "  ;!@  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ 0(6P2,0+W>38 0  V00  !D
M         ( !LF(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " ! A;!(=_R/_<L!  !%!   &0              @ '!9   >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( $"%L$ACC!H@BP$  #T#
M   9              "  <-F  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ 0(6P2(K3X>?2 0  'P4  !D              ( !A6@
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " ! A;!(#*3\
M7_P!   6!@  &0              @ &.:@  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( $"%L$C;&SZVN $  &\$   9
M  "  <%L  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M0(6P2+/"J(/F 0  M 4  !D              ( !L&X  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " ! A;!(R[GYE9H!  "H P  &0
M            @ '-<   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( $"%L$CL]UF7EP$   $$   9              "  9YR  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 0(6P2-NG;]SJ 0
M-04  !D              ( !;'0  'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " ! A;!(':B(+L,!  ",!   &0              @ &-
M=@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $"%L$@\
M& VNY0$   0&   9              "  8=X  !X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ 0(6P2",SB=3M 0  V@4  !D
M     ( !HWH  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
M" ! A;!(T9Q>60P"  !_!@  &0              @ ''?   >&PO=V]R:W-H
M965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( $"%L$BH/XV\X2\  .#%   4
M              "  0I_  !X;"]S:&%R9613=')I;F=S+GAM;%!+!08
...  X #H/   =KP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.4.0.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>11</ContextCount>
  <ElementCount>236</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - CONSOLIDATED BALANCE SHEETS PARENTHETICALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDBALANCESHEETSPARENTHETICALS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS PARENTHETICALS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureNOTESPAYABLE</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - CONSTRUCTION LOAN FACILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureFAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureCONCENTRATIONS</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES</Role>
      <ShortName>ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureBASICANDDILUTEDLOSSPERCOMMONSHARETABLES</Role>
      <ShortName>BASIC AND DILUTED LOSS PER COMMON SHARE (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - INVENTORY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINVENTORYTABLES</Role>
      <ShortName>INVENTORY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES</Role>
      <ShortName>PROPERTY AND EQUIPMENT (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - INTANGIBLE ASSETS (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINTANGIBLEASSETSTABLES</Role>
      <ShortName>INTANGIBLE ASSETS (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES</Role>
      <ShortName>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - INCOME TAXES (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureINCOMETAXESTABLES</Role>
      <ShortName>INCOME TAXES (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000290 - Statement - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_OrganizationAndNatureOfOperationsDetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000300 - Statement - Trade Accounts Receivable and Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Trade Accounts Receivable and Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000310 - Statement - Numerators and denominators used in the calculation of basic and diluted loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_NumeratorsAndDenominatorsUsedInTheCalculationOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Numerators and denominators used in the calculation of basic and diluted loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000320 - Statement - INVENTORY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_INVENTORYDETAILS</Role>
      <ShortName>INVENTORY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000330 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS</Role>
      <ShortName>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000350 - Statement - ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_ESTIMATEDUSEFULLIVESOFTHEASSETSASFOLLOWSDETAILS</Role>
      <ShortName>ESTIMATED USEFUL LIVES OF THE ASSETS AS FOLLOWS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000360 - Statement - ASSETS DEPRECIATION (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_ASSETSDEPRECIATIONDETAILS</Role>
      <ShortName>ASSETS DEPRECIATION (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000370 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS</Role>
      <ShortName>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000380 - Statement - Intangible assets amortization expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_IntangibleAssetsAmortizationExpensesDetails</Role>
      <ShortName>Intangible assets amortization expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000400 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000410 - Statement - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000420 - Statement - NOTES PAYABLES (DETAILS)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_NOTESPAYABLESDETAILS</Role>
      <ShortName>NOTES PAYABLES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000430 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000440 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS</Role>
      <ShortName>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000460 - Statement - SUBSIDY INCOME (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_SUBSIDYINCOMEDetails</Role>
      <ShortName>SUBSIDY INCOME (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000470 - Statement - ENTERPRISE INCOME TAX RATES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_ENTERPRISEINCOMETAXRATESDETAILS</Role>
      <ShortName>ENTERPRISE INCOME TAX RATES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000480 - Statement - PROVISION FOR INCOME TAXES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_PROVISIONFORINCOMETAXESDETAILS</Role>
      <ShortName>PROVISION FOR INCOME TAXES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000500 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS</Role>
      <ShortName>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000510 - Statement - FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000520 - Statement - CAPITAL STOCK TRANSACTIONS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CAPITALSTOCKTRANSACTIONSDETAILS</Role>
      <ShortName>CAPITAL STOCK TRANSACTIONS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cphi-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000530 - Statement - CONCENTRATIONS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20160331/role/idr_CONCENTRATIONSDETAILS</Role>
      <ShortName>CONCENTRATIONS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cphi-20160331.xml</File>
    <File>cphi-20160331.xsd</File>
    <File>cphi-20160331_cal.xml</File>
    <File>cphi-20160331_def.xml</File>
    <File>cphi-20160331_lab.xml</File>
    <File>cphi-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001010549-16-000606-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001010549-16-000606-xbrl.zip
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MLFOHMM?M_D@CI>D"6E]Q6:"L!!_$#+ T#E[A#Z^QB[>Y*(2<!O\2.+'@5"9
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M/8,=LS"BJ07$R&96%J@EJ+D$7G.:!,CY#,:B3H.LMCS]GB'7-?FJ1D&NO<^
M;Y.TCB2G:0R=Y:")@F-6,-CE);?8MT09?4>;]'__*#- -?L _?DZ^#T3:9$L
M B%EJ1: Q-5P]:-(!8Q%3 >&PYI%G(0!NSRCA00RWO$KGF1S*RF@W+)\1@]
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M)*\EV"2,UI;;A,,B%>ALX>K,Y\G">%.66KO78M3>^).1-OVD7=5.\%O-BEV
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MGXD-2Q=>G9/<BK_FU#W'I9<HJR@T1IIF/!81R.DXR_'-1!FP^3S/KD"&X)L
M/L9E1,(R6M!SQ^#@,Q"]+"9)>9>7D^"H)M_0\I7"BN/W[X[4I]>=X!(?S69S
MEBZ"6,1!FL'HHX*!7&.[^D"* $52@.V72 SB,J==>"_1IP]I1O.6P37/.3 D
M@@E+,18XVSR;P4:]8FG$)>YPL<+ !XV[=@LY)S%'9N%710*8Q6997HC_&$XA
M$V)6<+5Z=LGP*@BM*EX6T7="1 Z\!/4BXA*0;A&(&&00F$Y7+EKNBXPY 2,P
M,X<%X'H\GN*B%%.1%QP^TQ%DI\88^^FT0"I8$22<@8CG\/]9"F,M IBHI/4L
MIO S"Z(I]0\B>/O-E16>1%F9P!RCJ,Q-#RG0!(3F,Y 4CM2J :3Y/>8SE(JQ
MANT8MHXD.:'.@6=2;X,:D^7JT)W@2*U%$\3KVFE5=@GBA\/P<*^G$/YP&.[W
MAY:8APIT2-\OJRKL\0X*L!-\7&9KL9CC%[!:<48@,67P ,,Q27[0@@3F,@5B
M0*A>(! R5N<*Z"21Q2YOMSHB<IP5R!ZPG@'/V9J=2*LEX!&1D\VAN4#[$-C0
MV(JXAV"?X,Z+B"4DRO6'85,;A4!KU.R,"!D#UJ=@+20P<?@>GVM N9J--/3K
MZV(C)O5=L;2^JX 2";LFQ3]27@01DS!"DEV#V,4<" 9U#XO,"61A6^&U"I #
M=L5$0E@!G/P"SP&%S,HM23V^38]Z"*=1M%!G:= ]R"E,OA.<JJT=L3Q?X)A*
MM-HW/,@L^ *Q7(**<5F Q=*<CL0]4><TF#42^0+Z)IND"D,U^=BKM""S3(FY
M5#>&GFZDS@ F#!)S1" "8*VQ*VIK"]!*>"<XRU8(Q[U=H_Q!2M#E?;AJ*)$<
M2N22S!+ N*6]U:HA_8U&>Z/QFR\N/GYRP@==5]S8JW'/F/OF(8QMOZF] 7RM
MQ!7F"I,TW_>_+U<W_GJA\;BM\FASL+W0>S#9)KYZ,'E:,'G'(SX;@0'M\<2!
MMYN<L 35^V/>%GP",7XX:S=!D!\9P)_I!92M@7(,)3@,X2]0]CUG/:IL :H,
M/*IXT_#6RVT;E&7X;SE&[.TQ IMAM-\YT;Z!V2\BU^*+X.9WR/_2VWLVQC[W
M;=?GR/PR"/N[@W#8W?4B[@'#<W.SN>GA=P/AM]L+N[Z X@MT/V[,;':K ^+,
M6WI'M?(F]=MXSDGT]F62\YDH'>#J'13@H[/U>5_A?98<^GOAWF 8'FQ;91-G
M8'K+ZIIL W)X//9X[# >[PZ[8;>[YW%CDRJ:..6C.!3K.*-W'MP^(G&V6,]+
M5HD.R?!SQ>N>73UN8N1N?_\@W!\./8AL(HAX?GI0]J"\?:!\L(>'*>V9<#R(
M/-EQBOIX0V:AA[[X6V6<N4/F&$PT,Q;)FR.=S^-]EG\J\VC*))?GX^4.OC'A
MS(.RRRQ-\?9L,@_/83,(:+ _]0;=7X*C=_\Z.CL^^1R\/[\(/OUZ<?SWH\_P
MU_G[C4US$Y#@8]8+_G5N,@"D);W[8_+;4&Z-6F: 8,;2<LPB? =>Y;%1F0%X
M' 8"<T[@^^P%SRF;!2;R +G(H;D$8"BFF%2!S_&%=WQ'GL'.8T66"ZZ2>5 F
M)VG?\)]KN6O+M=,)CI)BFI63Z5(:E2E3&7)&F.K$)E317;:D!*DG;[#9!*HT
M'17](?V2C7[7/YC$ W9^HJ+<\ KF;R>!9.ZL?PT^@\VFGFU,!_ZA- >ZE%""
MC&ZF!,IYQ 5V27D%1)&H'#S%-8P-<TH+J9*VJ'0/^--J0A:;,4(G(&FGP<P.
M$\A0_I#ZBV*8K&"7*(.YFH$I PFN!LB7 )&X.9G!$Z1 ^\8M\BD7F=H?*-(8
M]&B3Z=J*ATVAKE*R,$J:]$>)7*#\-GHQ,8-9-1?,*4)O\N)NB/D53S*5(@V>
ML-DIK-CA#VM2;IC-/..P26A G1ZGRB\C(KO!E4#!>B<ZX8G*%Z3E8"F9E16+
M&3 4MAGL_YB;A!FU=H 1(A'%0DG?M4B2!@TF^XA^ O:S5+EJRJ0(,<.0YG&-
MASBNB+F6Y_H^&Y4+V<H'FW#)+LO"\J;V%648J18',UO)Y@B")IY0X$LEUXHU
MN@B=TJ,U#9<9'AGI<B:/(\/F6[9^;9(@>:PI2<RL< 'LNLH2S '%:OI$%GRN
M%T]G.$H6AN\Z(PHP?XS@2CFJZOO$IIQ97F%8.@.Q-A'//!.85A"3^*R(>XU(
MC9S2KI#BAUQ*HQ9$P$EZ4!9EO*@EC+G"=.V&<4O8K]1%\U$U=YWM1&V)4JK,
M7@7[HM-U9;##*:D0H&<R5CL16=/"DJ,Q0(+YV\CA,K5:G\&V4MG(9#F:B:)0
MDEZ!/8W8)L-U6$ 5)Q)XM,(]%.P 3(D9)L6+&.5F%'J_TZ1&O+A&74R"2%B*
M'_ ;G?Z&P(G/*5,:4*'H6[NEZN14F[ IMIW@U[E]QO!EC12$%0^$E"6);&W<
MB.>8<"U"U;F4(PEFBYDE9P#0&M/J].),6%*9%&N&;^">:BNDV7;A:HHXS/\5
MZ<4;\4KY"SW=KY2O" 4*]']S-S62S[6E?ZO/30*2M$.J57XNX]FO::P30*'2
ME"O&6MC4 &2 +FGH=B508?ZZM(NM*>^:BB#XR%(VH9Q@N D$4*!XC:G"2FES
MB"VSGFI(YGP"GW-=/5+4C'C,P819IZ:<,J*VSG#.<^R-SF]BF*T2EM*RJUI=
M!%RV"NR2[#EKQYK4EC"M$%,Y<=30:61_P0R&L*W0E50: W[%I&@ 6+ R88!9
MV<;+ZGB4X_0U,!N*PN56=:6].@%M\R YQ+1QF5:(I]=32\6X!*Q2IUGFJSE;
MS,B")>-&/U8;6RTT@;G.(K9D^2,V5*JM:5S1&)FLC8*+EZH\MLMK;I%6LEF=
MA!;@X&::%,D(FZ(K VAGP$%K3)*"=#4W5X5-4032!<TP6V&3)W-C&N,H]25N
MVQ<U*='[#/M%A2VKQ*%D9YI0 V7<6TXOYC+B7&:$JR$F2C5KA\[PF)'"!$9I
MK%Z?M#4%!N C#<N64R9"[!$3 \*V!]:!(+!KY"/NJ'1AQR.)G+$%#5H?4I8V
M-2)JQ[]GU^!;Y"0A.5=[&EE<YDRI,FU'+<F#-EE,IZW:&:1/[V>;LC;C"C-:
MB:F,!8Z3A-&%2B-'FQBS5I(PR_IL:I+>9M\3%W4S*[.T_S2PWW>G.2QU1[11
MFJD#FQL?<Q!F(QB ::L!6+(V\M(T(7[8"_</!F&WVPU*M*<4O"IC4\'8%0,4
M (4UMWNV<HTQT_<M68K;XCJ/QNP___R ,&8]S?:%\E _L;Q87.*[PXS(=S3=
M]K >JKPX^7!T>?(N^'1T<?GOX/+BZ.SST?'EZ?G99D0FCT LC-/8DI1TE+&<
MDM?&H%TC,IXPZ@=.Q!5*(T9;U*HWS774=),)F$]DRUMU_T,OW!WLA8/A/FJC
ME=VD4G4O!;H&V@=<UF4*6&"'811?UE?$ACM FG#3Z>W$HDA1AZH8DV?BF10U
M'+&$P%A..6H^%:$QJG*$$3A!859)N6S!$-#)9WN=[H]HY9'1WYKE^3(KT)<P
M3YLDR,B*W7#W8+B<MA3U,IFC>C4>E+NT.H.XQ[:J[\9W?-26%]^!G;=?7V?\
MYC/LNW\?O?UPLA&;#7SW,[#^2+QAT?::ZJ,1RV=!RJ\#JEV/4 _?D_*NJ\T1
M2[^@<*M,Y8CLY("U"F)@P-GLAN6>T3C!?. 8$J&@<S-_NI9'O2M4-FU\A,K
M%QA?(OD%XQ.]>-1$IOZO-BK"8*2K>"HMB+NQ3"G?/UH:E 86OU_=;NC@IV2=
M:$*&G=[PQ^"5RM],VK+7@XVH2?QT<1Q,,"=Q2D5S-([IL#ML\2PO5/9ST]V@
M,_SQ-<55\!@2]T?8AH3'4\''P<E7'I5T)J'*\ZCHY/$44Q]K EH@$S "L[MC
M\&E2,MB(!=> N;K(1$E=2@8-(8%9\&L4$F#=TAKJ X4*;B\^O@UV\4HL_=<B
M/>V8M2H=&"910$N#7&=8482 #;SH)%%FGQZP-[ #OOJAW]GM!3,P.8&KKVT?
ML&*?^;Q0,T0CRB+9.?"+OCQ47[82>(LHL^\DEH-.]S'%<N^1Q'+&4D/#6Y+,
M]<*X)(@. RG*:%86('TIKIW5X(A@57P"C)0LH:#D,MJ!UEW:'/>P1UZ!L3X<
M],/A_L'ZQ[!-OQ<>'IHV*_V\7KO[S%Y'!Q6]1;W^S$1.9"W;/)91*.R<Q3(H
MK!D#2T\HF, QR/&M%1F!KT@@=T@@P87CS?W?8DS%:-?$-YE5K:QR6<:J2Q#P
M0>"']XCR_]()[FEH80V.ENL2S8?/B(V?%!O;'JZ;-F]-;0*E4/(\NT9&YW1P
MWE9T8"G:AG8DF0=)!E:?0GXI (AUZ0]=T(,592[01@Z;B?V-F,%Z-5>_ON?N
ML6-JOFZL(Y6U8@$C'K%26AM#S-!1)13,ZW*HJ36A1'B@JON BB@O=?B!X%IU
MB?W1WE"GB?5F3417G%455^K$&H#6)1FH6:NIO<9FKIO5'[)T<@DSP:8N&=4'
M=<D[!L?U\N)7\F"##^='9\'[H^/3#Z>7_]X("[L.G_9&"AVDX,JKF CNB>K(
MO-5J.J@4@ZJX=%,/"NW^40+N]NN7,Y8'DOHT6YW*[2Q,'1YSRFG.MVCC_Z.$
M_=W3W:GM*5+8JR#L<<ZN=^+L.E6F.<4!:\<>E6] XERA1>U,?]5HDE1VHY12
M'7 A6@7[:S44'9IAG1&]9VFFY!"44KNQ9$VUFF+ZZ*!B9WOH 4WCMCL.YFC0
M5O*I-:)95=7N%,CI8M^U-:EX,J+CNFMU3AHW++Q!9W_WQS"XESVWM++*F./C
ML;G'9)0G15N;ZQCB:2Q>>%)Q4S(M68Q[0..540EU*L8PG<)H!GLD1A)0+.:T
MP#1A,W": AFY9'BL8OV[%G&"\8 :"9Q4;*P>H[M;G>#<2&@WK'R4!IJ2D:4F
MH(*A@\[AWH\UB:J6PQXMV0ZR%.75!)3-O,8BQU-"<#]47:W@+0<0H!/"^G89
MJ.UBS ]SS)2#P(BY.MI%.Q&/<4WY+>SS5?^UX7O#K[%NDQI>-]'$@0#A\-@?
MMH,^I?BJ C:ZN%/ Z.9 DUM&AB5'VVE]G_6GE')5!8_H6@,V(E&S%7A2 ,_&
MI8YI3M?V:MSI]XTP+(4-" *XC'(Q0L@<0:?$> HNH1OR#P9$@@2LQKWID(K5
M.&PFLH*M2T'OW>ZA<A0!<_L&<5]7',_Y3)\ &PZM#*&CBGWM<1Y8W(8N7]<X
M*;3 DM49W![+5W<;[VE[&XQRV:S]M,S"VM&NV6C+<M1NZN$EDI=44&C_AH)"
M^]]>4.A@X$AF5B!D>_+G7E[S!.3XHPJAGRC791-*N&QW9EV?5?J[[HJCZGUR
M+_T;F-CMD77%#6_=K5$&FUY]'BP8]_(V.?I^J4OO[7INWIV;_6=C9W\+W\SM
MA8-!-SPX]'FFO3Z\CSY\NLQ93ZH-#[9)S+<A*YSGY39JPLW+J]<+^WO=<+_G
M7EJ];1/J;=*"&^L5^KSVSJ&WY^9VZL)-] K[X6Y_&.[N>ICP^G#[O<)^=YO$
MW$FCS_/2:\(-] JW4@\Z*=3;I 4WU2OL][9)S!TU]SPWO2[T7J$7[ W3AS=F
M2MY6O[#OG* [6F/')7WH:W,]B5Y\=+9Z;]'#AM>/3ALA&RNR+X6?OK[+]NF]
M3?0,>_VP>S@,#X=;9C$[BB,UY:<^WK'$RQ.40]BJY"7']=?U/^ [V^_UJZYM
M/;F9R60E[4 S/</MJ4WJ>4'P#?F6%"9K\XWH1 ,L77I)_JX91QY?YJK4):UY
M2>J)2TY3S(-[R;X^6E+ )J%MDMTBRI2LY##8"4[/CL\_G@271__WY/LEV;S/
M%-[Q,<]5@@/**%RPKSK-,DEO(M@(A= D#I]Q)JGD3TEIHWG*5!IZ>$KMFWIF
M>BJ50;N&?=49FF@,_>Z]>H$;_E Y1@H^FV<Y)7(08R"*4R(U''0UVSVF%5")
MD('2(C'%<%0Z"]S2L9G6#?.A1.31E*4311*T3-BUQ%[57$0C :9(E^C7211H
MG^B,'RJ!"7&%MA:FI+C/&_>WB-NS2,2O #2 #6)4(LMAC3#+ 7'K[SR9RS7)
MW@ ,H;^4<G.(6, RA@"&J<[DS*(_2B%UJC@%?%9$&ED7#CH#DY2O/2L7K#/F
M3#=D4;;Y:XZ9VZ5.]''%55X27"9-<4M^A_YN9]>,%.IL,"E0SG,K9UBD:HR9
M;3@5*%$]JVI7(649LSG1TRSXM?.Y$XQYC-ED2"X+Q-!J4W%=!HD2FNET-['*
MO)VENE*%Y7LC/;Q= 2UVF"-9Y7"D)/LQ"2REG+T6DB^E?<[*!%-.U1.X-"BE
M A6KI+Y*N4J*D=82O9#",^N,NT4EZ)&O5<Y-4'_3C/(5ZDY,9BZM-C]=''>"
M=[I\$:MGUZF2<)1I;</9/4P4U_#);.*%J4,PQUS3E"]D*6&7RE/]5>.7E%DD
M2).I(F18FFHQ1]:IA^&_J$R(M%^"J<F.WJ"I9?J4:AU8W+ 3X"<L<<0"@+3Z
M5&DJC3D\=T*.^T#!AR7T!_F'"0HYU0DYRM3DKL0IP5.TPU?*DV !F+2&GZ0M
M.)A%J:K.0ZG@JZ=QI-_+>**>GW&NTM K!V,&"["3B"^P)W< >=,=6'_M>F!&
M8HDB6"4D4J4_HJDJA3,#P*X,+CM@)SB1A3&>;):E%--1IBRAR9N\S4#/NCDC
MU3;O$^87(N'+4IT)1N6$UEF6*9&SRG]S<Z(7)=XJ'8[*?Y@NUE*@%)'*FT@L
M[ZSL',7U9@TWD[UY.3=>W^;H:<F:9VK@8/XJR5L6=KE*7,L  ^)9!AQ111\R
M*:G* __*#$*XO#G.4[UX*DUL=U\MWAG327D^\0RPQ^A'<%,F.=9E 5E K@$R
M,,IHAL^<H-3-<X#O0!FT 5BTP0=V';PZ.;W$#PIC0:(M$QN#?B8(/P88!9>A
M&H)*&:DA3A$($<45\EY0^1@E-V:I]%#&',NR+S6#2J=8JEA+:]@]4(:7>12)
MO&&DBQ+SH0O8%A*QL4R54./30'-_\"/5M@%E'@,/8$6B':MTN661,N3>:R ^
M-0V A]K+@NF\/SV1B-P)<ASFM@@P*3"LL$Z)9%/N@KM&O7^-^%R!@<,25\\@
MB.E4LTAC%O 2*U5B!KZ<3\BB48N(J:)8T /&@K6"UG71W*OX]XBC4K,IG_52
MJG6M?8%YMS3TJYQEG&QT2ONWOG-MLS2I:U:NI,09!&%5,3(<%\7!]D-YQ%B5
M^,D8WVJ:(SY1F>1,(C KG.]*JM<(:--M8JNI!&+R =H26C (NX+)D"*WPX^)
MB60 @:,),X$>>Q8@,1$BI?*BM%O2%'#2D\=\?*00IK"L2AUE2399U&2:LIA5
MZ10MD1.F*PZVDFH3ZK50K/.C[2%):]-55_6QC&NOG: :Z2L%A)2QER1+9J4R
M34WRMVIJRR)Q2SJN;]PBCY&AZUN3<0UL,BX5;UQJNIJA"QXPH4E*23F7_(WY
ML!2.O/>1V5YK9K"[QD85?7O=SF[_QS7AW!NBZ#JBNAK(O2D$W!;374VQ\ZRG
M/>V<[3T"9T%^>YZS*S)[^ @R>]@9[#G.V0?>B5I=A):CGY8@Y:J5V1:A?,SS
M^B<#G]4#OI>YI/\&4^B61?2(MLV(MOT;H47JT3F^:%:OW2 @6WM2_5R;Y3N!
M%D9\7$(H]]9ALW')/7X^CUSW!C]N$N@T;H9N^=)@X,--R'%C%;8%<-S@IH>;
M%V_C7.)Y/E75<!-V7%F-;0$>5_CY3.KT=NBYU]76!YRF?=M$[WS*1A=T)-5V
MRO+FU1BZ)D0GCJ;0D3GTV/J#C5[WOB<;],0#3C >LD?OM >;-\NW)>C4N);O
M>?<HE3V&C\;.[8_1W2U8?4D5XZMR-_6*\0\)8GNI?[JW+CT[/0!_9P"^H;22
M!^ ' ; -AWF@]<BP ;SSR/",R##PR."6"=:H[SG\]N@5].%BZ.IF%M\HOL?J
MTNH#Q?6NKZ_?-=BZ@=Q]1-7FN7FSK#Y&ZHM'"&$?.LG7!Z6[N.<"['C!]C#A
MN;EMW/2@ZT%W*P5[HYV+>US(>4SG[C&QPR1&<5&"-X.]FZ+HVKCYC($A-[CZ
MZ&K.-:X^A[KK]\.#_E.7J_6(X;FY]=ST^.OQ]_[XVSL,^P=/70W8(X:;/L>]
MW#I7O8[JLE16L*2>.T.GCOKF4SIW7.M-$'0G^>FN<MR6:-RV*TIW'16/()Z?
MF\=/C\@>D;?5==DZ!*DY+^KCT[VN=I?'CUK27"_G@8T#2L@\YSDK@$=!DDFI
M*@F,L_R:Y;'*XHF9!BDG;)E#[SK%^5*&[4$MP[;*GHA96!O)B[/Q6/*"<LV.
MRZ+,^7("]RKO8;_73.;($IFIO+4K]')%XZ\I9=RDC*72YJ&N.3HW$+_7Z=V1
M]E:ZPT!@2NM%6)O [M#EC)^G*26OEY1L'T4BY]#9?TSZ:\P"OIKH/@1A2MF$
M<K#:K.824RU3#F)18!9'S*,<J#S*F#@XI43#E$%8XD+8M-4YY6/5KSJV9=6G
M5)#X\,A0Q^/69),H)F6B$BV;>9C4V&T= Y$QGV/J8)A&.=?9G"<\):%2S[6+
M9ZR2?E8Y^NM5!BBG>KW"P(BKAS!C=T$)B#$?+N;!M)LLL+L,Y:TLQ/I9MK(>
MA/AWE1"[G6!*IXRBG[ 4<[V#"&&JS FFG@;*9^R+FH^06ARP_];A54T3XA9+
M:XW-"B;\BM-R0E]%EE-:[!9B-,$V/7 [V924M<[EK.)RN[ @^YJ,CH#,4<73
MANR.>"* 7JE%%H5,2ZQ)66QSR&9&]DA<1R DXUJJ[U926@NII"UIJM=)<TZ)
M<YM0;3/[4[)6*L&BA)7A2\(,ZR%04E=94*+8-L* JA]ZX)\=[H?[AUTB"?_>
M/SP(!_O]>] = D\P\6XA8,V=SC._HD% P$KBRQ4#R2JE3I].;V"'E%@=TQBB
MG *<Y"(A*!QA31)*^*R:4?V;'; J%'_QJS(?@;PU2NWH7U HU4K)$E@+Q.M$
MTS2R[ 1'E'E]SD1L*_>@-(,0)&IKFT)"+*%EEE.NQ8Q%45X:&DQ5A-IR5.5N
M;JIF4Z]Z@P63J%[21U6.!7?+:3HO"_EH97 >7G:J*HC3Z];++;T_.KT(_G7T
MX=>3X./)T>=?+TX^GIQ=?K\J.?>9X?NJGA*II;%(599_*O?R51>1 6F,=-TD
M6WC#)FM6V9O5)D?@(TG"O,GX^L&8LEM7=2U>04LL6Z&Z?&TKSH!>B\1<51B9
M95BF(+YB:0& B9M$UV4RX&B'JM7+(+5 QG>B,V\SM0U&O+C&TB2ZCSD#_8]#
M484J-?JL$C95V":XS,R7M8I3(66Z!B4-VTC5,*":)_7:$4I)Y/R/4N2TS3!?
M--*']1X8V'L(Y%2P2I7RR$:2YU=:]:"8J\I:(EUI6:8K;=% A46K2"HEU>G!
MEY%)'1*@ZGZ+:D:4VZ%:=[1&U]1%DCH'A'P3?"#]VJO+_3_!&U-0%2EUS@B1
M-:>5?E45'E 9&R60UX?HZ'[[]7[/5YBB01*M.4.'JDB!UL,?#3)P4%.KK'7(
M<.D!3):/V-HD/K2U9UK6B#:"UN\1EE<;48YXV!:+>FLM<2!1S,QSMS[/7U>7
M%#!ZCA:JZ@L(+I0QD6:F-R(3)4JE;$\!D@6Y&:;J&=K#: G6-K6J3&-K6^'$
M\=]9%H.,A%B=)]*%BR(FI\$85AR$!0S*&-.YF](#504X+#OR1\F;-8KJ%"!M
M=7MIJ31.3?CL5I& 8&(,DD)EV*REA.52E)F7XT9#&_L[5,^X#Z)>DJI,O_!<
M?4=JDL\+9JM^8=6=G(JIH"D-6*<]OLHEK->Y6^MR6">:)_%2DOHU^[D^<&T-
MV@ROFU.^W)O#]\CEHB(H+6E<'BG!RY/F<EF*(=T4#:I%]VYZ<V\UQ-3RYM\=
M@V!+T:OO%\CVG'O:EX4],[T8>LZYPKEU&[C7EEYL*[CYP)?\[UGGV_KDM3++
MM;@!V#_%-U\JVKJE<2SWTOV9J0[BMHR=SR2(+X=WWFCR@NAYM^&\^P;#:?56
MS8;MYV<VH2XX'8RGD^ =GF+_BH'"ML#3G2O3^,W@C:O'9.=#!?L=EU$NJ 2N
MEU@WX/MV&\RC]_V$O!F[]W+N3;Q-X9W'B.?""'UP[L'!@\.F\,Z#P_."0]^#
M@P>'3>&=!X?G!8==#PYN!7SJ]YL&_1M>CGLHDU?XJ*Y+P5AM'%W[7MWW# .]
M77<1[X$B?-?W$1^9Y;WOR'$GWFC^5N1VD*_WE.2G?J/YB3A\^,P<?M ;S?=<
MBEYO&.[V]CV$;"*$>'YZ2/:0O&V0_-3IN#UX>'YN #\]&'LP_OY@[.WC#880
MST\/R1Z2MPV2O7WLP_CW#>,W,GM_3QRAC-';)<!/Q]N7K/N<D=@MU7R/RU_O
MBC@GYBZ!A^>FAV(/Q=L#Q5OF@KP,V/#<]"#L07A[0-C;PQL+'IZ;'HH]%&\/
M%'M[^%D#\NKC$Q1$J9*<WRMY>3WK^><"OIAF"?!)GOQ1BF)QEA7\^V0\3QIY
MSGO!3O#Y\OSX__O[^8=W)Q>?5</@Y)^_GE[^FWC@>H+S>J9<K#)1%M,LQX(,
MF!%;2%GRX' 0=KM=_"^04Y:K BU1-IMASGQ<FC#XH=OI=GN8/-RF D_CH.VY
M>6XJ'ZQY5)6566H6S-@"LTD303'FI)8\QY2]UZ*8!K*,ID',,44RI3^6H7Z>
MZGR$T 5EGZ;NX4_::I3G&MB&*955N0M*@ST3A?Z3-3)# T9C^8G1HE[T07%1
M!F\SEL<NYUQ^IE',WL /)7XXF<V3;,%Y0#LX.*<T(^K=DM+N"]=W"'8H\$._
MV^L&IRF^+8:9T#\E3*5,$8Y/X#P-SK(K52*DUZ<<&-UPK1SC)GTG<AX560Z[
M(,[FN'=:6K>P(WB%[93.)?;0I]>ASN!]K>HFI"J5]Y5*XBYKX(X%!VPUD[XF
M50$"=3]A5[Q9_@6K'>@2!X!7DQS3HRO$R.8:"@!XBEQ0I0X-.:H!$L$CH;*N
M*TQ0)7!X/L[R&=7R*%.A:@/@/UQ+,Z6$MPR")["L2)D46#*!,L&K4D/7TTS5
M2-)UAN[RN*E;8VNBI/'/6"6 ,M^/I(@%RZDL@&4)E4M)BV2A"LVHW/*<E&3
M5.DBK(XPQTGLW8+CV*TJC]52E"R'&>'_]?8'2UTL,U@M Z91QRHJH-YA:FC-
M #=C73<(2:\E;@?Y-.NE!JD_U5KW9KFKF[;/$R#EP[J\K+B89J#!8.U4XGFM
MUL9Y-K-S,L6L.(-Y:[%0M2M@O8HIB&.*J>I;Z@$MERYR%YGJQ@<FWY^D9'D
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M([A C5(PD:"> --4Q:W523+Z_-;AKQ_:C#B8Z2"(QGI:YKY9K5H\D?9AVQY
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M:0R+]Y991^134IOJRP_:R("=52F!C@Z9H10SZ"A6)D;._R@%KAS\ U:)2*_
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MNAX^GO-417V\:QF FW/XU_/^?\JS.<^+Q:>$I<51&I_\48KY#!]YOHS_AH:
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MLKB2D_A1\UK41U/GN*IM?'N=8JQJ/!;)FU\E'Y?)!W'%Y?GX<LJ/I.2%;%9
M?OJ:QN]JQQJ!D##@_VOOVIK;QI'U\YQ?H9=3\V(G!.^<RJ;*L9W$M7;DM9V=
MFD=:A"SN4J26I.QX?_T"O$B@"%X 4C(I(P\SLD3VUV@ C0;Z@N5JG=QE[$]L
M1#6T,9E33'+R:$?HB> 9ALDUQS"*W67B&UDG39EXN"WY)<AVTASTO^PZY.@
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MS>42JZ&T%VL9$O/K0/>/BV"VQJK@X74%*4/J,Y!.__'IX^Z3NV^GQXB7:.>
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M6]+=*RF'%?H/30"?/OYZ#-&VYG]02P,$%     @ 0(6P2)QN UQ;%   #\\
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M:QY[J!U4J<\UNLN=3T'1F9964"4LKB'C$,4K/?#H/[2P]8!\8"[6DVM\3X(
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MAUMRT[5/L0T BS\],,C]*OF"441SZE(/.Z 45$6VLU1;V65'6\#I7C8V KI
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MXD,AL_Q;IW0.Y[.>@KY#(@EB^6JQ_1 1Q(6B.X5+NAF*'?+Z#*(=9'[6$]
M<BA+$DCX+3B%F"930;YJ^3Z?0;,#K,]Z'G(AQBMZ&1)M&7T&3;9Y?<!TM%Q/
M_Q2Z*_P!4$L#!!0    ( $"%L$@E\3=1IP8  /5'   5    8W!H:2TR,#$V
M,#,S,5]D968N>&ULS5Q14Z-($'Y>?T7.>_ )8];:K=5:]VJ$P4P=@1P#[GHO
M5P@3,W4$4D!6]W[]S1"C1DE",AWP10V9?/WEZZ:GNYGRZQ\/D[CSDV4Y3Y.+
MH][QR5&')6$:\>3NXHCGJ?;ERZ<SK7?TQ[>#K[]I6L=FJ1X'V2SO:!UN\IAU
MZ(P7; '1^7S\\?2THVEB><R3?\_EC]L@9QUA)\DO#L=%,3WO=N_O[X\?;K/X
M.,WNNA]/3DZ[BX6'!Q\^E&O/'W*^M/[^=+&ZU_TQL&@X9I- XTE>!$DX_US.
MS_/RLI6&02&_TF:#G94KY"MML4R3E[3>1^VT=_R01\\T1SQ>LA*.>1),QT$V
M"<9I+(7,C\-T(B![GT].3WO/GY30VRGRYA./FO3.SLZZY;LO%@NPJ'A:_1+[
M4W?^YO)BOH;+D\K?#C[,'1MD89;&S&6CSN.?ODO>6N-)T8WXI/NXIAO$\6&G
M9'I>_)JRB\.<3Z8Q6UP;9VRTDL:"MG3%)^F$WR5:5Y726/#(PMDMT\15EL@P
M!J18A:Y,^0E*B]@HF,4%(.&WV)!TTTG (>5] ZU.ML31)FQRRS)(IDNXSS07
M'%\3K)-+NB5C'F7_&&DX$TH4B]\HB7!2\.(724:I^'A1*ZK#Z9AK"_"2=6WL
MYR\DPH8G7%ZTQ,LEF^RA8$G$HH5527^?7QA:9=VQJ6,1 WG8N$06LG5,^QA[
MU$^"623VP6A7C6L@-ZWP5I3VK.\0N=CV^M@C.K(HN,BOX-^-TBMYP<M-/?%S
M(*Q1QW2&V$4>$>\BV]"=P=#%?6Q3<HTMA\+&^BYFVW2/&M_]NDU'M&]:SO?]
M>:C"PGMQQEIJ0'LLS\,XS6<9<]PK9)._2^<+WU-R91-3W*.VAW3=\6V/V%=#
MP5(G>.=DM:.UQO=A59K0OB'VM8@(Q[U1%_X9JCU5JSA 2S9T92KS;H37\%\^
M&<I;2EV]2M3VA-Q !SX,/61?D4L+(TK%5@X1C:\0VPS*E52@=43&=5D/F8X[
M]%V]CR@6V1Y>W9IVVM-\:X+0GG"Q)3==49-Z-YZ+1-6CE\6/NO8KD=M3NP8E
M:'UMQ\.BXK]!PIGJFBZAM:?C"AK0VLFJT'/]TD>6@VP3Z<0B'D -L!*Y/4UK
M4(+?S41_@SWT Z*>?0G6YAY6Q0):.!,1]QI9OFA3$/7=>;>B+F$U;'MB;N(#
M+2OU'/W/OF,9V*6RFH.XTRLPVQ-T+1GX[#D8$*_T63G)*%LU;,-TK^O V\RA
M=5CM89O2A<G'J1'(YO02K]4MJ9H(>#OP9I0 -V=9@]UBV5^'%+3*EXC*P8UA
M$,L75; <9XK>6=XSPKM]Y(IM4]1S )+7-=2>_MLSW-M "TKTUX#O8+BU=Q&K
MIC]0>J[!?E_CK@9"=7D: 1>QE;CO9P"V=V6IWL>&;V''7-7]06E=VU*+Q?'V
M%/?8$,,%^6O(=]$<-QC:E5TD?%RO,_,>@KH>/Q@W.-E=D/#_RN,R*(GLH)!/
M\D;.E&7EM=Q@1<#C?%?]:^,W+?P.Q& 4][(@8B@,TUE2Y"X+&?\9W,9,<$!Q
MG-[+4Y9FFAGI[+88S>+%0D4WJ!EMVC=0;&$<9L\F,B;2+!<$#):D$_%)^=+/
M6402;\ST( YG<1DVSN@RR'DH5_)X5K#(2O-\R#(J+#%%)\(3:=JQ^_P&,,Y^
MZD@,L?N1W8^:O<%I6NHU!&"4JFHP9#E&J&B3'=/K8].Q+.<[L:\4M=S!4M-J
M*U&$\8>HU,A /K/T*39]RR+7\OFPL#SO4!"=,Z"*SMC63-.>V)T?C!OF9@P\
M=+%.RG&HHN"K 9N6M@X3J"R\W%[KIH'04-QDU]@88$.>AC4==^!;2#6<=[#4
M?"97H CDCZ0(DCLN:[ \9T6.)FE6/!;/^&'*DIRI5JC;F&C< SMQ \HGM8[]
MJ.:8K8PTGG=V9 ?C@%4G@13C?1-LTR+7YP/45;TX&*0:OI58C?<VZTG J+9J
MWJDHX";8-@[YU^,#U<L06R=#9 G_E=,V5U;Q+C9$RA&EHXU_>*8H)&\P<BER
M,50MK6JV^2X'BB^,VZA_28EQ,Q]6*^;C2JRF!=Y  JA1M#WL"E=2_#3E=T7J
M5VX,-\ VW@C6Y@,V#[DF5"0L<3.\>'RB/OM8A]K"G*,>':"'1-C$KL@O3Z8>
MFWC;L BZA-CYMK#0^*.A7:C!Z%[Y! IY+AZ*1"]G6.)&\JGZ9&]K.TW[0($@
M4,&'AL1#5GD<=*DL5RSX-L V7O#5Y@-61[\XKZA>/5> M5 S5[/X6OXGF:?_
MQ//MX']02P,$%     @ 0(6P2'Y1%R/\40  ZFL# !4   !C<&AI+3(P,38P
M,S,Q7VQA8BYX;6SM?7MSXT9V[]_93]%WLXEGJJ09:1ZV9YW=%"51-FLE49$X
M=IS4K503:)+(@  #@-)P4_>[WW.Z&R!(XM' :4+8Q*Y=FR*[^SSZU^_S^*=_
M_KKTV9.(8B\,_O3-^9NS;Y@(G-#U@OF?OO'B\/3[[S]^.CW_YI___+M_^C^G
MI^Q.A)<^C]8Q.V7>M><+]KCV$I$VP;Y]\^[]>W9Z"L5]+_CR1_S7E,>" 9T@
M_M/O%TFR^N/;M\_/SV^^3B/_31C-W[X[.WO_-BWX^]_]W=_)LG_\&GL[Y9_?
MIZ7/W_[K[<VCLQ!+?NH%<<(#1]6+O3_&\NN;T.$)BE1/D)66P+].TV*G^-7I
M^;O3]^=OOL;NELV9Y^]0<19>P%<+'BWY(O11D?$;)UQ"D^??GKU_?[ZMB4TW
MT\A!#:V3\T^?/KV5O^8*0V-NDI7.M_WQK?IQM[!7P4NFY3__[N_^*0I]\2!F
M3!+\8[)9B3_]/O:6*U_\7G^WB,2LN#4_BMYB_;>!F/-$N*C63ZC6\V]1K7^O
MO[[A4^'_GF')SP^C4L8^[;2E*KWMB,5[$7FA.PS:\;I7NUNF'Q,>)02V<_6[
M8GP"\XMHQ7*N9F?,A@GWVS&[K2F957,H_GT#GW9X%E\3$;C"3;G&9BI&L*0B
M9PAH-VTX=/)-?N/CK!E&W^3U\(VS6GBGZ>0EI809[S\N^<H#5A^3T/DRB7@0
M<P?GVW@PC9,(/J=M2-[_](U1E;<YSK#:#F^1B,-UY(B]AN$__]&$'ZFE;VJT
MA$U_@RL64,%U4 2GGQ^_^;.FP6(DPI(<E3_^T]LM4WM2#"*'A9$K(KV\YH7B
MD9-^ 1]K>-,EWCHA3,2KY#1E4U:?1>'24,TI!V$#[;VU AJ%;O$D_/,"?.1_
MI4"A@ JEUV5S3+;'SBOZN0,6W=!9+T60R*U- :L7//@"LQWC#@($UVL6A(F(
M66(H0]=8+=!#'I9EB" B< 0;W*68\*_#KRL1Q*(4C(<%R;@LI4V'J">;9@G_
MRH1JW"9:28S7 7>P#-=!PL(9<]91! 4+A&&OIB(0,R]YS7C@,E?,!!1UJTNN
M1)1P+X!-.(P!!FA,O&"-?X7PB^0F?M.W\5"JZ8.A48U/DU&2/QS,>#R5'*_C
MTSGG*SRQ?'PK_"1.O\'Q]/'T[%R?@?Y>?_T?5[HO]OFY4-VP!RO36FW'6D.N
M* ,O)=$3"#64/,53FPYI/P4/W"=<F>+K,+J''ES "7<\&\'<$,R]J2\&<2R2
M^$K L/6K=I.MFJ%,WQ2^*1A+Z;)9&+&5IHQ3I9?19EP2ASE14K<T[1];X-I%
MH05]]N_II__;DS%)U61^TB=CGC!JEV&4>'^5?:6GA?A!^/!W,)^$^SP4C==F
M#9!&:BM>26,T1S'=A<0LTC1QZW$P6&T-TJ/)6C<\)PL093Z/Y,5%MO4"4$9S
MV)7Q.<<[0R9XA+LO/((P[DO P5X-JCIA+#=\W/FOM:?V<7L:>L,&<)2!$TS@
M\'B14CB!VE[,A"^6<I\(15P7JD\YGLE#%HAL\_B\$ %SN.^L=3_(=E91^.3)
M&AOV:AU+RJ]S^T&VCF6? 8]>X )K,*LL1;((W3[M%-OU^\YDTGY $J81!T"%
MW2'<//VB^:*D)&EBJ*9.F@&V33.>:]O6,*=S7KO<EDC X']^&,Q/$Q$MF8]G
M+U]PG-\<=6OD_15KQ&S%(SFB(P&'41AE>/;:]&K,5"MQ9W 8H*_]*+A8>_)A
MZ)9_]9;KY8TWV^_WLE(4]%=0I2 _;98M5;O,AX8MP9[(LLD2EG(-*\%L[4OF
M$<02\;[W)-P3MEIL8@_6D72;K1<-N40$8;2$7P!Y[MJ1\)_B^B'B6-Y2!"&N
M1NJB7F[@06#NBS=L^)7CDT.,:Y6_=H4<6"=060D<GP!C^)(HHHUL2, JN4)9
M3N2?(=".&.HP1IJS-:RRR3H2NV5UX] >MIQ(;GQOZ>$03\(3J#GS')%O>[>A
MF?<5/\>*)JRIJS5, KGV\>LXG"7//*KJ\JX'>@5L\H.\;H!U=X&2<A(/ G>T
MQ!V*W-W$/T9AO+^9-JM#O3PQXLC&M-$3V#22>__BQ+PK"#?7$7<%+$MX40K[
M-$=X3QQW9X$[@&WU,YX+X5AX%:ZG"<QC:<'Z>Q0[[9+NQ6U*1KI&1T982H!M
M69'S7,:,G,=3=K;%ZR]?.K]-MJG8G<MGZYCI;JI%LR%W[8OQ[$I,DQ&<42.Y
M1X@GXFMR 82_E,RW!A6IDZXY;Q28IU1PXW ?P1;!6^&&G6\D*=BAZ ,YPEQN
M<8 X; 6>!-O :3[&K3[4O()N7TYA-_#^_(2AKGL"_.:ZW)_-&W9T=]"]$\]Z
M+,%:<Q^% 7QTU$IS'_J>LU'_K@-RXV:HL&[+-P7D."O!!G5+E^T2[AE:VZIH
M'[NDONT.R?>1 *7,/#@[X=$L=]H>X\'F$DX:D5B(((991[U&W91OA%LV1D4U
M309;=TWJ(.CDB>GKSYXAG*:N?9Q;Z//NT'[C\:GG>XDGXDMEWE"R'S>H0$5M
M/2\D"SEMO9&CTA?3.',%[&/-L#<ZG3U7W'/UI;WFJ7QR+"AK8>XKYX "(-UP
M]H;6,_!4RETP1]6HOBED8N&\F8=/;UWA(5H^X <$R8<<2."K_QC"\I]L[M=3
M6.NO_9#O@Z.X3%M05%*D@$$URE2K3#;;$SQ4BISBH%[+W4T9&GW-#+1J*E$G
M$3.>+"Q'/0%-,[GW9Y,&G='^DC&[#KC7MP'OSMZ=[75A>3G*)6 E9=J*DMYP
MI"TS;-K2 Q69;7/+6+R*47;<J\-+FR7>7+KK*+5<X$&PAM]A!<+'2_AR)1UW
M^O0:6ZFZ_&UC/=BL O[\.S/ 0SG+@-]2M@[X\^^.!_AF;/\&^$+5U0!^#VSM
M 3]>)^C)B:]5%]S'F_JKM?@<@!8>Q%/H/\'W-UX@QK/+2+A>\G![\?Y,_5,P
M*@B-488.70;*^,I19U-%'H HV!H9  !J#A@0DE?LCF2"O0(VV/NS$^ "___:
MTGCL1A=U@_;X.NEZL-+UFA_1E@8*P>Y.3H^C(!& I^2!)^*"Q\+]O J#\_.S
M\>P^<GX,GT048"\_ZKWFXP+FTHF(EEA^//OX;<$48*EADE6?5=E(%[-J$?(T
M*RQ"8U=TX7?9&KAAP,X_R%>WATLVSUCZ1[X*XQ_BS/4I1M:8M+:3#4"%CV^^
M_0=;EH2=:ZMVQ7\AK75N?FA5\SO6BO8'8?NIYDXDESR*-C"GJ;U<P:QQ6(8R
M 912I(QE:)0YNE6TAUU7WB-TQF[=8&K&=M=#H%3T/)JKP4$(61 N5SS8/ @G
MG =HM#P(1L$3Z#*,-N-I#.S'C@#V'T0LHJ<BB]RF+9 "&K3CEG1=IDBR**,)
MQRJ8ES55%N;(HB$KTK4T)HXH;=V(L2QUY^$>VFEN)_H# =9=OGHICX)[Z+UD
M$+C#U K9S.K%N#K];:P9G[2['D5+&B@.MV;<BE1/4-I6,8?O:2UZL/URD0V!
MU-72_<5+%BK$QN,@B[!1Y.MH7)6R0#3ECX*SC%;F@.RR9Z &VW0DE^[%MW%'
M;+DW'D/(N@7!JK!=+P=-%99?!UK!MKL%8!0X$3J>70GUWQ&:_41KX4[X5Q'?
M\PW:()?,_F9UJ5-_(PZ)%F#8+ 8]$>AX)QON"0I;*6-_KF_>7R^)PRL!4X*7
M2-.S0@?X1E7MH["</RN!*9*0Q>O5RO<P]M1_G_\_"W/_L61)LF" I@+U?E25
M*Z1^4-6@KT/[E'"Y# ,9?^YQP0$8@W6R"",\C)09IU34(%NFU'-#/&=#\RJ,
MX F+)07&,Q(]0YR!,@YL50S[IE.3217;2#+U,_?793N%HI(6S"7+J!.-)74,
M- VE/YR].3L[1T=\]H1$?F ?T[>U0YC]P((P_=:+8]Q.A!$+MR]5/<-AA1(+
M+"\K^[!#;S-D ,- PTJ"Y]5D4V/Z75&![%U6RPO)JRS7NCHB,46D;P;@]6HX
M< @SZY/NX^W!9CAGG'X'LE?:@M=6LQ5QKXXO"LYNLE D601(#/WH:WI]N_0R
M54E9+#ZCONH.>:DOKSZ!24?@:@>$JAI4O!EP0_<'YZF#=S^/V08ZV,>6:9>\
MB(?4(' ;+YK&U2UZ3QGQ29KH1H.+T<UH,AH^LL'=%7N<C"__\M/XYFKX\)@N
ML/_R>33YM6> ;*JC"G<K\\X\EB?-E;XKOO9BA_LJ^\$U?+=_P5-=EN)94\L!
M!6-IXTRUSE3S3+;?$U@9Z2#O<F/6#<00X@<FNE<'!\KJLN1 XE4<D!:],HMK
M=VTUGCB5_]K87E*.K3&\LH615JG3C8Y *9^]>X)S(\4<1 "OQ99=7Z!W!1@O
M+F?;%^B=#6P7^P*].Z(O4".VZR#=G/T>N#AL55#GT_/.&G"5G4#>1.!.%)DA
MEI6D@;>2^C&L/0)ARS31 O.U\_)>S/)DP1/&(\$6PI<Q>7G A'+\Q0!$ZUBD
MH19748@Q%F5(TD@]T&S0S'<>AJZ*MHCF29Z#\0I5J,4 EX D5$$RX%OX$G_@
M[M(+/-Q%)A@N8[6.8#<M5!,9.^B![JA B6G(8(8Q)\*EYS"=7T*VM@PCC&C,
M,5"J"I'T@PQ"+&,;;P-UN&(5"<>3:OF?&/ZQ7YY6E3#>G8CJIX!.GY9UJ))K
M$.8R2U<RSJ)3PW[V@L>>(]]5RE^9&[5BX<&Y#=>4J5"VQGP@B8Y^ZAFC)P D
M:J7@T;9U9[9?0Z^Y%\EWDUO!8YP#8'Q<P8$*-"[_*H\G:5J3LL8VY([TK''Y
MT_#J\\V0C:_9]6#TP'X>W'P>LMOAX/'SP_!V>#=Y[,L#1PO-Y&?"-AU'L:[<
M.JL\>/&7:B->DQHT6THC;F@FE-J]"6DP)&+-1-(:[W5[MRT<U#YJ&UQO)8EB
MJ/A=-ZZH6L[NK2.-=+5K%&D.NPY#07+<F8UGVU6@9"]04) <SK&4-LFM.IKS
M($TY@!M+10:WMUM"/8%2O28.XC)6=T.'+RUA,$>G/PQM6N<R45R6_(92Q0')
MK&I\]SAY^'PY&8WOV,UX< <+]B6^H/QJV2B1+$&E%6*Y&#U#?Z4:#EYU:K'4
M?B^!;5;L2'=^INP2BN@<![ ]Z>DRH?/K8ZEVNSPUJR7ZGGMEUJ([1>CGW4-Z
M)!S(M%08]A!W5>D&JB<8J!+Z\*Q:HN4N8V0GJ,Y[G>3K8O,YQH26Z-H2XTYU
MX"3>DWQ<+MLPF3= CXO=E%>J0[M$VF>=OB:CP[:$>@:ZYAHZ#(C=JCN[ ^Q0
M)\B[%Y&\P)%7.278+"Y+A6$E!^1+NIXAJE+8??#4ZYMR ;(;R+'PQF.O".V*
MHY@>[4[C2!G'*<R:!YC3:2)?X37R:X8X*<X0SGB21-YTG<A<,$FH7J,XOB^]
M80,_#M$4U0M4%KQ(/(E@+9B/*<"R5*#R:4DZZTDRL!D.]VA,Q2R4STZPDX)!
MX04\VC O$<M8OMWP&3Z]P R6OH!A?+PP!CXPWATVL!4(-A'R9KQ"HNR92^7D
MU')AJDTH#FKTL7RZ$^E5BO0R:.S>V50,G#Z]YES(3L_8%?$PW_TC[/V[G3Y)
M=UBM7W[:4SS^*Q%9&S2[\C@;A%XVK_5N1]2!%IN_0-D!57<#4W,>S-.\MS7V
MQ>7EJ8.BEA/2E6K:>+8.]>6IREC\?2R:]<0+^JV.I"=="8[*2EOW5]WEPKJO
MJG(7[!F6:I10ZZ-:T!<OY9^J&,H%#2W!4UTMNWZKI5Q9]6'5$/M;\4,M54JU
M3VIU7QTW+\C/H0\'(%B8KSU?1$6>#,7EZ/E!2BA3\*-SA&0M,]5T3S!3*_IA
MKI JK;>_;7A$TT7W<@V#;"DB[0!VL$Y5E:3</=10)]GGR*:9H]M.;1(J5Z>.
M6:^[D&@C0M>G[AHUY _?)@ B>M_<B"?AOR\ ;_Y7LH?-+A6Z3XULC[VWZ433
MG,4Z,*IH7_GH9F@V# NRYEYE9.@1,@OT<. E4X"(%W'65R%VT,A.92U,DR67
M;.],:EITV:_CCC("LE;EA:-LMB<8:J&("E]]HWXBSG[IY4GYPT%A,?)\6$*7
M/C%F)H-V'Q&H3#?+5..$L?P\#:,H?,;TV>O C;>+N;*8C ^$E=^[8IKTZ9*]
M2G4'LVL5T$@&PMI32(VIRYG+!ROTQ!'NK7 ]A_O7883>-649ZW=>TEHW1C0K
M)LI M#C>\[6ZO+X:,*X98$O% 0)0L@ HE#ST"(=T!>Z9\MI 07M,7VCWKELO
M\);KY8TW*YJ]BTI14%A!E?2ZKYME2]4N\Z%A2U,WD>5:'T28KU.NU[&8K7W)
M/$[??BC3% $B3MAJL8GE"-'#9ZT-9W"Z#P H\ L>==:.FOC7L1?@HR^^]:*K
M'<[T@:MG?A"8^^(WQ[_CSA<5N,E/!'4CS$+0<),UJ:2HE:#@1UE/TKC85[4+
M1=<\&Z1%P0?,\QYAM4[LPLC<QUF7+A<\FHMX$A:F?=#[.KG7*[PR;%2=E!.E
M!9^DQR]%#TUC2O*!I)OX1!&UE0WE2'+6ID*Q*&_7PZF-SG:2H+0%,>%2WED(
M=^V+\2SO'3$*8&S+;JI:/<SKDB[NFW)(NLK7Q'!C<QE*&LK6[2;D ;OFCHSO
MV!<3AE;JV;DG;]6#[='V66YT;V!K&X]GL -69Z")C !8X79K5(V"L29\4>#U
M.=WH/ZF]L\P:+&E9FK5M"U(?264*1]6(N5NO7!!K72IFGS;J3725'S2-T=C=
M/?^^_SQVW2B DU.\=9NN\[ALU@;U[K\5QY0A6!) P;)[YM'$JG3;+)&M)V..
MI)O]]X[V*'V!T5@?M<2HBK6Q=J0X)7]C\#.(2=*X6[HV[)_PKUN6:K!55<..
M87TE-Z1KG[O+\>V030;_.NP;G PD+S9FK^^(/GJLUF"L14/=>;!:]9M'+]9K
M/WS6+DY%CJQ].2;2-=7>H_7E9\F]=%/IU4JY]W5U'?N9T0HXLG)%WC/T&0E>
MGRZLK"_:7TID!C+78705KJ<)G.[2] 3C0.8E>Q".\)[PA%>4:K5A Y2+BG:\
M4N"4451&(IKF-B,%^H'*!\%H2]?29<;QA*TUJY&YJ_:,Q:0"#F25T;R3$$/&
M:CMPS-/J;2.QLE=0+?=<&V8>4<[&\<4)>UYXSD(\0;->+-]^1?2Z. ;L5+ U
M[!U\'[[Q^I,&I'U?Y:]5"*.HP]PSKNLA*C!HM <KWB5?>0GW2U:2LM+DG#/5
M7)"&>]:TC 9S"D!V5.L] 9NA#@[RS1AT1;<1T#!_5/Z) 5\8= :<0>#6)M)J
MU(2->&E-^:5Y_.6>7GQ\>IGIIY>>H;"-8HK"DK7J24)HW<'H05[4Y.]I!LF#
MD)$<@OD53\3G&#?R%4%V&[=!"K?;EN-CW!4/)NQA>#]^F(SN?F17@\F0?7Z$
MCSW!)DE=.]%X23W<'IU#-.9=15Z\=>?'R*=8K@"'5:4IB#/@@N@TJ)MG.H0-
M$%"!>9&$I2VT)2'J]LOMA>EZ8!@H)#\$3,%%"1RYS<F@+3R*\@$4 -^T)BW<
M9"/N* ,B3XII6ICU8IMN)+/]M#0XCB!<W4"YUF=!^1JN#GD>QFMR?/C&FWEP
MSIMRYPL>]F0N$A0;TX_(.T;\YA0.H:=HQGLBV\EG],@,H^";<!Y@?F4X6XH@
M1W"/UALV6<BOH)%8YO*1;7JSF8BDJ=54),]"M^#P*-K@L56F=68\D=\F'@:I
MD9PX7HQ< .L9C0U27,H,EC*O2:X5G0M+JF#+X'.X!JD7_$G OUSFS9B7R$^!
M/"!/D9F<KGBLU(0G<U0*>Y59':-9=.RY.CP,6B$4Z>IUGPP2&N)Q-P)J\[F
MD-T(,)W<IC;B>0*W_&N%5X%9/5+FHR:<D6)&(*%20WGX_JMM?P3KHOV6)>FW
M+$DO/>4U O5.SJ3&4TF7CT[Z!>:!/]\"I"*/^^6/345EZ8],%1Q0ICUH#_"N
M&^P)CHR$/GQ8JM-[^^7Q%]CC #J+GHJRGRB+W'[[E Y-V[*T2+5AS<13CF=^
MSL^:0I]FL7VI\Q-588\3W#<Q_*_,BN3#%.^B0]&]B'0@,0SH).U0JZSVF[9
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M:H[E]B,,_</3G#?0\B 8>O-%\JO@$0;Q+1AA-14H(\R,%]K+  ^V28ND8TC
M!%(YE1%6\%[ T@"S)TS= ",*U?5 ,%-,?B T@!S!%0V:\I+Q[(8'[N=8U/B?
ME1<F.9W5\D#R-).MR[PPJ3?H,;S+K,A@E/1&,U^0].;TMZ0W?ZM^7+7PV7'>
M,AN'+^"Q]6-4_I2^5\B:C]8.3<I,L4V.,\<F>P*/:GE+_;(.E=QU;%W<NEV#
M",H*< V#>IS9)0""M8N%O#4H14S3=NS$X6W!.2ER@VI/'0^RBZ'>P:^E9HJC
M][;MU.Y _(O<2PIW\ 1\S<7=>CD5T7B6YRP>KY,X@4D8V"^!<--6J !NR;4-
M^#YKTJ=<T<ZN-=7M;;BEVC-HM]39/K I74VY('4QYTQY(N&] K1+T"):M&M/
M5R;.S6*O_/<[&W9)-&8K+9+V.7YQ;LTOHK;Q;=2K;1*RYPCVUJ=N^"PCO.3#
MLL*/R=9Q>"^*JHZABA%P1NHX$*L-NQ<?[-DS*]=MZ^E)0^2_[--VO+@W=F^!
M2T?5"VR[[T/?<S9U+D6EQ:UMQ4OXL+,IMVWQ3>>Y<J+H;QSQ:L%+3Q15J&F_
M?N7M>,XKW.Z+RU%6LTK*%,C>C2?#1W8_^%5ZR/>D^VLESL]N]<KN;I+[,0S=
M9\_W!X&[G_S;.'5+LS:HTV$KCDESY-UD</?C"-#&!H^/P]ZE#&JED/UYJ'T?
M=FBN%<UYX/U5;L4P'#',F*[R* O<>Q4C4/XYGEU[ 0\<C_N/:!4B'29S4@3N
MHS</O)GG\"#1?C-P9) SL"?BNH6^<S;(9F4OI#>2,>3#CX.[T;])5WKIW?LX
M^O%N=#VZ'-Q-V.#R<OQ9.ONR^_'-Z @NS7U66>6^J*G>>C:7O93>#ZP)7W*,
MOZ0O[.4Z3L*EB ;ND[0,+;\[KJMHWP>VC#>2OXMN2[GV.9J";0\NN[)43@ E
M O5LG)LKI-[SM1)Y'3HJY )SPF=?Z.EBL,1X]']-+Y"*1I-15;+S0@/^2!?6
M^4#&>!7%<P1Z!L,F.CGP9FC::=W>7,6)2CJ+ST&IG4O%S55A<1LW5U5\T&ZN
MM&V2,M;K&;#J)"^Z!JKM@@YS WN!EPA,(GYP&AQL8Q$;S&PM&B+G$6[-.VD?
MD0O1G)_P, /=E@UM,M0SL+;7V$$F8EIW=YCBRN-3S-A4GF<S7X*<H.J0&BEF
M2XB1A'*-]@Q/!>(>9)4JT6Z7V[69B"+AZB "I3NSW5+T35@A5=I^2S7)(M5F
MS\!0(O'A;JI<T1TF4#3P +7K\FG=QU--#KI!-NCC>F/DSTESX,S#(1;.FWGX
M]-85'B+A WY  'S( 0"^PFQ*7K)Y$'.9TB%([OARO^=*B[6%01U="A)4NVS;
M,,.6>X*%.L%3.!AIW(Y+[V"=+,(($Q,5/)"6%+3EUGM(VYYC+\_:/H)G;SO&
MFUCB!]+2*^_(J_V5I9GVUFK&B^.UV,W\DGJZ.U #+=7Q-F*ZZ9L35[4ZRSR!
M2T!(\%6)X"3MK3 %[49>8[\[>W=>,!**RY$\5*HHDYQ3TH99VC+#IFTYI5#9
M-K<MD[G,Y,*^RD1:I2+)#&;N.D(?2&E4%@1K^#U*$V'B2/%"MT^0KU3=CB]&
M+=BL O[\>S/ 0SG+@-]2M@[X\^^/!_AF;/\&^$+5U0!^#VSM 9]>*F*.T%]X
M/'#_<QW#^CD)"T!?7I8"_%H.K-P(1YC9]9G#SD>W#U"R- 2L"% W#-H*TC6H
M:Y61![89H+H[ZJ<)*&6JMGR&MBHGNYI*U,L ,YYH"T11QEHFVV?RZJ G^&JF
MDOW+@P;]U.&=,^@<>,'_C):8"E)9BY3=/Y>4)M]%5W-AUQ>\9V"JD?W@DMJ@
M"U[ '>%.)#4&N85%K;DA%-"WY()@Q3O)%K]_V^X'!4*7NAZ4H:3#G"'.0KAK
M7XQG0QX%&/  YA)YS[&7,DXFB*LST&W;&CFG"$T*VKJ^M4E,ST\!;#(C[#$5
M>\(5F',X4%_D8U8XW'?P8597G2*OJH9V/15:FMYZ3Q,5?Y"_Q )^.DU7N#5/
M-7-5JZQB(3UA+3^TR^U<^Q*GV"LR[DE^%/0,HB9:*<CN9]9-7<>>F/"OYJG6
M*JO8B2A1S0_-]^=R?#MDD\&_6G<QL,5Z]3XEQW_/1H2)_,71+0RP1,C^H!VJ
M'S+7Z<O4'?L7+UFH^)2/V_B417FTF[=!R@S1EF.BO=N!WWGFM\Z>@2YL))I'
MF^Z-W+57U<>1O^LKO-8ZW,DV08)['S*_P99.QP_/0C24KV8-VCA>'K@*CDG6
M0[NIT[:QY7+!*WH"7Y*.S/.IU74KY3E&G[_S&5H>8 <;/15%FJDL3GN4J>?#
MS@7/3L:=2%&P]C!C1XCZMYF6PG3_.%.OD-WW&4-X=9@K2"2U&01WRY#S Q51
M) 6K$(D,/-<38%3*>9 #J%2U'6=H45S@,XZ*!U27*["FDI4L+;4\D9S?Y9*K
MHY"_TH&E7O<M2["9'@KSM)AU3H?WS\*'-N?%8=Y*"I%OBPMI4F"C6TPCD?5M
MTBD6^.#RM5S+7=ZI2D-+S!AC&HJRL@K]3K6>'QL&PTC@I/\A)4W4<7B9:M@_
M'7J;;%WB3)R)2XT:2A!IK7FRCXME.6WY:;IY3W7X7[%Q3,^P;UN9!WXWQT!-
ME^FD$^X%PDU?[G;$F7F.5YY@NK8B/>6T*6\4A*=4LF?;G@'87 N'^9X;==&+
M>!/?@0*4SUK-(:6ZCD6/XW*.2 ?;,#C5S>8]D?MV1C'20X5S<DW7=+@CY?&B
M;.>)/Y%WF+GV23M):$>E!\$/N(@^<1^MYGH&C+R\!UO%?84>R^-T  NEBXOE
ME8B=R%L5!-(H+4;Q.*VB2]I<I>VR7,,]Z?@ZN?,.I[4*/Q8@M+OSM1<[W,=<
M5,/ O8+UK0 4I44IP*BC3YH9]&JA&F?8.H/F&;;?(XS4J2"/$Z,^H#@G Z=!
MHO-V7.'NQR^[^ZPO3W-5-N"$:-25(\ T!6O^RI:XKWL<N@R7*QYLE(-:YJ[&
ME>$D6G,ET=I19FOS2(@>G2Z-U;3KCFR*-]L9B@O 7U+0?E9B&W O2^![U#S$
M-I%>)L!)C_!<K87ZI,.6$)Q&MLELUW0\K/)YO*X&!=.&W%# G04DT@]8F#A7
MQ3WKR^FP@2+R,&G2+Z20)+B(7(>1\.;!XWH:>Z['H\TCJ%.,,) :'*IBK^"L
MT+0V,7A)4RZ)#Q1R99TI>BS.")ZP&$DR#U?:+5%[H4Z.(:;I1L*&N"\0SJ2I
MRO9BG+0"</L!-Y9I3[.+Z^HDO16%*<.IG@>2/<%>8M=CI.BU(\%O*7K_EZ;H
MK8=/?I(P'(7=7<_>IEUO&DF@H@+U*K>>%Y*G(3[TE6*])X@R5\7^W:]AO[1?
M;7+.A1@18Q5Y:&VL-Y08'".N]'%MU01E96K++\F02=/$B7)+E2FR#.@R2=C2
MRG5,"6O7,SY=^SQB;N;/A$D>^32$N1\7JPKIV1J6J$AY\.JK53QI^?PY7>GN
M'RY/Y(=T.^FI)0[S/&'$/-A5_J> )3 )^[02M.V._/I &B&=NNYN+] >O/C+
M)9PNO00_E;WU5=2PX+A;QPWI""=;8]A<3]#60/ "UURC?B#[(>:2!:7W#$5!
M&:M*6_ MK.+"@A<A&JVF[??ICLA ^@(_N-I.Z-(:2EK'W/,HV4PB'L3<47?U
MQM[;35J@VT<UYI9D*#6\&4R&5^Q^\##YE4T>!G>/@TO,FV;;T_M(<E4Z?I<+
MUY/Q15#.H5U8.XP2)F>=:NHZC.ZA\Q<\%O%XMI_RHFH/W[0%TB3>CEO2Q'[U
M\^#N<OC(KL</[/[SP^5/@T?X:WS-#K*I5NT]>R*ER:T41IR&W7MN(P^'%YXE
M8PLCMDJYPE^\_9PP?=J"MU3ESEI(P'</@D":+Y"-FCA:@,@C+9'W#^/[(2X@
MF$ET^"^?1_>WP[N)Y>7Q6$)5KH_%DO5D#%(T8QP*T\;J:,^V]=H/G]'8%CZJ
M7&BPBP9N=795^ Q+^I,TR35.2TYNUH9-K0VY2%=IZ]7*EY9&W&>:$99Q(J^#
M,E[8EIF^G,)LJ[+(U-<:1KH=,< B_F>X-;&^EV'/]T-95(P.XR9LC(2F_%+=
M[E^E#;YF*0F\&,T,U.6''#<]1'Q3E16ANU4?=^S@C_?3D5B((/:>Q#;F@+8!
M4%:V3OYH!T+)OU342A5+'.<XZ/?Q;,*_EF#^2,2L!!0XF@[H@0B</&NI5==I
M9ISB:-Y8LF5'1ZSOX9/@<95=&.W@N(CK;JS^* (1<1\]0-VE%\AL7+ TBNJP
M"76UJ*/'D"O*,- D5#;K'2)]C;5@J)1]N#;IJP[=*\-@/A'1,F]!?Q/RH#I/
M8UTMLHNE&5<V7&9D7AL5G=G)>Q'X0([-N(/.BGV+1&ZHG@/?RP:]UG5>T!*@
MZ1_M9 *U 9O)>#*XT;>K/4/%KI#%.3]?+#KD[MTD++;#K]H8[\<P=-%JH@0!
M1E7IL2#-^:.@YR!;^0D+A+23Y*4YSF?L#Q]./GS\]N3[]]_)51+^?/_MV<G9
MV8<3-*!<"3Q#"[]ODU03G1Z&C&S8Z<=^;FK]RM3!XY*5-R7SQY1.GY1LOB29
M4>S)*&JNHN8O1!UF?M9;C(<TC> C]-)Z?U35%J=G@J[F@S*"5/M9<O", E,D
M>@(K4TT<IH@VZ)+VD_!DX47N)9S$X?@>:5.?PE31)04IDVPU;=)>$5MFCFXZ
MC?QL+54TG?'ZM_?& G0]1U8K(3\G&D"'OHL8/\/0F(07(8_<\>S*BV!S%D95
MVX>R&C;V#37<6-DPA,\R56S(ID@%=PQN2L?R3L&"-*9;A)92O=0&H48S13L#
M$]@1AH/<7^1CW%6X9%<4)@V"6AY(^%?.;_GF^P2,6MEW,&'6 81LX#)YY7B&
MV1X_Q^+6"RJ\0"L*D_*"U_) ,N8Y2,_)EHJ"33]0.S(8^8%JY@O\0-EO?J -
M_$![-"G4HV<G6;K9,"1,"MIX*F\WA3?3'J:N'L\ A=>A[\N%6(>_.:]81"BM
MD:85NA2D>:<XY[23<I#FJYRE3#"W-OQ3Y[BDJW 'N):0T![9P]D,=E.XJ_+7
M>#7[*)QU)(V<*@!L4(F"4W.>2)<@DHK:+BLZ+,X(5=F]O9PH)JMA[HUP%84S
M7.@CF7I$+EXXOE;2[B>[S=]&Y\%EXGGA.0OI()HDD0=+CLQH!H<+69/CM<H;
M]N\I\_^W1T/37-7Y$=@0RNT'VIU(T-BCR&DO^XDR:/;;IYK-2<C8R<3=EKU*
MPVV#C#K'YJ]N.*9M]FB0[(N9'PJ%,*2D-=OS\9 YTRI6E9H*M-1F)KQ8>BW5
MQ^U7BLCK'O6^F1IVLX$9]TF7WJRQ (G1I/5*/ D_E/LF;9ND\B.7/-";U*1[
MKQIS1_):U63D;CI'J"=P:Z&-0W?.9IW5:4(ZM*6&W?N3YPKW8@.'3G<4C&%G
MQ9,=3P'8S,,7:_A._PB;^QIW%4N-6TB!9U%&DO4;&NBC<P9L80%;+&.AQWXJ
M=K57D)'/-D1>)$D&C&R9B&D1^M ],1Z!D[*IN[::Q509E7S1+?)N1H.+T<UH
M,AH^2K?#Q\GX\B\_C6^NA@^/*DVT]$2<_-HS4)MJJ"*/1GW7=>@\E;ZOZF>F
M:C/BLM)DEZAJ+NP82N&TF3Z-]^4ZS5 !![Y,!OW0M4%PS8IN*6QS-4T24/IK
M(ERW%!XE]/(X$ ?&%VB>)B(,]L3G8CP[S'5?<*)MUPXI?BR%<Y*'6" *C&^4
MB69&7!L/JYSRVTSRMB+/'EOVNON>(^F@\Q"L%#WN1&<EPY_PKE$<[V^R$)'@
M,_BMZ%FCM@[I5<.4(Z)E9TF<2+8E9.MMPZ9 =6.+*ECGKQ&FRMEYC&@$P/:#
MX\8+8.RI4(6C^)YO<."-@LES"!MR[H^"..&^+[/6C&</R^GYQS/Y3\&8:=T4
M92A1^:>,,*0M'?!4&$LOQ@0_\I$,[4F>0WS9YC[\L>4!BS_<7K#SCR? !/[?
MT@CL0@\F;XX.CZ(-7L@\<7^-OA?I4_Z4^S(G3+P0(F$NCE;]2QJJ5IG8I,D5
MT]?+. OD#J!?LG#J>W.=$LJ-^'.@3C2<^3N=D7^]!-+!%W68CM'N9>E)SVE\
MR5SR+T*Z3,9LO<(O.$/')&_F.>C.M,87SLRX!Q]($[&,@6F>L*4W7R08,E?;
M_&1&1'RU\CTG\X)*%L"#4/%6@-XF-7*08HD$'[;R;,O\T]--T4^HGT@\A?X3
MZE>##M0-72!;CT]T_%\E^C2,(FDN $+S #F5.:A2.=.0^4I,W5$8$7@5>M+8
MB"4>3*UH"R4S*P"0,1TXR!7/E$LZ5M#:0A,DZ)T8J& (@).L.9?)R4HJ)NUS
M[#8W?,:>51K#KGN#<SGJ,0:$0,\?]K;4^G.X]EUMI^5O4"C'YW&L6 "B*7C\
M[3V#-);"C9=2RRO^&D2,DP(\>G&\EM\AZ\IH;(\+5!U,IC(,C)"\2V8/BF&T
M@UP#4PX]?H*O[Z^FKV4UL5W#%L"V_%-"2/;-+ N_DR4%4^([ON 1R+V25D[Q
M?E/%W.VKLI [V5>[)C=9U\./$: ' ZB<*_:W;+DA:!A-T<37%0:[>_8 \ $[
M9QM,YH>->NIW!YGRY>P(\);=+B1:Q5=</&4//7FAGPT<P&PH@U%++T$T $*A
M ]G""J\[8RAXPEZ]>PWMYZJ*KS"ZT&A!$KEXE'VK1L^K]Z_SE \T+^4OT#V.
MX*_HL"A-[1!UNI0$H<-7DBG@>1$"-*4)=EY)?8KC1UTG\GL4*PM^^ZW+0SH7
MYOGX!? WP.1=0*]@CU)?A[(9,>:(]MJ7+@&[2YX<>GJU8Z]@DU'UW/QB4OVV
MA_AM#_';'N*W/<1O>XB_W3V$\8*0WRPT6WD)%_8R-7>1ZV+Z"^E2?;=UTC6Y
M:LK6C7=SQDR68CVS RQ#1:!/.-R3>>>^N:"ON[1*>Q+!6CP()YP'<OI3-DKU
MF17JZM$MT@PY(^Y0D0C+4>D):AJKX= 0K4D/O7Q6CYKGZ-IJQ\K?8?/)^F\^
MKT7=PW:C7CIV2*$JC^AF#1P_Q)!5PPCS]!4]@5U[/36/R?/"AH3[[)CG:C"I
M:3M,VY$R,QS@T')2!LMB5+KT]'5,M=!%79"XXZ4D*H[U/4@NQ-P+ C0$GJG
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MTY[H,-"NLQ#NVL=49^%R%09"/C!G*-96R!<B$#,OD6Z[=9ZPE!;)H7OITI
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M/I@IK ZT#O,^%@:,-#-1,ZM+SA#9A$/2U6A91-L3IJCU!,NM%'.0[;%QW[U
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M5L? &\J1P':]T*LO%M!-S$5F#'J$-MG,1)PLX(*%!LZF*'3MI1JET_<91!'
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MU-,?]HX!Z<CIR_87Y'\/N!'\Z[O_ E!+ 0(4 Q0    ( $"%L$@_O:6S/(H
M !IC!P 1              "  0    !C<&AI+3(P,38P,S,Q+GAM;%!+ 0(4
M Q0    ( $"%L$B<;@-<6Q0   _/   1              "  6N*  !C<&AI
M+3(P,38P,S,Q+GAS9%!+ 0(4 Q0    ( $"%L$@$.Z)[2@,  +L3   5
M          "  ?6>  !C<&AI+3(P,38P,S,Q7V-A;"YX;6Q02P$"% ,4
M" ! A;!()?$W4:<&  #U1P  %0              @ %RH@  8W!H:2TR,#$V
M,#,S,5]D968N>&UL4$L! A0#%     @ 0(6P2'Y1%R/\40  ZFL# !4
M         ( !3*D  &-P:&DM,C Q-C S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M $"%L$B<P65?HB,  .@5 @ 5              "  7O[  !C<&AI+3(P,38P
A,S,Q7W!R92YX;6Q02P4&      8 !@"* 0  4!\!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
